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IDear Readers,
I have always avoided inserting a message from the editors or myself in this journal. However, I 
just felt that this occasion called for some sort of statement. One of the several tasks suggested to me 
when I first accepted my position at Touro was to get a Science Journal re-established. It was probably 
more than coincidence that Rivka Borger and Michelle Gordon (now Grunin) approached me with 
the same request. In my previous 44 years of teaching I had never been in involved in a similar activity. 
The three of us plowed ahead with the overriding goal of keeping this a student publication from start 
to finish. Given the multiple facets of my new job, it was difficult to maintain the priority for this one. 
I am not sure that starting this journal could have been accomplished without the strong motivation 
and commitment of Rivka and Michelle, and of course all of the student editors and contributors. We 
have enjoyed support and expertise from two individuals in particular, Dean Robert Goldschmidt and 
Mrs. Esther Greenfield. Dean Goldschmidt has championed our efforts and provided the funding. Mrs. 
Greenfield has always been there to find even the most miniscule errors in my “printer ready” versions. 
She has unknowingly challenged me to continuously move even closer to perfection. Thank you both!
The Science Journal is available on line at http://las.touro.edu/departments/biology/. At that site, you 
can open each paper and see the full content. You will also be able to see the mastheads. That will docu-
ment the student nature of this publication. Submitted articles are sent to the Editorial Board members 
for peer-review (I review them as well). The reviewer’s comments are then forwarded to the authors 
for their rebuttal or acceptance. After all of that they are formatted, assembled, and sent to the printer. 
A few years ago, Professor Antony O’Hara of the Digital Multimedia Imaging Department learned about 
the formatting and layout difficulties I was having. He graciously volunteered to involve his students in 
the effort and has performed those tasks for us when students were not available. Additional thanks are 
extended to Professor Atara Grenadir, Chair of the Art Department, who has arranged for Art students 
to assist in designing and producing the more recent covers. Please enjoy the variety of articles we put 
forth for you.
Sincerely yours,
Robert S. Bressler, Ph.D.
Letter from Dr. Robert S. Bressler
II
Dear Readers,
The Science Journal of the Lander College of Arts and Sciences has been in existence for ten years. 
Ten years is a major accomplishment, not only in how far we have come, but in how much wonderful 
and amazing scientific research has been written and published throughout ten years of excellence. 
When we were students in the Biology track of LCAS, we were interested in working on our own 
research, and looking for opportunities to advance, write, and publish work. Dr. Bressler, head of the 
Biology department, encouraged our idea, and decided to revive the Touro Science Journal. The Touro 
Science Journal had been in existence previously, but with Dr. Bressler’s guidance, we revived the idea, 
revamped the Journal, its peer editorial committee drawn from interested students, and managed to 
produce something unique: a science journal filled with excellent research, done and edited by the 
Touro students themselves. 
It gave students who had a desire to read and learn, to publish and to review, a place to submit their 
work, where they could undergo for the first time in their college years, peer review and processing, 
and to see their final work in print. It showcased original topics and ideas, and both the students and 
professors gained in the creation. Editors changed as the student body graduated and shifted, but the 
idea and concept remained the same, allowing it to become the gold standard for a Touro student to 
show their research. 
We feel privileged to have started it on that path, and we hope that it will continue in the future to 
allow students a taste of what taking a research concept from start to the finished publication, can be. 
We owe a tremendous gratitude towards Dr. Bressler, for encouraging us in our notion, helping us give 
it its start, and continuing to produce and maintain it every year since, and for being the amazing science 
teacher and professor that he is. He gives of his time, his devotion, and thinks big- and that’s exactly 
what this Journal has become: from a thought to an amazing 10 year anniversary. We also owe gratitude 
towards the Dean of Touro, and all the excellent scientific faculty, for funding, support, producing the 
research, their time, effort and help every step of the way. 
We both graduated from Touro College and pursued careers in the medical and biological sciences: 
Michelle, defending her PhD thesis this year as a research geneticist, and Rivka, who has been working 
as a Physician Assistant for over 6 years. We are sure that Touro College and the Lander School of Arts 
and Sciences gave us the background and start we needed to pursue our goals. 
We are honored to present to you the tenth edition of the Science Journal, and we hope that it will 
continue for many, many more years. 
Sincerely, 
Rivka and Michelle
Charter Chief Editors
Letter from The Charter Chief Editors
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3Introduction
Breast cancer can almost be considered an epidemic in today’s 
world.  It is the most frequently occurring cancer in women 
worldwide. (Li, 2016)  It has become evident that breast can-
cer diagnoses have increased because screening methods have 
become more efficient and because overall life expectancy has 
been lengthened in recent years.  In most cases, breast can-
cer is treated by removal of the tumor and surrounding areas. 
Sometimes neo-adjuvant (prior to surgery) therapy is given. 
Alternatively, treatment only begins after surgery.  Afterwards 
radiation is applied to the tumor site and surrounding areas. In 
addition, if the tumor is hormone receptor (estrogen or proges-
terone or both) positive, patients will undergo hormone ther-
apy as well as chemotherapy.  This paper will discuss radiation 
therapy and hormone therapy as a systemic treatment but will 
not cover chemotherapy.
Methods
This article was written through the analysis of various original 
research and peer reviewed journal articles.  Access was ob-
tained through PubMed and the Touro College Library.
Results and Discussion
Breast Conserving Treatment and Mastectomy
Breast cancer treatment has shifted from total mastectomy to-
ward breast conserving therapy.  From the 1970’s, studies have 
shown that breast conserving surgery with radiation have the 
same effects as the Halsted (radical) Mastectomy for tumors 
up to 5 cm. (Veronesi, et.al 2013)  When a patient with breast 
cancer undergoes breast conserving therapy, radiation of the 
breast and some surrounding areas is usually applied (Aebi, et.al 
2011).  Even after mastectomy, radiation is required if there are 
four or more lymph nodes found that ae positive for cancer.. 
There was no observed benefit from radiation in women with 
node negative disease. (EBCTCG, McGale, et.al. 2014)  Post-
mastectomy radiation is recommended if the tumor is 5 cm or 
larger, there are at least 4 positive nodes, a positive margin of 
resection, or skin involvement.  However, because of the psy-
chological effects of mastectomy, breast conserving surgery is 
now considered an acceptable form of treatment even when 
the tumor is large, as long as the breast can be reshaped.  Now, 
about 25% of women diagnosed with breast cancer undergo 
mastectomy, usually because of large tumor size, location of the 
tumor, or local recurrence following a previous breast conserv-
ing surgery. (Orecchia, 2015)
In order to reduce the psychological effects and cosmetic draw-
backs of mastectomy, the skin sparing method has been intro-
duced.  One recent development in the skin sparing method is 
nipple-sparing mastectomy which allows for the preservation of 
the nipple areola complex.  However, there has been increased 
recurrence behind the areola following nipple sparing mastec-
tomy.  Therefore, radiation is performed on patients that are 
at greater risk of recurrence.  There is no standard practice in 
patients who have an intermediate or low risk and radiation’s 
role in this case is unclear. (Orecchia, 2015)  Although further 
research is needed, this new method can open up new opportu-
nities for better methods of breast reconstruction.
Comparison of Mastectomy, Lumpectomy, and 
Lumpectomy plus Irradiation
A study was performed to see whether mastectomy, lumpec-
tomy, and lumpectomy plus irradiation had different effects on 
survival.  Follow up after 20 years showed no significant differ-
ence in survival between the group that underwent mastectomy 
as opposed to the groups that underwent lumpectomy with or 
without radiation.  This study did not show any risk of radiation 
causing cancer in the contralateral breast which is a common 
concern.  The findings at 20 years of follow up did indicate that 
lumpectomy with irradiation significantly decreases recurrence 
when compared to lumpectomy without irradiation.  However, 
perhaps, if wider margins were removed at the time of breast 
conserving surgery, the need for radiation afterwards would be 
eliminated. (Fisher, et.al. 2002)
Effects of Radiation following Breast Conserving 
Surgery
Breast conserving surgery can be performed on women with 
a less advanced stage of breast cancer by removing any micro-
scopic residual of the cancer.  However, macroscopic bits of 
the tumor can remain in the breast or nearby area; therefore 
radiation is commonly used to prevent local recurrence and dis-
tant metastases.  In one study, 10,801 women were included to 
see how radiation can reduce the risk of recurrence and death 
Abstract
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including different variables, such as age, tumor size, and nodal 
status.  This study differs from previous studies in three ways. 
Firstly, it assumes that all recurrence whether it is locoregional 
or distant is related to the tumor that preceded it.  Therefore all 
recurrence is considered as first recurrence.  Secondly, previous 
studies obtained follow up results for 10 years, and this one 
goes up to 15 years.  Lastly, previous studies considered death 
of unknown causes within the first 10 years to be attributed 
to breast cancer, but this study attributes it to other causes. 
(EBCTCG, Darby, et.al. 2011). 
When radiation was applied after breast conserving surgery, the 
10-year risk of recurrence dropped to 19.3% as opposed to 
35.0% in women that did not undergo radiotherapy.  The risk 
reduction in this case is 15.7% for women who had radiother-
apy following breast conserving surgery.  Three quarters of the 
recurrence in those that had no radiation therapy was of a local 
nature while fewer than half of those in the radiation group 
had a locoregional recurrence.  In addition, radiation reduced 
the risk of cancer related mortality to 3.8% in 15 years, which 
suggests that for every 4 recurrences avoided due to radiation, 
one death was prevented.
Radiation halved the risk of annual first recurrence and it re-
duced cancer related death by a sixth.  However, mortality with-
out recurrence (death from other causes) was slightly higher 
during the first 10 years in the radiation following breast con-
serving surgery group than those who did not have radiation. 
The higher death rate in the radiation group can be attributed 
to the toxicity of the radiation.  However, this is not considered 
significant because it is such a minuscule percentage.  On aver-
age, including all the women of all the different groups (node 
status, age, endocrine receptor responsiveness, etc.), during a 
15-year period, one death was avoided for every four recur-
rences avoided by year 10.  
This study considers any instance of recurrence, no matter 
where it occurs, as a first event rather than only considering 
locoregional recurrence as a first event as other studies have 
done.  This gives more accurate results than previous studies. 
Different kinds of recurrences cannot be ignored because radi-
ation is assumed to reduce all recurrences.  Because this study 
gathered data from patients with a wide range of risks and over-
all, radiation halved the risk of recurrence, it can be assumed 
that it will reduce the risk in future patients as well by a half. 
(EBCTCG, Darby, et.al. 2011).
Boost
After 50 Gy radiation on the breast, a 16 Gy boost is rec-
ommended except for in patients with a low risk for local 
recurrence. (Aebi, et.al 2011)  As stated previously, radiation 
prevented one death in a 15-year follow up for every four 
instances of local recurrence prevented in a 10-year follow 
up.  However, because of the intensity of the radiation, fibro-
sis frequently occurred which caused a poor cosmetic result. 
(Bartelink, et.al. 2007)  In one trial, the boost dose was lowered 
from the previously accepted 25 Gy to 16 Gy because of the 
high percentage of patient fibrosis which resulted from the in-
tensity of the boost.  There were 5,569 breast cancer patients 
who were included in the boost vs. no boost study.  The patients 
were no different from each other with respect to surgery or 
whole breast irradiation.  Local recurrence in the no boost 
group after 10 years was 4% higher than in the boost group. 
Incidence of fibrosis at 10 years was 4.4% in the boost group as 
opposed to 1.6% in the no boost group.  Although a boost of 16 
Gy was shown to decrease the rate of local recurrence in this 
study, no improvement has been discovered in disease-specific 
survival or overall survival.  However, this could be because of 
the success of salvage mastectomy which was performed on 
the no boost group when they began to exhibit signs of local 
failure.  The risk of fibrosis for those in the boost group is not 
of a significant level. (Bartelink, et.al 2015).  
The above study was done over a period of 10 years.  A different 
study was performed which included 20-year follow up for all 
patients.  This trial was performed to see if a boost dosage of 16 
Gy decreased the rate of recurrence.  A 5-year follow up study 
showed that it does decrease recurrence.  A 10-year follow up 
showed that when a boost is delivered, the rate of salvage mas-
tectomies decreases.  In the 20-year follow up, local recurrence 
was 13% in the no boost group as opposed to 9% in the boost 
group.  Incidence of fibrosis was a little bit higher (about 4%) in 
the boost group.  The cumulative percentage for salvage mas-
tectomies performed on the boost group was 6.4 vs. 10.3 for 
the no boost group.  The fact that there was no improvement 
in overall survival in the boost group seems to show that the 
boost is not needed.  However, this must be the result of the 
high rate of successful salvage mastectomies performed.  The 
boost the number of salvage mastectomies by a third. (Bartelink, 
et.al 2015)
Effects of Radiation following Mastectomy
Post mastectomy radiation is used to treat women with four 
or more positive lymph nodes to ensure complete removal of 
any residual tumor foci.  However, the role of radiation in treat-
ing women post mastectomy with one to three positive lymph 
nodes still remains uncertain.  As of now, post mastectomy ra-
diation is not given to women who have node-negative disease. 
The following study included 8,135 women who had 1 to 3 pos-
itive lymph nodes.  About 20% of the women had node-negative 
disease, 72% had node positive disease, and the nodal status for 
the remaining ones was unknown.
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Radiation therapy was shown to significantly decrease the rate 
of recurrence and breast cancer death in the group that had 
1 to 3 positive lymph nodes.  Radiation was not seen to have 
any added positive benefit in women who had node negative 
disease.  Radiation reduced the 10 year risk of recurrence in 
women with 1 to 3 positive lymph nodes from 45.7% to 34.2% 
which is an overall absolute benefit of 11.5%.  Today, radiation 
treatments cover more of the high risk areas, such as the chest 
wall.  In addition, the doses are lower than they used to be so 
the risks of radiation have decreased.  Therefore, the propor-
tional gains of radiation today are probably greater than the 
results of this study.  However, within the 20 years in which this 
study has been performed, methods of detection and treatment 
have improved; therefore the absolute benefits of radiation are 
lower than those reported in this study.  (EBCTCG, McGale, 
et.al 2014).
Intraoperative Radiotherapy
There is new research in the field of intraoperative radiother-
apy to treat many different kinds of cancers including breast 
cancer.  Instead of a few weeks or months of radiation post 
breast conserving surgery, patients can be treated with a dose 
of radiation at the surgery itself.  Although the average time of 
radiation has decreased over the last couple of years, it is still 
a strain and inconvenience on the women who must travel to 
the hospital every day for about 30 days to receive treatment. 
Another advantage of intraoperative therapy over mastectomy 
is that if recurrence occurs after breast conserving surgery and 
a mastectomy is needed, it is easier to perform it with the now 
popular method of skin and or nipple sparing procedures if no 
radiation was applied to the skin because radiation can cause 
necrosis. (Veronesi, et.al. 2013)  In addition, intraoperative radi-
ation therapy can target the cancerous tissue while protecting 
the normal tissue around the tumor. (Najafipour, et.al, 2015).
In one trial, the effects of intraoperative radiation on a number 
of different cancers was tested.  Intraoperative radiation was 
found to increase survival in patients with pancreatic cancer. 
When used on patients with early breast cancer, it was found 
to decrease life expectancy by less than a day.  Although it may 
increase operating room load, it is generally a cost effective and 
considered a safe method to treat breast cancer. (Najafipour, 
et.al, 2015)  However, more research must be done to see if this 
new method has any real advantage.
In another study, 1305 patients were randomized, 654 belonging 
to the external radiotherapy group and 651 to the intraoper-
ative group.  Only 11% had more than 4 positive nodes.  In 
this study, ipsilateral breast tumor recurrence was defined as 
“the sum of local recurrence plus 2nd ipsilateral tumors.”  Local 
recurrence was considered the recurrence of the carcinoma at 
the previous location.  Within five years of follow up, there was 
a significantly greater instance of recurrence in the intraopera-
tive radiation therapy group than in the external radiotherapy 
group.  Overall survival, however, did not differ significantly be-
tween the two groups.  Predictions are that in the future, better 
methods will be used to differentiate between patients who are 
at higher risk of recurrence and therefore need external whole 
breast irradiation or intraoperative radiation plus external ra-
diation.  (Veronesi, et.al 2013)  It must be noted that this study 
only measured 5 years which considered short term follow up 
in a study of this sort.
Testing for Endocrine and HER-2 Receptivity
Trastuzumab
Overexpression of HER2 protein occurs in 20-25% of breast 
cancers, causing high-grade tumors, increased growth rates, 
early systemic metastasis, and reduced rates of overall and dis-
ease free survival. (Slamon, et.al 2011)  Trastuzumab (Herceptin) 
is given many times in conjunction with chemotherapy, but 
it can also be given alone.  Trastuzumab does not cause the 
negative side effects that other chemotherapy medications 
are known for, such as alopecia, myelosuppression, and severe 
nausea.  However, Trastuzumab has been known to cause car-
diotoxicity in 1.4% of those to whom it was administered to. 
(Piccart-Gebhart, et.al 2005)  Various studies were performed 
to find out how much Trastuzumab actually improved disease 
free survival and whether the increase in cardiotoxicity was a 
cause for concern.
One study included 4,482 women.  Both groups received 
Trastuzumab after undergoing primary treatment (surgery, 
chemotherapy, radiation, ect.).  One group received it for one 
year, the other for two.  Patients with a history of cardiac 
trouble were excluded from this study.  The study shows that 
Trastuzumab given after primary treatment reduces the rate of 
recurrence by 50%.  It does not seem to make a difference what 
type of chemotherapy is received.  The risk of cardiotoxicity is 
low; however, it is possible that this is because there is a short 
follow up in this study.  In addition, there is a concern that lon-
ger term follow up will show that Trastuzumab does not reduce 
disease recurrence in the central nervous system. The results of 
this study indicate that one year of Trastuzumab should be used 
following primary treatment of breast cancer. (Piccart-Gebhart, 
et.al 2005).
A study was performed to see whether an anthracycline-based 
regimen increased Trastuzumab’s toxicity.  There were 3,222 
women who were divided into three groups.  One group un-
derwent an anthracycline regimen.  In the second group, the 
patients received anthracycline with Trastuzumab.  In the third 
group, the patients only received Trastuzumab.  All three groups 
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underwent an intense cardiac monitoring schedule.  A signif-
icant benefit was seen in patients who received Trastuzumab 
as opposed to patients who did not.  There were no appar-
ent differences between the two Trastuzumab goups; however 
the trial was not set up to discern a difference between them. 
Congestive heart failure occurred more often in the group that 
received anthracycline in addition to Trastuzumab.  In addition, 
treatment time is decreased when anthracycline is not given. 
(Slamon, et.al. 2007).
Hormones and their effect on Breast Cancer and 
breast cancer treatment
In the Million Women Study conducted in the UK, over 1 million 
women between the ages of 50-64 were recruited to have a 
breast screening every three years.  The women were given 
a survey to complete shortly before their screening.  (The 
questionnaire can be viewed at http://www.millionwomen-
study.org).  The purpose of the study was to see if and how 
hormone replacement therapy affects breast cancer.  In total, 
50% of the population had used hormone replacement thera-
py at some time.  The results of the study proved that recent 
or current users of hormone replacement therapy are at in-
creased risk of breast cancer.  Those using estrogen-progesto-
gen combinations have a four times greater risk than those 
using estrogen-only preparations.  However, past users of 
hormone replacement therapy have almost no increased risk. 
In all, hormone replacement therapy results in 5 to 6 more 
cancers per 1,000 women with 5 years use and 15-19 extra 
cancers per 1,000 women with 10 years use. (Million Women 
Study Collaborators, 2003).
The Million Women Study, because of its large number of par-
ticipants and span of time, has been the source of much con-
troversy.  It has been pointed out the women who participated 
in the study are not a good sampling of the general population 
because women that use hormone replacement therapy are 
more likely to be concerned about their risk of cancer and go 
for a mammogram. (Eden, 2010)  However, the Million Women 
Study represented 53% of the population, so although this may 
be 53% of the population that is more likely to be affected by 
hormone replacement therapy, over half a population is a good 
indication of the rest of the population.  
Hormone Therapy
Soon after a patient is diagnosed with breast cancer, she is test-
ed to see whether her tumor is hormone receptor positive of 
negative, defined by estrogen and/or progesterone receptivity. 
Accurate assessment is critical in deciding whether to treat 
with hormone therapy; however, accurate results are difficult 
to obtain.  
In the past, tumors that showed less than 10% positivity were 
not given hormone therapy because they seemed similar to pa-
tients who tested negative for hormone receptivity.  Recently, 
however, The ASCO/CAP guidelines were revised to treat 
women in the 1%-9% positivity group with hormone therapy. 
Now 3% more women are being treated with hormone thera-
py.  The problem is that although for a small minority of cases, 
hormone therapy has a good positive result on those in the 
1-9% group, physicians must consider the benefits of endocrine 
therapy versus its cost and side effects. (Yi M, et.al 2014)  The 
goal of this study, as noted above, was to show that perhaps 
the benefits of treating the 1-9% group with endocrine therapy 
do not outweigh the costs.  However, this study has limitations. 
They retroactively collected the data and because of that, the 
Estrogen receptor status is not known for certain because the 
patients obtained their diagnosis outside the facility where this 
study was performed.  In addition, the study’s limited sample 
size makes it very difficult to analyze the data based on results 
from adjuvant chemotherapy and endocrine therapy.
A later study shows that even with a very small percentage 
of Estrogen receptor positivity, adjuvant hormone therapy cut 
breast cancer mortality by a third for fifteen years.  Those who 
had hormone receptor treatment were found, initially, to have 
lower rates of recurrence than those without; however, they do 
risk relapse for up to fifteen years despite usage of Tamoxifen 
for five years. (EBCTCG, Davies, et.al. 2011).
The suppression of hormones and the target of HER2 recep-
tors is a not a new development in medicine.  Two cohorts, 
comprised of 7,178 patients, were studied to see whether 
current hormone treatment is more effective than that of the 
past.  One cohort was diagnosed recently, and the other was 
diagnosed from 1986-1992.  Relapse event was any disease re-
currence.  In all, 1,700 patients had relapsed in 9 years of follow 
up.  The result showed that the current treatments are more 
effective because they are used for longer and they are more 
efficient.  However, patients with ER+ tumors do seem to have 
a late relapse and ER- tumors have an early relapse in patients 
that were recently diagnosed. (Cossetti, et.al 2014).
Another study was performed in 1996 to see whether there 
is a difference and how significant of a difference 2 years of 
Tamoxifen makes compared to 5 years of treatment .  The re-
sults showed that 5 years was more effective.  They did not test 
past 5 years; therefore, they do not know if more than 5 years 
would be more effective. (Swedish Breast Cancer Cooperative 
Group, 1996).
Premenopausal hormone receptor positive breast cancer is 
treated by ovarian ablation or suppression.  The ovaries still 
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function in premenopausal women and they are the main site 
for hormone production.  The aromatization of androgens in 
the adrenal glands produces hormones in postmenopausal hor-
mone-receptor positive breast cancer.  Aromatase Inhibitors 
(AI’s) inhibit the production of those hormones.  AI’s fall into 
two categories:  non-steroidal and steroidal AI’s.  Across the 
board, AIs are superior to Tamoxifen.  The ovaries are only 
temporarily suppressed when women are premenopausal for 
preservation of fertility. (Li, et.al. 2016).
The Premenopause/Post-menopause treatment 
methods
Tamoxifen is the standard drug to treat hormone receptor 
positive breast cancer.  Premenopausal patients, however, are 
often resistant to Tamoxifen.  Therefore ovarian function sup-
pression medications are combined with Tamoxifen in order to 
reduce disease recurrence in pre-menopausal women.  Ovarian 
function suppression medications increase toxicity, complicating 
overall treatment regimens.  (Kim et. al, 2016).  
Two trials were performed, the Tamoxifen and Exemestane Trial 
(TEXT) and the Suppression of Ovarian Function Trial (SOFT), 
to determine whether the aromatase inhibitor Exemestane 
improved survival in premenopausal women when used in con-
junction with Tamoxifen as opposed to women treated with 
ovarian suppressors with Tamoxifen.  The combined data from 
the two studies shows that Exemestane plus ovarian suppression 
as opposed to Tamoxifen plus ovarian suppression significantly 
improved survival and decreased risk of recurrence.  (Pagani 
et. al, 2014)  However, in the SOFT study, the women who re-
mained premenopausal and had an increased risk of recurrence 
and therefore needed adjuvant chemotherapy, the addition of 
ovarian suppression treatments improved survival rates (Kim et. 
al, 2016)  Because these women received additional chemother-
apy, it is not clear whether it is the chemotherapy or the ovarian 
suppression that increased survival.
A Korean Study was performed to compare ovarian function 
suppression with Tamoxifen versus just Tamoxifen in young, 
premenopausal women who had undergone chemotherapy. 
The main purpose of this study was to compare the 5-year dis-
ease-free survival rates between the two groups.  The Korean 
Breast Cancer Society focused on this age range because al-
though South Korea has an overall smaller number of breast 
cancer diagnoses compared to the world at large, 48.7% of 
breast cancer diagnoses are in premenopausal women under 
the age of 50 which is a much higher percentage of young 
women than in other countries.
The advantage of this study over other studies is that there 
is repeated evaluation of ovarian function, which allows for 
better selection of patients that should be receiving ovarian 
function suppression treatments, avoiding unnecessary side ef-
fects.  Ovarian suppression causes menopausal symptoms which 
significantly alter the the quality of life.  These symptoms can 
lead to a lack of patient compliance and can also destroy phy-
sician-patient relationship (Kim et. al, 2016).  This study shows 
the benefit of Tamoxifen plus ovarian suppression therapy in 
premenopausal patients with Estrogen receptor positive breast 
cancer treated with chemotherapy.  This trial helps determine 
the optimal endocrine therapy needed based on ovarian func-
tion status of premenopausal patients.
Conclusion
The patient must undergo a mastectomy if reconstruction of 
the breast post breast conserving surgery is impossible or not 
feasible.  However, mastectomy is not as radical as it once was. 
Moreover, now there are new skin sparing methods, such as the 
nipple areolar sparing method which allows for a more natu-
ral reconstruction after surgery.  Post mastectomy radiation is 
given in women with 4 or more positive lymph nodes, but in 
women with 1-3, the question still remains.  Studies show that 
in women with 1-3 positive lymph nodes, recurrence is reduced 
by over 10%.
In about 75% of cases, patients undergo breast conserving sur-
gery.  Except in cases of very low risk of recurrence, patients 
must have radiation afterwards.  However, perhaps better tumor 
residue removal will be employed which can eliminate the need 
for radiation therapy.  After breast conserving surgery, radiation 
reduces risk of recurrence within 10 years from 35% to 19%, a 
significant difference.  Radiation prevents one death for every 
four recurrences prevented (a 3.8% decrease).  Radiation does 
increase toxicity; however, the percentage is so low, that they 
give radiation anyways.  However they do try to keep dosages 
low.  A radiation boost after the radiation treatment regimen 
decreases recurrence by 4% over a period of 10 years and after 
20 years.  There is no difference in overall survival between the 
group which received a boost and the one that didn’t because 
of salvage mastectomies and other retroactive treatments per-
formed.  The risk of fibrosis does increase by the same percent-
age as survival in the boost group.
Trastuzumab is given to those that test positive for HER2 ex-
pression.  Although it does increase cardiotoxicity in 1.4% of 
cases, it has less side effect than other chemotherapy medica-
tions.  However, the risk of toxicity may be low in this study 
because of a short (5 year) follow up.  A longer follow up may 
show a larger percentage of toxicity.
Hormone replacement therapy increases one’s risk of getting 
breast cancer.  Those who take an estrogen-progesterone 
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combinations have a four times greater risk of developing can-
cer than those who take estrogen only.  Each woman together 
with her doctor must decide whether the benefits outweigh the 
risks in taking hormone replacement treatment.  This treatment 
increases the quality of life for post-menopausal women; howev-
er if someone has an increased risk of developing breast cancer, 
they should not take this treatment.  The Million Women Study 
does represent most of the population.  However, sometimes 
large studies cannot take certain factors into because although 
they do divide their sample by different characteristics, there 
are too many people to be very exact and specific.
New guidelines have been set up, so now women with 1-9% 
hormone positive lymph nodes get hormone therapy.  However 
the study that proved that this change is necessary (from the 
previous about 10%) has limitiations.  Firstly, they collected the 
data retroactively, so they could not be certain that all of it 
was correct, and they had a limited sample size.  Those that are 
hormone receptor positive and take hormone therapy for five 
years do initially have decreased recurrence, but they do risk 
relapse for up to 15 years.  
In the study where a group received hormone therapy from 
1986-1992 was compared to a more recent group, it was prov-
en that hormone therapy is more effective now because the 
therapies are more efficient and they are used for longer than 
they once were.  Although those with hormone receptor pos-
itivity have a better prognosis, they are at risk for a relapse 
albeit much later than those with hormone receptor negative 
cancer.  Hopefully new research and discoveries will lead to a 
more permanent and better prognosis.  
Premenopausal women are resistant to Tamoxifen, so it is usu-
ally applied together with ovarian suppressors.  These suppres-
sors can increase toxicity, but they do improve.  As the Korean 
study noted, repeated evaluation of ovarian function can allow 
for better selection of patients which can avoid unnecessary 
side effects which lower quality of life.
All the above research shows that there is no one best method 
to treat breast cancer.  Treatment must have a multidisciplinary 
approach.  Each patient must be treated as an individual with all 
symptoms and disease specifics taken into account.
There are various limitations that studies have.  One limitation 
is that studies, by their very nature, must be performed under 
certain assumptions, like assuming that death of an unknown 
cause within 10 years is disease mortality which may or may 
not be the case.  In addition, a large sample size can cause a 
“one size fits all” attitude. Trials involving breast cancer patients 
have an advantage because there are many people who have 
breast cancer.  However because of the large study size, at times 
there is not enough specification of treatment.  One woman 
may seem to have the same diagnoses as another, but some 
important differences may not be accounted for.  For example, 
a woman who tests positive for HER2 receptor and has 8.5% 
hormone receptor positivity will be given Trastuzumab and hor-
mone therapy, but perhaps she has a risk of heart disease in her 
family and the increased cardiotoxicity will be more harmful for 
her than the average patient.  It is not enough for doctors to be 
up to date on different treatment advances, they must create a 
treatment plan that takes each individual patient’s needs, back-
ground, and overall health into account.
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Introduction
The French Paradox, a term coined by Serge Renaud in 1986, 
has stymied scientists for years. The paradox is presented by the 
fact that France  is one of the world’s  highest consumers of sat-
urated fat and cholesterol-containing foods.  Yet, as a whole, the 
French people have lower rates of coronary heart disease than 
the rest of the Western world (cited in Ferrieres, 2004; cited in 
Agarwal, 2002). This presents a paradox since it has been firm-
ly established that large amounts of cholesterol and saturated 
fat increase the risk for Coronary heart disease (Shestov, et 
al, 1993). How could a nation that consumes more cholesterol 
and saturated fats than the United States of America still have a 
significantly lower CHD mortality rate?
One possible explanation for this conundrum was proposed in 
1986: the French have a larger intake of alcohol consumption 
than Americans. It was, therefore, hypothesized that alcohol, 
through various biological mechanisms, can lower the risk for 
Coronary heart disease (Rimm, 1999). The detrimental effects 
of alcohol have been tested and proven. However, most of these 
terrible effects stem from long term alcohol abuse and binging. 
Perhaps viewing alcohol from a moderate intake perspective 
will present different data. The purpose of this paper is to re-
search and assess this hypothesis to determine if a moderate in-
take of alcohol has a deterrent effect on coronary heart disease.
Method
This is a meta-analysis of more than twenty papers including many 
original experiments. The information gathered in this paper has 
been collected from numerous sources including databases such 
as PROquest and JSTOR. Additionally, a great deal of information 
was gathered from medical journals publicly available on the in-
ternet or in libraries. All of this information was read, analyzed, 
and compared to determine each piece’s respective authority 
and veracity. Each article was also assessed in accordance with its 
respective levels of diversity and sample size significance.
Results
In this review, the words “moderate intake of alcohol” will be 
used. This term obviously excludes excessive consumption of 
alcohol as well as total abstinence from alcohol. For laypeople, 
the term “moderate intake of alcohol” has a wide and subjective 
purview that will always fall somewhere between abstinence and 
excessive alcohol consumption.  For the purposes of the ex-
periments referenced herein, moderate intake of alcohol refers 
to 15-30 milligrams of ethanol (the alcohol found in what are 
commonly considered alcoholic beverages, such as beer, wine 
and spirits) per day. This is the amount typically contained in one 
to two alcoholic beverages.  Any alcoholic consumption below 
or above 15-30 milligrams may have similar effects. However, 
this level of consumption it is not within the purview of this 
research paper. 
When focusing on the intake of a moderate amount of alcohol 
(15-30 mg of ethanol), several experiments have found positive 
effects that alcohol exerts, directly or indirectly, on coronary 
heart disease. Graphically, it is represented as a J or U shaped 
curve. Below is a summary of the effects of alcohol on relative 
risk of death (Tabl1 1). Some experiments show that moderate 
levels of alcohol intake will decrease the risk of coronary heart 
disease by as much as 20 to 30 percent ( Rimm et al, 1999b; 
Emberson & Bennett, 2006; Pearson, 1996). There are numerous 
mechanisms proposed for this decreased risk. Some have great-
er scientific support than others. This paper will present those 
mechanisms that have sufficient scientific ground upon which to 
stand. The various mechanisms that will be discussed are:
High-density lipoprotein increase; Apolipoprotein A-1 and A-2 
increase; Change in lipoprotein size; Increase in fibrinolytic ac-
tivity; Decrease in fibrinogen; Decreases in platelet aggregation; 
and Increasing insulin sensitivity.
Apolipoprotein A-1 A-2 Increase
In a process similar to High density lipoprotein increase, mod-
erate intake of alcohol is hypothesized to increase the transport 
rates and concentration of  Apolipoproteins A-1 and A-2. These 
proteins are produced in the liver and are  part of the large 
complex of HDL that helps start the process of removal of “bad 
cholesterol” from the blood stream by HDL ( De Oliveira e 
Silva et al, 2000; van der Gaag et al, 2016; Frank & Marcel, 2000). 
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There are two primary ways that Apolipoproteins assist in the 
removal of bad cholesterol: 
First, in particular, Apolipoprotein A-1 is a cofactor for the en-
zyme lecithin cholesterol acyltransferase (LCAT) which con-
verts cholesterol into cholesterol esters (http://www.ncbi.nlm.
nih.gov/gene/335; Frank & Marcel, 2000). The cholesterol esters 
are more hydrophobic and help form the sphere of HDL that 
gets transferred in one of two ways: directly, through specif-
ic HDL receptors to the liver; or indirectly through very low 
density lipoprotein (VLDL) and intermediate density lipoprotein 
(IDL) conversion. Therefore, an increase in the concentration 
and transport rates of Apolipoproteins A-1 and A-2 will speed 
up the process by which the HDL will esterify and remove cho-
lesterol from the blood. 
Second, in addition to its role in speeding up the rate of cho-
lesterol removal by HDL, Apolipoprotein A-1 has also been 
associated with prostacyclin stabilizing factor, which is involved 
in anticlotting. By stabilizing prostacyclin, better known as 
Prostaglandin I2 (PGI-2), platelet aggregation is inhibited which 
helps decrease the chance of clots forming. The positive effects 
of inhibiting platelet aggregation will be discussed in more detail 
later in this paper (Yui et al, 1988).
Change in Lipoprotein Size
Experiments have also shown that ethanol can increase particle 
size of HDL and LDL. Small, dense LDL’s have been associated 
with a  risk of Coronary heart disease of three times that of an 
individual with large “fluffy” LDL. Additionally, an increase in the 
size of these lipoproteins has been associated with cardiopro-
tection (Mukamal et al, 2007).
All of the above mechanisms  hypothesize  how alcohol cre-
ates a potential downgrade of risk for heart disease based upon 
changes in lipid profile. More particularly, these hypotheses are 
based upon increases in HDL-Cholesterol and Apolipoprotein 
concentrations as well as lipoprotein size.
The Hemostasis Hypothesis
The next set of  mechanisms that hypothesize how moderate 
alcohol consumption has a possible downgrade on heart disease 
are based on  hemostasis. Put simply, these hypotheses suggest 
that alcohol affects the way the blood clots and breaks down 
clots, thereby reducing the risk for coronary heart disease. 
One possible hemostatic mechanism proposed is that moderate 
intake of alcohol can decrease fibrinogen concentration (Mennen 
et al, 1999 Stec et al, 2000). Experiments have shown that the 
moderate intake of alcohol decrease the levels of circulating fi-
brinogen by 18-20 percent (Wang, Barker, & Fuller, 1999). This 
decrease can cause a significant reduction of the risk for cor-
onary heart disease. Fibrinogen is a blood soluble plasma pro-
tein that is activated by the enzyme thrombin and produces the 
protein fibrin. Elevated levels of fibrinogen in the blood can lead 
to potentially devastating effects on the heart. First, it can cause 
an increase in platelet aggregation. Second, it will increase fibrin 
levels which promote coagulation, which leads to an increase in 
blood clotting. Third, elevated levels of fibrinogen increase plas-
ma viscosity, which is associated with an increased severity of 
coronary heart disease (Junker et al, 1998; Stec et al, 2000), In 
some scenarios, these factors can cause acute clot formation and 
block arteries, including coronary arteries, leading to myocardial 
infarctions. Finally, elevated fibrinogen levels play a role in ath-
erosclerotic plaque build up.  A moderate intake of alcohol will 
decrease  fibrinogen levels thereby decreasing the above factors. 
On the  antonymic aspect, alcohol has been proven to increase 
the levels of fibrinolytic activity (Pikaar et al, 1987; Aikens et 
al, 1998; Sierksma et al, 2001). In addition to alcohol decreas-
ing fibrin building, it is also able to increase fibrin catalysis. 
Experiments have shown that moderate levels of alcohol can in-
crease levels of plasminogen activator, which converts plasmino-
gen to plasmin, one of the enzymes that catalyzes fibrin clots. As 
a result, the hemostatic process of fibrinolysis is increased. By 
increasing the fibrinolytic activity in the body, clots are less like-
ly to form thereby reducing strokes and ischemic incidents. In 
fact, many medications that treat heart diseases work through 
similar mechanisms by inhibiting Plasminogen activator inhibi-
tor-1, which acts exactly as its name indicates -- by inhibiting the 
inhibitor, the activator is increased (Vaughan, 2011).
Another hemostatic aspect of moderate alcohol intake is its 
effect on platelet aggregation. Experiments have shown that al-
cohol can decrease platelet aggregation, subsequently decreas-
ing the risk of cardiac incidents (Zhang et al, 2000; Pikaar et 
al, 1987; Renaud & Ruf, 1996, Parson,1996). Platelet aggregation 
is a pivotal player in controlling and carrying out hemostasis. 
Moreover, it is a significant factor when it comes to athersle-
rotic heart disease. Atherosclerosis starts with the oxidation of 
lipoproteins which are responsible for creating lesions on the 
arterial wall. These lesions expose the endothelium thereby al-
lowing platelet receptors to open to accepting signals that allow 
platelets to begin adhering to one another. Platelets are also re-
sponsible for amplifying the signal that attracts leukocytes such 
as monocytes and lymphocytes. These cells have been previous-
ly proven to advance atherosclerosis through many mechanisms 
including the uptake of cholesterol up to the point of rupturing. 
Additionally, platelets contain chemokines within them that are 
released when platelets are activated. These chemokines are 
also factors that play a role in the propagation of ahterslerosis 
(Kaplan & Jackson, 2011; Weber, 2005).
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Insulin Sensitivity Increase
Alcohol has been shown to increase insulin sensitivity in in-
sulin resistant individuals.  (Sierksma et al, 2003; Joosten et al, 
2008; Fachinni, Chen, & Reaven, 1994). There is a correlation 
between these individuals and higher risk for coronary heart 
disease. The precise mechanisms for this correlation are un-
known but hypothesized as follows (Sparks, Sparks, & Adelhi, 
2012). In one hypothesis, muscle and fat tissue resistance to 
insulin causes an increase in plasma insulin and free fatty acid 
concentrations. Subsequently, this deadly combination will lead 
to Very low density lipoprotein (VLDL)-triglyceride secretion , 
which leads to higher triglyceride plasma levels. Another pos-
sible hypothesis suggested is that in insulin resistant individu-
als, there is a defect that does not allow insulin to properly 
regulate VLDL-triglyceride secretion thereby leading to hyper-
glyceridemia. In both of these mechanisms, the end result is an 
increase in triglycerides found in the plasma which, through an 
additional mechanism, is associated with coronary heart disease 
(Hokanson, 2002).
Discussion
Many scientists disagree with these hypotheses set forth above. 
Some attack the conclusions themselves while others question 
the experiments based on external biases and statistical errors. 
One proposed argument is that the control group of abstainers 
from alcohol in the experiments had been tainted by ex-drink-
ers who became abstainers due to health risks. These individ-
uals either realized themselves or were directed by medical 
providers that they had to stop drinking for their overall health 
and/or their potential for a cardiac event. If this were true, then 
using these individuals as the control for the experiments would 
completely ruin the results as these individuals are much more 
prone to having cardiac problems due to their previous con-
sumption.  However, this contention has been accounted for in 
many experiments. The experiments have made sure that their 
control groups consisted of individuals who have never been 
excessive drinkers as well as others that  have been lifelong 
abstainers from alcohol.
Another potential problem that has been raised concerning  the 
experiments is the determination of what type of people make 
up the moderate alcohol intake group. The concern is that per-
haps individuals who are moderate drinkers of alcohol come 
from healthier homes or have healthier lifestyles. These con-
cerns extend to the possibility that they have potentially better 
exercise routines, higher education, and better health insurance.
With regard to the claims of cardioprotection by HDL increas-
es, there is some question as to whether increasing HDL will 
even have any impact in cardiac incidents.  According to Dr. 
Daniel Keene, pharmacologically increasing HDL and its effects 
did not improve the individual’s risk for cardiac incidents (Keene 
et al, 2014). Now, this is strongly contended by many other ex-
periments and it would seem likely that there is some other 
explanation for why Dr, Keene did not find any improvement 
in his experiments. However, this is a curious experiment that 
should be taken into account.
All in all, there is sound evidence and scientific proof to say 
with confidence that alcohol exerts some level of cardiopro-
tection by increasing HDL concentrations, in particular the 
HDL2 and HDL3 subfractions. The mechanism behind this is 
not fully understood. However, the hypotheses reported above 
may shed some light on this area. The experiments supporting 
the cardioprotective effects of moderate alcohol use have been 
performed with significant numbers of subjects representing all 
people of all races, sexes and socioeconomic backgrounds. There 
have been over 40 experiments proving this point. Granted that 
some of these experiments do have some faults and biases with 
patients, but taken as a whole, the experiments clearly indicate 
a significant cardioprotective trait of alcohol. However, this only 
accounts for roughly 50 percent of alcohol’s cardioprotection.
Regarding the other 50 percent of cardioprotection, there is 
also sound basis to say that alcohol will decrease circulating 
fibrinogen, increase fibrinolytic activity, and decrease platelet 
aggregation. All these factors have been proven  by proper 
scientific experimentation. Although some may contest these 
results because a few of the experiments were conducted in 
vitro and not on people, the results were sound and the newer 
experiments have verified this to be true.
With regard to increasing insulin sensitivity there is a lot un-
known about the mechanisms by which insulin resistance harms 
the cardiovascular system and how alcohol increases sensitivity. 
However, from all the experiments it would seem clear that 
there is an increase in the sensitivity even if we are not clear 
about how it happens.
Conclusion
Based on all the evidence and experimentation is seems evident 
that there are benefits to moderate alcohol intake. To go so far 
as to recommend alcohol as a remedy or even a supplement to 
those in risk of coronary heart disease does not fall under the 
purview of this paper. It may be true that alcohol will reduce 
the risks for heart disease up to 30 percent.  However, we need 
to be cognizant of the potential risk and damage that alcohol 
may cause on other parts of the body. To summarize, medical 
professionals should not be so quick to dismiss alcohol as a 
deadly drug, rather they should research and weigh the cost 
versus benefit and advise their patients accordingly. 
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It would seem clear that since alcohol has cardioprotective 
attributes, the French paradox is not very paradoxical. The 
French diet includes a consistent moderate intake of alcohol, 
which would explain the lower coronary heart diseases rate in 
France.  Although this may not be the only explanation for why 
the French cardiac mortality rate is much lower, alcohol intake 
is proven to be a valid hypothesis.
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Introduction:
Objective
This paper will explore how targeted use of the hippocampus 
leads to its morphological modulation and growth, with the 
overall goal of demonstrating how targeted behavior can de-
monstrably alter the brain. Specifically, the hippocampal growth 
correlated to its cognitive-map character will be explored. The 
correlation between the practice of spatial mapping activities 
and hippocampal growth will be examined in animals and hu-
mans. With hippocampus growth in response to these specific 
activities firmly established, this paper will attempt to correlate 
this observation to an area where it can have real-world appli-
cation: therapy. The therapy that will receive particular focus is 
Cognitive Behavioral Therapy (CBT). This focus is due to the 
observation that CBT, out of all psychotherapies, specifically 
effects brain modulation along the very same lines as spatial 
memory and practice of mapping skills.
What Is the Hippocampus?
The hippocampus is a seahorse shaped structure located in the 
medial temporal lobe of the brain. It has two lobes that each 
process a different type of memory. The right lobe is mainly 
responsible for viseo-spatial memory and the left lobe primarily 
works with verbal or narrative memory (Burgess, et. al. 2002). 
However, this lateralization is general; current research suggests 
that the storage and retrieval of both types of memories, espe-
cially the spatial subset, are more universally distributed across 
the whole hippocampus. This is evidenced by “cells coding for 
the same location [in reference to viseo-spacial memory] being 
distributed over the entire hippocampus.” (Moser, Moser, 1998). 
The hippocampus is considered the center of the declarative 
memory system. Declarative memory, also known as explicit 
memory, is the type of memory that can be consciously recalled 
and put into words, such as for facts and verbal knowledge 
(Ullman, 2004). It includes “episodic memories” which are au-
tobiographical and personal, and “semantic memories,” defined 
as general knowledge about the world (Burgess et. al. 2002, 
Schachter et. al. 2009). As part of its role in declarative memory 
“the hippocampus is central to the rapid acquisition of declar-
ative knowledge about the environment, generating a so-called 
cognitive map.” (Voermans et. al. 2004). 
The cognitive map theory is the most current explanation for 
how organisms create and store memories of their environ-
ment. This theory “proposes that the hippocampus of rats and 
other animals represents their environments, locations within 
those environments, and their contents, thus providing the basis 
for spatial memory and flexible navigation.” Essentially, the hip-
pocampus builds a personal map of an organism’s environment 
Abstract
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as the organism navigates its way through it. Interaction with 
the frontal lobes of the brain “timestamps” each addition to the 
cognitive map, creating context and adding episodic character to 
the map (Burgess et. al. 2002).
The hippocampus has been observed to work in close con-
junction with the caudate nucleus of the basal ganglia, a part of 
the brain responsible for forming associations between place 
and stimulus, thus leading to habitual behaviors. Both systems 
can work together, but non-competitively, in route recognition. 
When an organism returns to a previously visited location, the 
hippocampus uses its cognitive map to help recognize the lo-
cation while the caudate contributes by recalling the person-
al memories of what occurred in this place the last time the 
organism was there. The hippocampus and caudate traverse 
different paths to come to the same conclusion: place or route 
recognition. Each are capable of recognizing a location on their 
own, via their alternative methods, but the possibility of en-
hanced recognition resulting from interaction between the two 
has been studied (Voermans et. al. 2004).
This is an example of the current trend in scientific research, 
in which many scientists study the interrelations and delocal-
ization of brain function, based on the premise that “because 
the cognitive systems of the brain work in an integrated fash-
ion, presumably the different memory systems do not work in 
isolation.” (Voermans et. al. 2004).   As such, much research has 
been done on the interactions and communication between 
the hippocampus and various other parts of the brain whereas, 
historically, focus had been placed on defining each brain area 
and its specific function. This makes focus on the morphology, 
function, and effects of one specific brain structure difficult but 
this paper will attempt to focus on the hippocampus specifically.
Methods
Information for this paper was obtained through various data-
bases made available through the Touro College library. Relevant 
Internet searches, via Google, were also used to help lead to re-
sources. Keywords included hippocampus, declarative memory, 
cognitive behavioral therapy, and brain modulation.  Textbooks 
on therapy were consulted as well. 
Discussion:
Animal Studies of the Hippocampus
The clear effects of an organism’s mapping behavior affecting 
physical changes on its hippocampus were initially observed in 
black-capped chickadees in Ithaca, NY. Chickadees are small, 
non-migratory, food-storing birds in the same family as jays and 
nutcrackers. These birds “showed a peak in relative hippocam-
pal size in October, at the same time of year that food storing 
was reported to be greatest in this population of chickadees.” 
(Sherry, Hoshooley, 2010).  This peak was specific to the hippo-
campus; two other brain areas measured for control did not 
undergo any change at all. Additionally, this change was assuredly 
due to their increased mapping activity and not the alteration in 
day length (photoperiod) that occurs in the fall, as manipulating 
the day length experienced by captive birds had no effect on 
hippocampus size (Sherry, Hoshooley, 2010). Taking this togeth-
er with previous studies that lesioned the avian hippocampus 
and observed how this specifically “disrupted memory for the 
locations of caches, because caching performance, feeding, and 
other behavior were not affected” assures the hippocampus’s 
central role in cache mapping/memory (Sherry, Vaccarino, 1989). 
Therefore, it is safe to conclude that the correlation between 
the chickadees’ behavior and their hippocampus size is causal. 
The chickadees’ food storing activity, which involves tracking 
down nuts and seeds, hiding these finds in multiple caches, and 
most importantly recalling the location of each cache, exercises 
and expands the hippocampus. 
In fact, the research team in this study worried that their ob-
servations may not be readily replicable because “in captivity, it 
may not be possible for birds to engage in enough food storing 
and cache retrieval to produce the changes in hippocampal size 
and neurogenesis observed in the wild.” (Sherry, Hoshooley, 
2010).  This concern insinuates that once a certain threshold of 
practice of this behavior is reached, the hippocampal change is 
inevitable. It also shows that certainly it is some excessive level 
of practice of these activities, food storing and cache retrieval, 
that directly enlarges the hippocampus. 
In a remarkably parallel finding, the hippocampi of Northeastern 
red squirrels, creators and hoarders of multiple caches of nuts, 
in an activity self-descriptively named “scatterhoarding,” are 
larger than the hippocampi of their close cousins, the gray 
squirrels of the West Coast. The non-hoarding gray squirrels 
have no winter to contend with and so have no need to utilize 
the spatial mapping and recall skills specific to the hippocampus 
to scatterhoard for the future when food will not be available 
(Johnson et. al. 2010). 
Notably, red squirrel hippocampus size has even been shown to 
fluctuate along with their hibernation patterns. When the squir-
rels are up and about, busily finding, hoarding, and creating mental 
maps of their caches, their hippocampi are larger than when their 
body temperature decreases to the point of initiating torpor, or 
hibernation, and thus cessation of all such activities (Millesi et. al. 
2001).  Like the chickadees, the red squirrels are clearly modulat-
ing their own hippocampi through their behavior. 
Homing pigeons, known specifically for their mapping and 
spatial skills, are a natural species to look for the hippocampal 
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growth observed in chickadees and squirrels. Citing studies 
similar to those discussed above, researcher Cnotka and her 
team hinge their study on the fact that “the hippocampus plays 
a critical role in processing spatial information both in birds and 
in mammals.” (Cnotka et. al. 2008).   And indeed, when these 
researchers examined the brains of the pigeonsthey found that 
homing pigeons possess disproportionately larger hippocampi 
for their body mass (Figure 2). A separate research team com-
pounded this research by finding “morphological and histologi-
cal differences in hippocampal tissue in homing and non-homing 
pigeons” (Shapiro, Wieraszko, 1996).
Additionally, comparing carrier pigeons that are allowed to fly, 
explore their barns, and map out new routes with pigeons that 
are confined to their cages, revealed the explorer pigeons to 
have measurably larger hippocampi (Cnotka et. al. 2008). The 
comparison between the explorer pigeons and the cage-con-
fined pigeons directly parallels the above comparison between 
the red squirrels and gray squirrels. Both directly prove that 
when an animal stresses its hippocampus, the hippocampus will 
remodulate and enlarge. 
Neurogenesis
Although it has been firmly established that animals who exercise 
their hippocampus directly affect their hippocampi’s growth, the 
cause of this phenomenon has not been determined. The team of 
researchers who conducted the study on homing pigeons admit 
just that. They write, “in our study we have not determined what 
is responsible for this increase in volume, but it would be inter-
esting to see why the hippocampus might be larger. Existing cells 
could increase their cell body size or build up larger dendritic 
arbors, new neurons or glia could be added, or there could be 
increased vascularization.” (Cnotka et. al. 2008). 
Meanwhile, the researchers who observed the hippocampus 
growth in New York chickadees were able to squarely implicate 
neurogenesis as the mechanism of growth. They did this by ad-
ministering to wild birds “injections of tritiated thymidine, [3H]
thymidine,  which is incorporated into the nucleus of mitotic 
cells” (Sherry, Hoshooley, 2010). [3H]thymidine is a commonly 
used radioactive cell marker that newly forming cells incorpo-
rate into their DNA, thus differentiating the new cells from pre-
existing cells (Toyohara et. al. 2002). The researchers then re-
leased the chickadees back into the wild. When they recaptured 
the birds, they found that “birds given [3H]thymidine in October 
had more labelled hippocampal cells when captured six weeks 
later than birds injected in August or February/March.” (Sherry, 
Hoshooley, 2010). Evidently the birds generated more cells in 
their hippocampi in October, when their scatterhoarding ac-
tivity levels were high, than in the months when they were not 
exercising their hippocampi excessively.
Neurogenesis would seem to be the most likely explanation for 
hippocampus growth but the possibility of new brain cells being 
created “on demand” should not be taken for granted. This is 
because “in most brain regions, the generation of neurons is 
generally confined to a discrete developmental period,” and so 
growth would really not be possible at any time for most areas. 
Eriksson et. al., (1998), originally demonstrated the presence of 
progenitor cells, from which newborn neurons are generated 
and so the prerequisites for new cell growth, only in specific 
parts of the brain. Among these parts was the hippocampus. 
He showed this by injecting human cancer patients with “a thy-
midine analog, BrdU [that] is incorporated into the DNA of 
dividing cells” and then after the patients died, dissecting their 
brains to find labelled cells in the denate gyrus of the hippo-
campus (Eriksson et. al. 1998). These labelled cells indicate the 
presence of new neurons, and so progenitor cells, specifically in 
the hippocampus. This finding is crucial to correlating the animal 
studies to humans and offers the mechanistic explanation for 
how the hippocampus gets bigger. It shows that new neurons 
can indeed be grown in the hippocampus and that this growth 
can be initiated at any time – including whenever mapping skills 
are exercised. Eriksson’s study essentially opened the door to 
neurogenesis and, as he ends off his report, “the potential to 
regulate human neurogenesis should prove to be an interesting 
area of investigation.” (Eriksson et. al. 1998).  The data in this 
paper enthusiastically supports this proposition.
Neuromodulation
In contrast, another research team focused on “the plastic pro-
cesses that underlie long term potentiation” as the mechanism 
by which an organism can remodel its “mental map,” or hippo-
campus. This team defines long-term potentiation as “a long-last-
ing, activity-dependent enhancement of synaptic strength that 
has been extensively studied in the hippocampus.” (Kentros et. 
al. 1998).  In their study, they observed how rats build their 
Figure 2: Coronal section through brain of homing pigeon with area 
of study, hippocampus, outlined  (Cnotka et  al  2008)
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mental maps by encoding each cell in their hippocampus with 
a different aspect of the place they are in. These programma-
ble cells were appropriately named “place cells.” It is then the 
“conjoint activity of place cells [that is] thought to be the basis 
of a map of the environment that the animal uses for solving 
spatial problems.” (Kentros et. al. 1998). With this proposition 
for the construction of the mental map in place, the researchers 
then demonstrated that place cells, and the connections and 
interactions between them, can be reprogrammed based on the 
rat’s activity. Essentially, the team demonstrated the ability of the 
hippocampus to remodulate, in addition to expand, in response 
to excessive use (Kentros et. al. 1998).
Taken together, notable hippocampal neurogenesis and neuro-
modulation correlates with the specific exercise of the hippo-
campus via practice of hippocampus-centric behaviors, namely 
those that rely on spacial mapping and recall activity. 
Onward to the Humans
Having examined how the hippocampus specific behaviors of a 
wide range of animal species cause direct growth of the hippo-
campus, and accounting for this growth with evidence for neu-
rogenesis and neuromodulation in the hippocampus, this paper 
turns to the likelihood of this causation occurring in humans as 
well. Are human brains, specifically the hippocampi, as manipu-
latable and malleable as those of rats, squirrels, chickadees, and 
pigeons? 
Blithely referencing the sum of the extensive work that we have 
examined thus far, researcher Eleanor Maguire states, “the vol-
ume of the hippocampus in nonhumans is known to vary as a 
function of the demands placed on spatial memory.” (Maguire 
et. al. 2006). With this firmly established, Maguire and her 
co-workers performed a landmark study comparing the brains 
of London taxi drivers with the brains of London bus drivers. 
London is famous for its convoluted cityscape and so its taxi 
drivers are required to spend about two to four years studying 
its design and navigating its intricacies in order to be ready to 
pass the test required to get licensed as professional drivers. The 
taxi drivers’ process to proficiency is rigorous and heavily reliant 
on the hippocampus. Just as it was observed with regard to the 
chickadees, squirrels, and pigeons, Maguire and her team report, 
“...years of navigation experience correlated with hippocampal 
gray matter volume only in taxi drivers [and not in London’s bus 
drivers], with right posterior gray matter volume increasing and 
anterior gray matter volume decreasing with more navigation 
experience.” (Maguire et. al. 2006). Since London bus drivers 
matched with London taxi drivers in “driving experience and 
levels of stress, but differed in that they follow a constrained set 
of routes,” they provided the perfect comparison group to the 
taxi drivers who must learn and then navigate “25,000 streets 
and the locations of thousands of places of interest.” (Maguire 
et. al. 2006, Woollett, Maguire, 2012) Therefore, comparing the 
taxi drivers, who must continuously re-navigate and calculate in-
tricately mapped out routes, to bus drivers, who merely retrace 
a limited set of preset routes, shows that it is specifically the 
mapping activity that remodels and expands the hippocampus. 
Maguire confirms for animals and revolutionarily proves that 
for humans as well, that to modulate the hippocampus “the key 
factor seems to be utilizing a complex spatial representation 
over years of navigation.” (Maguire et. al. 2006) 
The clear growth of the hippocampi of London taxi drivers 
in response to their spatial mapping behaviors highlights that 
humans are indeed capable of modulating their own brains. 
People who spend years stressing their hippocampi will reli-
ably enlarge them. The London taxi drivers study also shows 
that, surprisingly enough, changing one’s own brain is real-
ly not that hard. This opens for consideration the reach of 
self-induced brain manipulation. To what extent can humans 
modulate their own brains, through what activities, and to 
what benefit? 
The Relevance to Therapy
Answering these questions is of particular pertinence to psy-
chologists, specifically those who practice therapy. This is be-
cause, “if psychotherapy is regarded as a form of learning, then 
the learning process that occurs in psychotherapy may produce 
alterations [in the brain].” (Gabbard, 2000).  Researchers seek 
to highlight the physical, observable effects of therapy on the 
human brain to help prove the therapy’s efficacy. And indeed, 
multiple fascinating observations have been made. Figure 3: Hippocampal activation upon naviagtion through novel 
environments  (Maguire et  al  2002
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In 1992, a study contrasting different forms of treatment for de-
pression found that “behavior therapy and fluoxetine [a common 
antidepressant] appear to produce similar decreases in cere-
bral metabolic rates in the head of the right caudate nucleus.” 
(Gabbard, 2000). The caudate nucleus is part of the basal ganglia 
and responsible for “the acquisition of place-appropriate respons-
es leading to habitual behavior,” (Voermans et. al. 2004). While it 
does function in a memory system separate from the hippocam-
pus, the two do have comparable enough roles that in the event 
of degeneration of one, the other can compensate (as detailed 
earlier in this paper). According to this study, “both memory sys-
tems support navigational memory, albeit based on the processing 
of different representations. It has been hypothesized that both 
systems work in parallel, receiving similar input information, but 
processing this information according to principles that empha-
size different relationships among the elements of a given event 
or situation” (Voermans et. al. 2004). Importantly, the basal ganglia, 
like the hippocampus, does possess progenitor cells for growth by 
neurogenesis (Erikkson et. al. 1998). 
The similarity between the roles of the basal ganglia and the 
hippocampus help the modulation of one stand in as evidence 
for the possibility of the modulation of the other. Similar func-
tions means that similar activities will affect their size and shape. 
With the overwhelming evidence that this paper has examined 
for hippocampus-centric activities modulating the hippocampus, 
it follows that similar activities, only different in that they are 
reliant on the caudate, would modulate the caudate. If this is so 
then we can consider how the activities that the researchers 
found here to modulate the caudate, Behavior Therapy, might be 
similar to the activities that modulate the hippocampus (spatial 
memory and mapping behaviors).
Another research team comparing the effects of different men-
tal health treatment forms showed that “cognitive behavioral 
therapy appears to cause biological changes in people with panic 
disorder.” (Gabbard, 2000). These researchers first observed 
that individuals with panic disorders inappropriately release lac-
tate in response to certain stimuli. This lactate then serves to 
trigger the panic attack. The researchers treated the individuals 
with CBT and tested the CBT’s effectiveness by injecting them 
with the triggering lactate. The team saw that, after treatment, 
“the induction of panic by lactate... [was] effectively reversed 
through successful cognitive therapy. In other words, panic dis-
order sufferers in whom, before starting therapy, attacks were 
precipitated by injection of lactate no longer responded in that 
manner after therapy.” (Shear et. al. 1991).  While this study does 
not bring the physically observable effects of the therapy studied 
down to the level of the brain, it does provide another exhibit 
of therapy, an action, inducing physiologic, measurable effects. 
A similar set of results, proving that performing the actions 
proscribed by therapy induces physiologic responses, comes 
from a research group who measured the variation of certain 
hormone levels of depressed patients in conjunction with CBT. 
They “observed that in a group of outpatients with mild major 
depression, responders to cognitive behavior therapy had sig-
nificantly greater decreases in T4 levels and free T4 index than 
nonresponders” (Joffe et. al. 1996).  The researchers propose 
that this is part of the whole “cascade of biological events that 
effect a therapeutic response in depression” (Joffe et. al. 1996). 
Here the physiological effects of therapy are found in hormone 
level variation, but it is assumed that digging a bit deeper would 
reveal modulation to the brain.
The Specific Effect of Cognitive Behavioral 
Therapy
Notably, these studies all tend to refer specifically, out of all 
the forms of therapy available, to Cognitive Behavioral Therapy 
(CBT). It seems that CBT is different from other forms of ther-
apy and that it is especially effective in inducing measurable mor-
phological brain change. 
A practical guide for clinicians to employ CBT helps define this 
treatment method: “CBT is based on two central tenets: 1) our 
cognitions have a controlling influence on our emotions and 
behavior; and 2) how we act or behave can strongly affect our 
thought patterns and emotions” (Wright et. al. 2006). The cog-
nitive portion of CBT works to resolve cognitive errors that 
contribute to an individual’s disorder, such as overgeneralization 
and magnification, and the behavioral component consists of 
the patient learning and performing actual tasks such as breath-
ing modification and journaling “ (Wright et. al. 2006). CBT’s 
in-practice structure consists of four basic steps that reflect 
these principles: 1. relabel unwanted thoughts as symptoms of a 
brain disorder, 2. reattribute these thoughts to the dysfunctional 
brain, 3. change behavioral responses even though the thoughts 
are still there, and 3. revalue the thoughts as less important 
(Beauregard, 2014). Based on the evidence thus far of actual 
behaviors modulating the brain center they rely on, it makes 
sense that the action centric, goal oriented CBT would be the 
type of therapy most likely to induce brain changes. 
Dr. Aaron Beck, the founding father of CBT, stressed the impor-
tance of patient action and involvement in his or her own ther-
apy. The structure of the patient - therapist relationship, termed 
“collaborative empiricism,” expects the patient to work as an 
equal partner to the therapist in solving his or her problems. The 
patient is assigned behavioral tasks and homework assignments 
to personally, actively accomplish (Wright et. al. 2006). More than 
the therapy “being done” on the passive patient until the patient’s 
problems are fixed, in the CBT model the patient is taught how to 
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remodel his or her own beliefs in conjunction with being told to 
perform self-driven actions. It is through fastidious participation 
and performance of these actions that the patient is “fixed.”
Evidently, the actions proscribed by CBT rely on the hippocam-
pus because, as this paper began to describe, multiple studies 
correlate the effectiveness of CBT with enlargement or modu-
lation of the hippocampus. This relationship has been observed 
in patients treated with CBT for panic disorder (Beauregard, 
2014), social phobia (Goldapple et. al. 2004), obsessive-com-
pulsive disorder (Goldapple et. al. 2004), post-traumatic stress 
disorder (Levy-Gigi, Keri, 2014), spider phobia (Paquette et. al. 
2003), and depression (DeRubeis et. al. 2008). And so, just as 
the London taxi drivers’ spatial mapping behaviors modulated 
their hippocampi, the active CBT patient evidently relies on the 
hippocampus when he or she performs the CBT-assigned tasks 
and thereby enlarges his/her hippocampus. 
CBT for Depression
An illustration of CBT’s effect on the brain can be found in 
a clinical study comparing the effects of CBT and paroxetine 
(a standard antidepressant) on the depressed brain. Based on 
the premise established by multiple clinical trials “in patients 
with both mild and severe major depression consistently 
demonstrate similar rates of response to cognitive behavior 
therapy (CBT) and antidepressant pharmacotherapy,” a team of 
researchers hypothesized that, while the observable effects of 
these two treatments are practically identical, their mechanisms 
of action are likely very different (Goldapple et. al. 2004). After 
administering a full course of CBT to a sample of depressed pa-
tients, the researchers imaged the patients’ brains (Figure 5) and 
indeed found a pattern very distinct from that of paroxetine. 
They found that “areas of increased metabolism before to after 
treatment included the hippocampus and dorsal midcingulate” 
and that the changes effected by CBT were actually in the in-
verse direction of those caused by paroxetine (Goldapple et. al. 
2004). CBT treatment effected “regional changes [that] involve 
sites similar, and in some cases identical, to those seen previously 
with paroxetine and other pharmacotherapies, but the changes 
were in the opposite direction.” (Goldapple et. al. 2004). Where 
paroxetine decreased hippocampus size and connectivity, CBT 
enlarged it. Therefore, it is seen that modulating the hippocam-
pus is a unique, effective method for treating depression that is 
distinctly accomplished by CBT. Notably, CBT was seen here to 
both expand and remodulate the hippocampus.
However, it seems that opposite conclusions were observed 
in a separate imaging study. Here, “MDD [Major Depressive 
Disorder] participants displayed a greater activation in the sub-
genual cingulate cortex, medial PFC, and left anterior hippocam-
pus/amygdala before treatment, and a reduction in these brain 
regions after long-term psychodynamic therapy.” (Beauregard, 
2014). Essentially, the research team here saw therapeutic in-
tervention shrink the hippocampus! A possible explanation 
for this opposite observation is the use of a different therapy, 
not CBT in particular, as intervention. Perhaps its mechanism 
is like that of paroxetine, which helps alleviate depression but 
via a pathway that modulates the brain into a pattern inverse 
to that of CBT (Goldapple et. al. 2004). Therefore, rather than 
confounding conclusions formed thus far, this contradictory ob-
servation can help reinforce the special effect CBT alone has on 
the hippocampus.
CBT for PTSD
A separate research team headed by Levy-Gigi examined the ef-
fects of CBT on the brains of patients suffering from PTSD. They 
found that “morphological changes associated with psychother-
apy were confined to the hippocampal formation and cingulate 
cortex.” (Levy-Gigi, Keri, 2014). PTSD is especially relevant as it 
has long been specifically correlated with smaller hippocampal 
size. Researchers in 1997 “showed that the left hippocampal 
volume in adults with post-traumatic stress disorder who had 
experienced childhood physical and sexual abuse was dramat-
ically reduced when compared to that in matched controls.” 
(Gabbard, 2000). Therefore a treatment that directly enlarges 
the hippocampus would likely be especially effective. 
Indeed, Levi-Gigi’s team reports that “the most noteworthy 
finding of this study was that clinical improvement during CBT 
in PTSD was associated with increased hippocampal size and 
elevated FKBP5 gene expression, a cellular regulator of the 
glucocorticoid receptor.” (Levy-Gigi, Keri, 2014). First, confir-
mation of the way CBT enlarges the hippocampus is proffered. 
Second is the introduction of the gene FKBP5, a “regulator 
protein of the cortisol receptor and [since] abnormal cortisol 
secretion is linked to hippocampal atrophy, it is reasonable to 
hypothesize that the amelioration of FKBP5 gene expression 
had a causal role in the normalization of hippocampal volume.” 
(Levy-Gigi, Keri, 2014). This hypothesis says that elevated levels 
of this particular gene, FKBP5, can be aligned with and seen as 
confirmation for hippocampal enlargement.
Levy-Gigi and her associates also returned to the previous dis-
cussion on what exactly is behind the hippocampal enlargement 
observed, considering how “possible mechanisms may be en-
hanced neurogenesis, increased neuronal size, and enrichment 
of dendritic arborization.” (Levy-Gigi, Keri, 2014).  According to 
the evidence examined previously, it is likely that the progeni-
tor cells observed in the hippocampus, and so neurogenesis, is 
the mechanism behind the hippocampal growth observed here. 
Neuromodulation, or the reconnectivity and recharacterization 
of hippocampal cells, likely occurred as well.
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CBT for Spider Phobia
Anxiety disorders, such as phobias, respond well to CBT inter-
vention. This is because anxiety disorders typically include and/
or come from cognitive errors that CBT can specifically target 
and solve (Wright, 2006). One specific phobia studied in con-
junction to CBT is spider phobia. The team behind the spider 
phobia study says that “although several psychological models 
have been proposed to explain the therapeutic effects of CBT, 
little is known regarding the neurobiological mechanisms un-
derlying this form of psychotherapy.” (Paquette et. al. 2003). To 
investigate this matter they administered CBT to a sample of 
spider phobic females, all of whom were deemed responders 
to this intervention. However, when the researchers examined 
the brains of their spider phobic subjects (via fMRI) before and 
after CBT, they found a decrease in hippocampus activity. Before 
intervention they found an overactivation of the hippocampus 
and after intervention they found this overactivity greatly de-
creased. This finding directly confounds the extensive research 
examined and discussed thus far. Therefore, the generalizability 
and validity of this study must be questioned.
The Connection Between Declarative Memory, 
the Hippocampus, and CBT
As laid out in the beginning of this paper, the hippocampus is 
considered to be the center of declarative memory, which is the 
collection of conscious memories people are capable of artic-
ulating. The foil to declarative memory is procedural memory, 
the contents of which are implicit, operating outside of con-
scious awareness (Gabbard, 2000). New research has begun 
to understand the effects of talk/ interpersonal therapy and 
psychoanalysis to be in the procedural, implicit realm. Sigmund 
Freud, father of psychoanalysis, himself alluded to implicit mem-
ory years before the concept was defined when he “stressed 
that what the patient does not remember will be repeated in 
the relationship between patient and analyst.” This concept is 
defined as “transference,” and in light of modern psychology can 
be seen as stemming from implicit memory (Gabbard, 2000). 
The patient in therapy will be implicitly affected by the therapist 
and his or her relationship to the therapist. Characteristic of 
this, he or she will not be able to explicitly articulate the effects 
of the psychoanalysis or psychotherapy even though he or she 
will exhibit behavioral change.  
Illustrating this concept is the lament of psychiatrist Gabbard: 
“therapists are often disappointed when they see former pa-
tients and ask them what they feel was of most benefit to them 
during the years they were in psychotherapy. Much to the dis-
may of the therapist, patients often do not remember any of 
the psychodynamic formulations or interpretations that the 
therapist carefully constructed to provide insight. Instead, they 
remember a joke the therapist told, a belly laugh they shared, 
a moving moment of emotional connection, or a glance ex-
changed between therapist and patient when a special form of 
closeness was felt.” (Gabbard, 2000). 
Psychologist Lyons-Ruth interprets these moments in therapy 
as a form of “implicit relational knowing when something emo-
tionally reparative transpires without involving the realm of in-
sight or cognitive understanding.” (Lyons-Ruth et. al. 1998). She 
and her colleagues believe such moments are a crucial part of 
the mode of therapeutic action. Alteration of implicit/ procedur-
al memory and the manipulation of the manifestations of these 
types of non-declarative memories, such as transference, seems 
to be characteristic of all therapies besides for CBT. 
CBT is unique in that it specifically targets explicit memory, 
rather than implicit memory. CBT does not attempt to grope its 
way through the murky depths of the subconscious, non-declar-
ative, implicit realm. Rather, as illustrated above, CBT’s two 
central focuses are on understanding and controlling cognition 
alongside altering behaviors in order to affect emotions and 
thoughts. Both these actions are necessarily declarative as they 
rely on the patient’s explicit understanding, self-motivation, and 
complicity. 
The hippocampus is the center of the declarative memory sys-
tem and, stemming from this role, is its spatial mapping respon-
sibilities. Therefore, the linkage between the identical effects of 
spatial memory/ mapping skills and CBT on the hippocampus 
is their reliance on declarative memory! Both make excessive 
use of the hippocampus and so enlarge it. The scatterhoarding 
squirrels, the homing pigeons exploring their barns, and the taxi 
drivers navigating London make use of the same exact mem-
ory modality and brain system as the traumatized, phobic, or 
depressed patient carrying out CBT-proscribed actions. Both 
groups over-rely on the hippocampus, in its declarative memo-
ry role, and so the same pattern of hippocampus enlargement 
emerges in both.  
The diverse areas of research explored in this paper converge 
on the central point that exercising the hippocampus, via exag-
gerated practice of the skills and behaviors that it is responsible 
for, effects its measurable modulation and growth. The pointed 
use of the hippocampus’s cognitive map function by the black-
capped chickadees, the red-tailed squirrels, the homing pigeons, 
and the rats enlarged the hippocampus in each species. When 
the London taxi drivers exaggeratedly employed their parallel 
cognitive maps to navigate the city, they enlarged their hippo-
campi as well. Intensified use of the hippocampus in terms of its 
explicit memory responsibilities by CBT patients modulated the 
hippocampus along the very same lines. The search for an under-
lying feature to relate these actions leads to the very definition 
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of the hippocampus: the center of declarative memory. All of the 
parties discussed in this paper evidently over-employ declarative 
memory, and so the hippocampus. 
Further Research and Conclusion
Based on the observations and correlations in this paper, further 
research could examine if or how other areas of the brain could 
be modulated. The declarative memory - hippocampal growth 
correlation is so clear and definitive that there must be similar 
trends in other areas of the brain. This paper has already ob-
served that similar modulation is possible in the caudate nucle-
us. Perhaps identifying the specific skill that a different brain area 
is responsible for and then excessively practicing this skill would 
modulate or enlarge the corresponding brain area as well. 
Further research could also examine whether the correlations 
in this paper could be looked at in reverse. Could invasively 
entering the brain and somehow forcibly enlarging the hippo-
campus effect an increase in spatial/mapping memory or explicit 
memory? And, assuming this enlargement were possible, could 
it be used as therapeutic intervention for the same patients that 
typically benefit from CBT? 
Viewing the relationship in reverse has already been ventured 
towards by Maguire, the researcher who studied the hippo-
campal enlargement of London taxi drivers. She proposed “ex-
amination of the characteristics of those who succeed at taxi 
driver training, and [asking] whether innate pretraining cognitive 
factors and/or hippocampal volume are predictive of successful 
qualification.” (Maguire et. al. 2006). In other words, do individ-
uals with naturally larger or more malleable hippocampi, and so 
an inborn propensity for spatial memory, gravitate towards jobs 
that benefit from this characteristic, such as taxi driving?  
The researchers who studied the effects of CBT on PTSD also 
mentioned viewing the correlation they observed in reverse. 
They proposed the “possibility that small hippocampal size is a 
premorbid vulnerability factor for PTSD” (Levy-Gigi, Keri 2014), 
looking at the hippocampus size first and the effects that follow 
after. If a smaller hippocampus could predispose an individual 
to disorders such as PTSD, then perhaps a larger than average 
hippocampus could protect them from this and other hippo-
campus-centric mental disorders. While still strictly conjecture, 
research on and validation of this theory might then lead to 
hippocampal enlargement becoming standard intervention for 
individuals deemed at risk for mental disorders correlated to 
the hippocampus. Having observed diverse correlations and 
multiple angles, this paper concludes with the vast potential for 
practical implications that may arise as researchers begin align-
ing and synthesizing some of these ideas. 
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Introduction
Long flights across several time zones can result in jet lag, sim-
ilar to what is known as travel fatigue. The effects of this jet 
lag are caused by the tight space of the aircraft, limit of food 
options, dehydration from the dry air, as well as climate and 
lighting changes. The consequences of such jet lag increases with 
every additional time zone crossed, as the internal body clock 
is unable to adjust properly. This can result in the inability to 
sleep at night and improperly timed daily functions. Circadian 
rhythms, the internal bodily processes that follow an approxi-
mately 24 hour biological clock, require an adjustment period 
to correct the negative effects of jet lag. Natural clocks follow 
a morning-night schedule which allows a person to function 
during daytime and reboot at night. Jet lag can cause a disorder 
in this natural system. Prolonged and repeated travel over time 
zones have been linked to health problems such as depression, 
irregular menstrual cycles, diabetes, fluctuating melatonin secre-
tion, as well as other issues. Upon arrival to the new destination, 
the traveler should attempt to regulate his biological clock to 
the local time zone. Planning ahead will assist the traveler to 
maintain a healthy balance of the body’s internal functions.. The 
goal of this paper is to understand what jet lag  is, how it occurs, 
and how the internal biological clock can be adjusted to relieve 
or avoid the symptoms.
Methods
Research articles were obtained from the Touro Library da-
tabase (tourolib.org), which lead the student to various sites 
including ProQuest, PubMed, among others. The articles were 
compiled from an assortment of science journals and exper-
imental studies that discussed the definition of jet lag and its 
symptoms, the explanation of a body clock and its makeup, with 
testing and trials to prove the connection between the two. 
Each article was reviewed intensely, and the findings were sub-
sequently arranged into a comprehensive paper in order to fully 
describe the term jet lag.
Discussion
Jet lag, also known as circadian dyschronism, is a temporary 
syndrome characterized by various physiological and psycho-
logical effects that occur following flights across several time 
zones, most likely resulting from circadian misalignment in the 
body. An assortment of symptoms have been linked to jet lag, 
including fatigue, coexisting with insomnia, irritability, disorienta-
tion, headaches, loss of concentration, gastrointestinal problems, 
such as: indigestion, loss of appetite, among others. Comparing 
the studies can be challenging due to the lack of jet lag symp-
toms. Yet, fatigue, difficulty concentrating, decreased alertness 
during the day, weakness, and lethargy have been found as con-
sistent effects (Waterhouse et al, 1997). 
The word ‘circadian’ originates in the Latin ‘circa dia,’ which 
means ‘about a day,’ because circadian rhythms do not equal 
exactly 24 hours, but vary in that range by each organism. These 
unalterable rhythms are caused by the constant ticking of the 
body’s biological clock in the brain and other organs, and there-
fore keep many aspects of our body in sync - specifically behav-
ior, metabolism, and physiology (Rosbash, 2003). Jet lag results 
from these circadian rhythms breaking out of their natural har-
mony when the body clock is unadjusted from traveling a great 
distance. Our sleep/wake cycles seem to be the most disturbed 
by the journey.
Crossing three or more time zones is what generally causes 
the desynchronization associated with jet lag. The more time 
zones crossed, the more severe the jet lag will be. Jet lag will 
not occur from traveling north or south. Interestingly, it will be 
worse from eastward travel than westward since traveling west 
extends the day, thereby allowing for easier correction. After 
a flight east, travelers are not tired during the local nighttime, 
which is daytime for their unadjusted body clock, but they get 
tired as the new day dawns, as it is nighttime for their body. 
After a flight to the west, people are more tired in the new 
evening at their destination and yet they awaken early. Although 
this also a challenging transition, the traveler will be able to go 
about his day and settle in (Waterhouse et al, 2007). In one 
study, subjects flew between Europe and the United States, over 
a 6 hour time difference, and those who traveled on a west-
ward flight adjusted back to peak performance in about 2-4 
days. Meanwhile, those who traveled eastward required 9 days 
to recover, because instead of shortening the day by 6 hours, 
most of the travelers’ internal clocks were delayed by 18 hours 
(Coleman and Kim, 1998). 
The body clock is located on the suprachiasmatic nucleus 
(SCN), which is connected directly to the retina and receives 
information about light from the eyes, as well as having recep-
tors for melatonin type 2. Without external inputs and rhythmic 
time prompts, the body clock and its daily rhythms can contin-
ue, but with a period not exactly 24 hours, as circadian means 
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about 24 hours. Regardless of the exact amount of time, for the 
body clock to function properly it must be adjusted to the solar 
day via recurring signals in the environment, known as zeitge-
bers - time-givers. 
A zeitgeber’s effect on the body clock depends on the time 
at which it presents; a zeitgeber can produce a phase advance, 
phase delay, or no phase shift. A phase-curve response is the 
relationship between the time the zeitgeber is presented and 
the phase shift. The chief zeitgeber is the light-dark cycle and 
the secretion of melatonin when a person is asleep at night. 
The product of one’s environment and lifestyle, the exogenous 
component, together with the body clock, the endogenous 
component, form a healthy rhythm when they are in sync. 
However, the span of days after a time zone transition causes 
the rhythm to falter, because while the exogenous component 
has changed, the endogenous component has not yet caught up 
to it. Theoretical statistics evaluate rhythms before and after a 
time zone transition, showing the loss of synchronization. The 
external light is being sent through the retina and is telling the 
body that it is daytime, but the internal body clock still feels as 
if it is meant to be nighttime, and therefore jet lag reigns. Table 
1 advises when exposure or avoidance of bright light will assist 
in correcting the body clock upon arrival at the new time zone. 
It is based on the observation that light in the morning of body 
time will advance the clock, and in the evening of body time will 
delay it. These times may not coincide with actual day or night, 
and so wearing sunglasses or seeking a light box that mimics the 
sun may be necessary to keep the biological clock in its sync 
(Waterhouse et al, 1997).
Table 1. Use of bright light to adjust body clock on first day after time 
zone transition:
Bad local times for exposure 
to bright light
Good local times for exposure  
to bright light
Time zones 
to the west
4 h 0100-0700* (1:00 - 7:00 am) 1800-2400+ (6:00 pm - 12:00 am)
8 h 2100-0300* (9:00 pm - 3:00 am) 1400-2000+ (2:00 - 8:00 pm)
12 h 1700-2300* (5:00 - 11:00 pm) 1000-1600+ (10:00 am - 4:00 pm)
Time zones 
to the east
4 h 0200-0800+ (2:00 - 8:00 am) 0900-1500* (9:00 am - 3:00 pm)
8 h 0600-1200+(6:00 am - 12:00 pm) 1300-1900* (1:00 - 7:00 pm)
12 h @ @
*Will advance to body clock  +Will delay the body clock 
@Treat as 12-14 h to the west, since the body clock adjusts to delays more easily than 
to advances Source: Waterhouse et al, 1997
This concept of an endogenous clock following circadian 
rhythms has been around for centuries. A French astronomer 
named Jean Jacques d’Ortous de Mairan conducted a simple 
experiment on a mimosa plant, which he knew to be a helio-
trope. He saw that it was also responsive to the sun by raising 
its leaves during the day and drooping upon the fall of darkness. 
De Mairan put a mimosa plant into a cupboard to observe its 
reactions when kept in the dark. He noticed that the leaves 
still continued to open and close rhythmically, seemingly by its 
own internal interpretation of night and day. His clear-cut find-
ing from this was that the plant had an endogenous component 
with an internal biological clock (Foster and Kreitzman, 2014).
Baron and Reid describe circadian misalignment very clearly: 
“The term ‘circadian misalignment’ can describe a variety of 
circumstances both in the laboratory and natural environment. 
In the Oxford Dictionary (2010), ‘misalignment’ refers to ‘the 
incorrect arrangement or position of something in relation to 
something else.’ One of the most common types of misalign-
ment studied is misalignment of the sleep/wake cycle in relation 
to the biological night. Other types of misalignment include 
misalignment of feeding rhythms to the sleep/wake or light/
dark cycle, or internal misalignment of central and peripheral 
rhythms. Figure 1 presents a schematic depiction of the orga-
nization of the central and peripheral circadian rhythms. This 
diagram includes zeitgebers (light, melatonin and activity) as well 
as the potential causes of chronic circadian misalignment.
The timing of melatonin onset under dim light conditions (dim 
light melatonin onset or DLMO) and the core body tempera-
ture minimum are often used as markers of circadian timing. 
The timing of these circadian markers in relation to sleep/wake 
behaviors is commonly referred to as phase angle, and has also 
been used as a measure of circadian alignment. For example, 
the duration between circadian markers (DLMO or core body 
temperature minimum) and sleep timing (onset, midpoint or 
wake time) has been evaluated. Individuals with evening chrono-
type (preference for later timing of sleep and activity) have been 
shown in some studies to have a shorter phase angle between 
circadian markers and sleep, indicating that they sleep and wake 
earlier in their circadian phase. One of the most significant and 
immediate consequences of misalignment of the sleep/wake 
cycle to the biological night is sleep disturbance and/or day-
time sleepiness. Insomnia, difficulty waking in the morning and 
Figure 1
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sleepiness caused by circadian misalignment are typical symp-
toms that lead patients to seek care in sleep clinics for cir-
cadian disorders. However, the physiological and psychological 
consequences are much broader than sleep/wake disturbance. 
These include changes in feeding patterns, metabolic function 
and risk for mood disorders. Other types of disruption include 
internal misalignment of rhythms, such as timing of central ver-
sus peripheral clocks. For example, research in animal models 
has demonstrated that altering availability of food timing shifts 
peripheral (e.g. hepatic) but not central rhythms.” (Baron and 
Reid, 2014).
There are many bodily processes controlled by day-night 
rhythms, such as blood pressure control, feeding behaviors, and 
lipid and carbohydrate metabolism, among others. The circadian 
clock, a continuous internal system of transcriptional loops, is 
what controls this regulatory biological movement, and these 
looping pathways balance each other out. In example, transcrip-
tion factors such as Clock and Bmal1 control the assembly of 
proteins like Per and Cry, which then regulate the assembly of 
Bmal1, resulting in the levels of Bmal1, Clock, Per and Cry fluc-
tuating regularly. Various input signals, zeitgebers like light and 
hormones, can change these loops and ‘reset the clock’ so to 
speak (Staels, 2006). In another study of two groups of travelers, 
after a flight with a 6 hour difference one group remained inside 
a lab for a week while the other group spent time outside. The 
group that went out adapted to the new time zone in half the 
time that the indoor group needed. Local time cues, like light-
dark cycles and meal times, among others, are what allowed the 
second group to synchronize quicker (Coleman and Kim, 1998). 
The concept of “social jet lag” has been mentioned in current 
research as well. This is a form of persistent circadian disruption 
that corresponds to the time difference between routine sleep 
cycles during the work/school week and free time on weekends. 
It is a weekly discrepancy in the internal body clock, which can 
be comparable to journeying across three to four time zones 
twice a week for someone who wakes up at 6:00 AM during the 
week and sleeps until 9:00 or 10:00 AM on the weekend. There 
has been discovered an association in the affirmative between 
the extent of this “social jet lag” and body mass index, suggest-
ing yet again that the interference of circadian cycles contrib-
utes to weight gain, among other possible issues (Summa and 
Turek, 2015).
It all seems to come down to the body clock and its adjustment. 
But what does that truly mean? What is this clock? It was first 
believed that there was a single master clock in the suprachias-
matic nucleus in the brain which regulated numerous biological 
processes within the body. It was later discovered that there are 
additional peripheral clock genes in the liver, kidneys, pancreas, 
heart, and other tissues. We now know that these clocks man-
age the activity of three to ten percent of genes in various tis-
sues, and in some cases maybe even as much as 50%. If any of 
these clocks fall out of sync with the master clock, which is 
possible from sleeping at the wrong times, the frenzy within the 
body can lead to obesity, diabetes, depression, and many other 
complicated disorders. The clock gene in the heart sends signals 
in the early morning to prepare the heart for the harshness 
of awakening, an explanation as to why so many heart attacks 
occur at dawn hours. The peripheral clock in the liver functions 
strongly with the metabolism, contributing to the regulation 
of normal blood glucose levels over the course of the day to 
make certain there is a steady flow of energy for brain function 
and body processes. There is still a system required to combat 
excess blood glucose due to eating, with insulin the primary 
hormone in charge of that regulation by starting the remov-
al of glucose from the bloodstream. Insulin is produced in the 
pancreas, where there is another biological clock that is vital 
to sustaining normal blood sugar levels. Any disruption of that 
clock can damage pancreatic function and result in diabetes, a 
metabolic disorder in which the body produces too little insulin 
and causes irregularities in blood glucose levels. An experiment 
was done by Marcheva and Bass in which pancreatic tissue from 
mice with mutations in circadian clock genes were isolated and 
examined. They observed that the amount of insulin secreted in 
response to a glucose stimulation decreased dramatically. They 
then bred mice with their pancreatic clocks deleted, and these 
offspring mice developed diabetes early in life and showed a 
drastic reduction in insulin secretion. Another experiment with 
mice allowed the scientists to observe a connection with Night-
eating Syndrome, a disorder in which people would consume 
an excessive amount of food at night and develop obesity and/
or metabolic syndrome. It was thought that this condition may 
be resultant of a deficiency in managing the circadian timing 
of hunger, causing patients a predisposition to weight gain and 
metabolic misalignment. These examples just provide further 
evidence for the fact that the multiple clocks throughout the 
body are required to maintain equilibrium by synchronizing 
their timing, all based on the leading master clock (Foster  and 
Kreitzman(2014),. any disruption causes a multitude of health 
issues, including heart and stomach issues, neurological diseas-
es and psychiatric illnesses among others (Summa and Turek, 
2015). Due to the fact that circadian rhythms don’t follow an 
exact 24 hour schedule, they have the ability to ‘reset,’ or shift, 
the phase in response to environmental time cues. The central 
clock in the SCN is mainly reset by light, owing to its direct 
pathway to the retina. The peripheral clocks, as mentioned 
above, are controlled by various signals from the SCN clock. 
For example, melatonin synthesis in the pineal gland, mentioned 
in depth below, is mainly affected by the light-reliant SCN clock, 
with nocturnal secretion (Wu et al, 2011).  
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The core body temperature (CBT) and melatonin secretion, 
as mentioned above, both play key roles in the body’s natu-
ral ability to follow a healthy sleep/wake cycle. Professor Jim 
Waterhouse wrote in the British medical journal The Lancet 
that “the ease of getting to sleep and staying asleep depends not 
only on the previous wake time, but also on associations with 
the circadian rhythm of core temperature. Sleep is easiest to ini-
tiate when core temperature is falling rapidly or is at its lowest 
and most difficult when body temperature is rising rapidly or is 
high. Waking is the opposite of sleep initiation, because it hap-
pens when core temperature is rising or is high.” (Waterhouse 
et al, 2007). In healthy people, core temperature will reach a 
low point between 3:00 and 5:00 AM, during which time most 
people are asleep, and steadily begins to increase at about 6:00 
AM, reaching a climax at midday when most people are awake 
(Brody, 2007). CBT measurement is a standard physiological 
method for studying circadian rhythms, because its rhythm has 
been determined to be the most reliable endogenous circadian 
oscillator. Hamilos et al performed an experiment of CBT in 
patients with Chronic Fatigue Syndrome and documented that 
“the rhythm of CBT should be a valid benchmark for which 
to compare other circadian rhythms for desynchronizations” 
(Hamilos et al, 2001). There has also been a parallel seen be-
tween core body temperature and mental performance - per-
formance rises with rising temperature throughout the early 
hours of the day, allowing for peak performance, and as it gets 
later, tasks that require central processing and short term mem-
ory decline due to the falling evening temperatures. There have 
also been changes in mood and performance observed under 
different groupings of the time of day and the amount of time 
awake, with more deterioration in mental performance with 
sleep loss (Waterhouse et al, 2007). Melatonin, produced mainly 
by the pineal gland and then secreted into the bloodstream, is 
a hormone that is secreted mostly at nighttime, when it is dark, 
seeming to stimulate the body to sleep. When there is trouble 
sleeping, oral ingestion of the chronobiotic drug melatonin can 
assist in inducing sleep. A phase response curve, which describes 
the relationship between a stimulus and a response, is the re-
sulting reaction to melatonin ingestion, shows that taking it in 
the morning will cause a delay in circadian rhythms, and taking 
it at night will cause an advance in them. This phase response 
curve is about 12 hours out of phase, with the phase response 
curve of light, which would cause a phase advance in the morn-
ing and a phase delay at night (Brown et al, 2009). It seems that 
the circadian clock regulates the timing of melatonin secretion, 
although darkness is necessary as well because light will inhibit 
the secretion. After a long flight, the SCN-generated night-time 
cue will be set to the home nighttime before the clock adjusts, 
and thus if a traveler will enter a dimly lit room when it is night-
time at their home, melatonin secretion can occur and cause 
sleepiness (Sack, 2009). But taking melatonin in the evening and 
remaining in somewhat darkness can aid in falling asleep, which 
can additionally help acclimate the body to the local sleep/wake 
schedule. A word of warning for female travelers: interaction of 
melatonin and menstrual hormones can lead to a stop of the 
menstrual cycle. Female athletes can even be at a health risk 
from this, since many of them already have stalled cycles due to 
“overtraining” (Reilly et al, 1996).
In reference to athletes, there was a study done on elite athletes 
that recorded sleep loss and mood changes after long distance 
flights. Athletes that traveled more than five time zones to the 
west showed shifts in performance, including grip strength and 
back and leg endurance, which were in phase with their un-
adjusted body clocks. A similar result was seen in a group of 
Olympic athletes who journeyed over ten time zones to the 
east. It was even observed that for several days after an east 
or west flight over six to eight time zones, the athletes had dis-
torted grip strength and weak performances in training sessions 
(Waterhouse et al, 2007).
Now that is it understood what jet lag is and the extent of its 
affects, counting the misalignment of the internal body clock, 
what can be done to alleviate the dyschronism symptoms? 
There are a number of ways to attempt to prevent jet lag, as 
well as suggestions for adjusting the body clock to combat the 
desynchronization once it emerges.
Trip planning can play a major part in prevention of jet lag. If pos-
sible and extra stress would not be caused, stopovers should 
be included in the flight plan. Breaking up the number of time 
zones being crossed by having a stopover can greatly diminish 
the likelihood of jet lag. Keeping hydrated is also necessary to 
counteract the dry air of the flight cabin (Waterhouse et al, 
1997). Also, unless it is nighttime at the destination, sleep should 
be avoided during the flight, as it can anchor the rhythms to the 
home time zone. Staying on home time by remaining concurrent 
with one’s circadian rhythms won’t allow the internal clock to 
be disrupted; however it seems to make sense only for short 
trips. Supposedly, this approach was employed by President 
Lyndon B. Johnson when he met with Vietnamese leaders. This 
may be difficult, but if possible it can help avoid majority of jet 
lag symptoms. Conversely, coordinating with the local time of 
the planned travel location, from the get go can adjust the clock 
quicker and avert negative effects of the journey. This can be 
done by eating meals by the local schedule, going out in the 
daytime, going to bed at a reasonable time for the local environ-
ment, etc. A sleeping pill may be required the first night to assist 
in an easy transition, but hopefully after that the adjustment will 
continue smoothly (Coleman and Kim, 1998). Melatonin, which 
we have seen to be a somewhat ‘darkness signal,’ can be helpful 
in aiding clock acclimation, since it has the ability to induce sleep 
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when necessary. However, the dosage is unclear, and it would 
seem that the timing of administration is more relevant than 
the actual amount. In addition, a boost in caffeine consumption 
may combat daytime tiredness; however caution is required so 
as not to aggravate insomnia. Exercise has been proposed to 
alleviate jet lag symptoms, but it has not been studied in clinical 
trials (Sack, 2010).
Conclusion
From the research obtained, it is evident that jet lag has no 
exact, scientific definition, but that it is a lack of synchroniza-
tion of the body’s internal clocks and the external environment. 
It can take a few days following flight travel over several time 
zones for the body’s circadian rhythms to realign. Repeated trav-
el over an extended period of time can have the same long term 
consequences as those of shift workers - extended desynchrony 
with persisting symptoms that exacerbate with age. Resetting 
the clock requires zeitgebers, the most integral of which by far 
is the fluctuation of light and darkness. Adjusting is the primary 
goal to adequately offset jet lag. To do this, travelers should set 
up a specific itinerary of predetermined sleep and activity times, 
meal schedules and exposure to light versus remaining in dim 
lighting. The quicker the circadian system acclimates to the new 
time zone, the shorter the symptomatic period of jet lag will be. 
Assistance from the hormone melatonin may be necessary, a 
chronobiotic which adjusts the timing of the central body clock. 
Recently the drug called modafinil, meant to resist the tendency 
to fall asleep, has been registered for use in shift work sleep 
disorder, and although no records deal with its use in jet lag, 
the two have similarities and so perhaps this drug would aid 
in preserving daytime alertness (Arendt, 2009). Each individual 
must know his body and research the best methods for him to 
avoid or resolve jet lag.
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Introduction
Parkinson’s disease was first formally written about in 1817, by 
a prestigious English doctor, James Parkinson. He published a 
short pamphlet about the disease titled, “An Essay on Shaking 
Palsy”. In the beginning of his paper he describes the symptoms 
of the disease as “involuntary tremulous motion, with lessened 
muscular power parts not in action and even when supported; 
with a propensity to bend, with trunk forwards and to pass 
from a walking to running pace; the senses and intellect being 
uninjured”. (Elis, 2013) Parkinson was not the one who discov-
ered the disease as there are sources referencing the disease 
dating back to the ancient Egypt and Mesopotamia. (Raudino, 
2012) As time, technology, and science advanced, scientists and 
medical professionals were able to further understand the caus-
es and symptoms of the disease. Treatment options for those 
suffering from Parkinson’s are as diverse as its symptoms. With 
the advent of modern technology, there are new and innova-
tive treatments that are becoming available. One of these new 
treatments is Deep Brain Stimulation (DBS). As with all new 
treatments, one has to assess its effectiveness, its side effects 
and how it compares with old methods of treatment. This paper 
will address these issues in relation to DBS and its treatment 
for Parkinson’s disease.
Methods
This systematic review was composed after reviewing relevant 
journal articles about the subject matter. Articles used discussed 
causes of the disease, current treatment methods and alterna-
tive surgical interventions. Articles were obtained using search 
engines like Proquest and MedLine and articles from published 
journals.
Background
Prior to exploring treatment options, one must thoroughly 
understand the disease and its causes. Parkinson’s has many 
different causes, some rooted in genetics, others in chemical 
imbalances. The genetic cause for this disease has been shown 
to include five different genes. (Pchelina, et. al. 2014) The first of 
these genetic proteins is ⍺-synuclein, a neuronal protein which 
serves an unknown function. These proteins aggregate in the 
Lewy bodies, causing researchers to conclude that they play 
a major role in the protein composition of the Lewy bodies. 
Although mutations within ⍺-synuclein are relatively rare; even 
patients with sporadic PD seem to exhibit protein aggregates in 
the Lewy bodies, leading researchers to believe that ⍺-synuclein 
plays a major role in both genetic and sporadic forms of PD. 
Several independent family studies done on groups of people 
with PD show that ⍺-synuclein mutations are a rare cause of 
PD. The largest analyses done on ⍺-synuclein and PD indicated 
that allele length variability is associated with an increased risk 
for PD. (Pihlstrøm, Toft, 2011).
Mutations in the gene encoding parkin, a 465 amino acid chain 
protein is one of the causes of autosomal recessive PD. Parkin 
mutations in familial PD suggest that the ubiquitin-protease sys-
tem has an important role in the disease. (Pickrel, Youle, 2015)
Mitochondrial abnormalities are also thought to cause the dis-
ease. These abnormalities lead to a failure of cellular energy 
production and increased free radicals. The newest gene dis-
covered which confirmed these hypotheses is the PINK1 gene. 
(Pickrel, Youle, 2015).
Another gene associated with Parkinson’s is the DJ-1 protein. 
Although its exact function is unknown, it is thought to help 
with proper protein folding. DJ-1 protein may be linked to ab-
normalities in the protein control system. Other studies show 
that DJ-1 mutations may lead to increased levels of oxidative 
stress. (Pchelina, et. al. 2014).
PD is not caused by genetic factors, although genetic factors 
increase one’s risk for developing the disorder. Sporadic PD 
is when there are multiple genetic alterations which increase 
the risk of developing PD, but they do not cause PD. One such 
risk factor is prevalent among Ashkenazi Jews carrying the GBA 
gene mutation. Those who do have a GBA mutation are seven 
times more likely to develop the disease when compared to 
healthy control groups. (Feany, 2004).
The most common cause for PD is from the progressive loss 
of dopaminergic neurons in the substantia nigra pars compac-
ta. Motor symptoms appear when approximately 50%–60% of 
these neurons degenerate, causing a 70%–80% depletion of do-
pamine levels in the dorsal striatum. (Pickrel, Youle, 2015).
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Discussion
Parkinson’s disease is associated with a wide variety of symp-
toms, both motor and non-motor. The four cardinal motor 
symptoms associated with the disease are; Rest tremor, brady-
kinesia, rigidity and loss of postural reflexes. The rest tremors 
seen in PD are usually found in the distal extremities, but they 
can also be seen in the lips, chin and jaw.  Bradykinesia can be 
described as slow movement and it is a hallmark of basal ganglia 
disorders. Although Parkinson’s patients seem to have impaired 
motor programes, when provided an external stimulus many of 
them exhibit normal movement. This phenomenon is known as 
kinesia paradoxica. Rigidity is often one of the first symptoms of 
the disease, but it is often misdiagnosed as arthritis or bursitis. 
Neck and trunk rigidity leads to postural deformities. Additional 
postural issues include, extreme neck flexion, trunk flexion and/
or scoliosis. (Jankovic, 2008).
Non-motor symptoms associated with the disease include; 
autonomic dysfunction, cognitive abnormalities and sleep 
issues, among others. Autonomic dysfunction features can in-
clude, orthostatic hypotension, sweating dysfunction, sphinc-
ter dysfunction and erectile dysfunction. Neurocognitive 
dysfunction was tested on 537 PD patients using the 
Neuropsychiatric Inventory. Eighty-nine per cent of patients 
exhibited symptoms for at least one of the Neuropsychiatric 
Inventory. The results of the Neuropsychiatric Inventory 
were as follows: Fifty-eight percent of patients showed symp-
toms of depression, 54% showed apathy symptoms, 49% 
exhibited anxiety symptoms and 44% showed signs of hallu-
cinations. (Jankovic, 2008).
Sleep abnormalities often seen in PD were thought to be a side 
effect of the medications patients were given. More recently, 
some physicians are beginning to view it as a part of the disease. 
Researchers began looking at the hypothalamic hypocretin sys-
tem, a system that regulates sleep/wake cycles, to see how this 
system differs in Parkinson’s patients. They have found that pa-
tients with PD had almost 50% fewer hypocretin neurons than 
the healthy control group. (Fronczek, et. al. 2007).
There are no known preventions that will stop PD, however 
there are some substances which have an inverse relationship 
with PD. Caffeine has been found to reduce one’s risk for PD. 
MPTP, one of the toxins associated with PD was injected onto 
the striatum of mice. This led to an 85% decrease in dopamine 
levels in the area. However when the mice were given moderate 
amounts of caffeine, there was only a 60% decrease in dopamine 
levels. This study leads to the conclusion that caffeine may help 
mitigate some of the symptoms of PD, however this relationship 
is not causal. (Holden, 2001).
Nicotine, found in cigarettes, decreases the risk for develop-
ing the disease. It also inhibits the MPTP pathway, ensuring that 
more dopamine receptors remain intact. Additionally, nicotine 
has been shown to reduce the activity of Monoamine Oxidase, 
which causes the oxidation of dopamine. Coffee drinkers have a 
30% decreased risk of developing PD, while smokers have great-
er than a 30% reduction risk. (Martyn, Gale, 2003).
There is no known cure for Parkinson’s Disease, however, 
there are a full array of medications and treatments to slow 
progression of the disease and to relieve some of its symptoms, 
both motor and non-motor. Drug therapy is the mainstay of 
treatment. Surgical intervention, such as deep brain stimula-
tion is recommended in severe cases. Physiotherapy, speech 
therapy and occupational therapy have all been shown to help 
Parkinson’s patients as well, particularly in advanced stages of 
the disease. (Rajput, Rajput, 2006).
The three main drugs being given to Parkinson’s patients are, 
Levodopa, monoamine oxidase B (MAO-B) inhibitors and do-
pamine agonists (DAs). MAO-B inhibitors are given to patients 
with mild motor symptoms, usually in the early stages of the 
disease. When administered in conjunction with Rasagiline, pa-
tients dropped 3-4 points on the Unified Parkinson’s Disease 
Rating Scale. When taken with other drugs, such as SSRIs, 
some patients began exhibiting serotonin syndrome symptoms. 
Dopamine Antagonists act directly on striatal dopamine recep-
tors and have a greater effect on motor symptoms than MAO-B 
inhibitors. DAs are often prescribed as a first order treatment 
in patients who are young at age of onset. Side effects of DAs 
include; nausea, headaches, sleep attacks and Impulsive Control 
Disorder, among others. DAs are usually supplemented with 
levodopa in the later stages of PD. Levodopa, also known as the 
gold standard in PD treatment, is the first order treatment given 
to elderly Parkinson’s patients. Levodopa is most successful at 
eliminating PD motor symptoms, however, it has many side ef-
fects. (Sprenger, Poewe, 2013).
Some side effects of levodopa include nausea and dyskinesia. 
Being on the drug long-term causes up to ⅓ of patients to de-
velop dyskinesias. Between doses patients can experience pain-
ful muscle spasms and the reemergence of other PD symptoms. 
The National Health Service of England recommends keeping 
the dose of levodopa as low as possible to prevent motor com-
plications. The Movement Disorder Society recommends taking 
levodopa with a DA to prevent long-term motor side effects. 
(LeWitt, 2008).
The most common surgical intervention for Parkinson’s patients 
is Deep Brain Stimulation (DBS). Prior to the discovery of this 
treatment, surgical treatment for movement disorders involved 
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ablations. More specifically pallidotomy, thalamotomy, and more 
recently, subthalamatomies. Thalamotomy relieved many of the 
tremors and dopa-induced dyskinesia, however it often left pa-
tients with speech and cognitive deficiencies. Unilateral palli-
dotomy have been shown to significantly improve contralateral 
tremor, rigidity, bradykinesia, and dyskinesias. Side effect of pal-
lidotomy include, weight gain, reduction in verbal fluency, and a 
higher incidence of recurrent depression in patients who have a 
prior history of the disease. Appropriate anatomical and careful 
physiological screening prior to placement of the lesions may 
decrease incidences of cognitive or neuropsychological damage. 
Subthalamatomies have been experimented with as a cheaper 
alternative to DBS. Preliminary findings indicate that there are 
fewer cognitive and speech side effects than in pallidotomy and 
thalamotomy. However postoperative chorea occurred in more 
than half of patients who underwent this procedure. This re-
mains a concern with subthalamotomy. Additional research is 
necessary to ascertain whether this treatment is a viable alter-
native to DBS. (Walter, Vitek, 2004).
Deep brain stimulation is a highly effective surgical therapy 
for PD and other movement disorders (fig. 1). To qualify as a 
candidate for surgery, patients must be first undergo testing 
by a competent neuropsychologist and neurologist. A neurol-
ogist will review the patient’s medical history and ensure that 
reasonable medical intervention has been applied. The patient 
will then meet with a neuropsychologist to discuss goals and 
expectations of the surgery. If a patient has unrealistic expecta-
tions, they are no longer an appropriate candidate for surgery. 
(Benabid, et. al. 2009).  
Once a patient is found to be a viable candidate for surgery, 
they undergo basic preliminary testing. The main test involves 
a patient skipping a dose of levodopa at night. The patient then 
goes to the neurologist so he can assess the patient’s symp-
toms without medication.  Afterwards, the patient then takes 
his dose of levodopa, so the neurologist can see how it affects 
the patient’s symptoms. Symptoms that do not improve with 
medication, usually will not improve with DBS either, hence the 
significance of this test  (Farris, Giroux, 2011).
Once cleared for surgery the patient will undergo the proce-
dure. The procedure involves the implantation of electrodes 
in the subthalamic nucleus, two lead coated wires and a neu-
rostimulator, which is technologically similar to a pacemaker. 
(Farris, Giroux, 2011) Prior to the implantation of the elec-
trodes, patients undergo stereotactic imaging to locate the 
subthalamic nucleus. Surgery for implantation of electrode and 
lead is usually done under local anesthesia, so the surgeon can 
determine the best location for the electrode within the sub-
thalamic nucleus. Using microelectrodes, the surgeon will stimu-
late different areas to figure out where the patient will have the 
greatest symptomatic relief. Once the best tract is found the 
surgeon will replace the microelectrodes with the lead through 
various means. After this is done, the patient is closed up and 
the second part of the procedure takes place at a later date. 
(Benabid, et. al. 2009).
The second part of the procedure involves placing the neuro-
stimulator in the subcutaneous pouch in the subclavicular area. 
This is done under general anesthesia. Once the neurostimula-
tor is inserted and connected to the lead, the programming of 
the stimulator begins. Programming of the neurostimulator will 
usually begin a week after surgery. Voltage is increased gradually, 
while the patient is tested by the neurologist. Once an appropri-
ate setting has been found for the patient, PD medication dos-
ages are lowered to prevent dyskinesias. (Benabid, et. al. 2009).
Deep brain stimulation offers many advantages to ablations, 
although it is not a risk-free procedure. When performing 
ablations, the lesions placed on the brain are permanent and 
irreversible. With DBS, the neurostimulator can be turned off, 
or reprogrammed in case of complications. In cases of adverse 
effects, the neurostimulator can even be explanted. Some of 
the adverse effects of the implantation of the electrodes and 
leads in DBS include hemorrhaging, seizures and/or infection. 
Although these side effects are relatively rare (4%), it is import-
ant to know about them. With regard to the neurostimulator, 
battery depletion is an issue. Batteries have a median life of four 
years, but in patients with high voltage stimulation, they may last 
only one year. (Grill, 2005).
Figure 1  This drawing depicts the components of DBS
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Studies done on the short and long term effects of the pro-
cedure on Parkinson symptoms show significant improvement 
in many of them. Following DBS of the subthalamic nucleus, 
levodopa dosages decreased on average 55.9%. Rigidity and 
bradykinesia symptoms decreased by 63% and 52% respectively 
after twelve months. Parkinsonian tremors decreased by 61% 
following subthalamic nucleus DBS. However, stimulation tar-
geting the dorsal border of the subthalamic nucleus produced 
an 86% improvement in tremor symptoms. Gait and balance 
issues caused by PD are less likely to be helped by DBS. In a 
one year follow up study, patients were found to have the same 
gait and balance scores as their preoperative scores with drug 
treatment. (Fasano, et. Al. 2012).
One must also examine how DBS affects the non-motor symp-
toms of PD. As mentioned above, there are numerous non-mo-
tor symptoms which are part and parcel of the disease and 
DBS effects these symptoms as well in various different ways. 
Cognitively, DBS is safer than all other surgical interventions. 
The vast majority of studies indicate that patients have a decline 
in phonological and semantic verbal fluency tasks. This decline 
is noticeable shortly after surgery and may be the result of mi-
crolesions to the cortical-basal ganglia circuit, which is involved 
with word retrieval. An additional reason for this decline may 
be due to the withdrawal of dopaminergic drugs. Apathy seems 
to worsen following the procedure. This may be caused by the 
inactivation of dopaminergic receptors in the mesocortical and 
mesolimbic pathways after DBS. Many studies show a decrease 
in anxiety following DBS, this may be caused by the relief of 
motor symptoms. DBS seems to have little effect on autonomic 
symptoms of PD. Further research is necessary to better under-
stand this. Sleep symptoms associated with PD, seemed to show 
improvement after DBS. This may be due to decreased bradyki-
nesia and increased bladder capacity. (Fasano, et. Al. 2011).
Conclusion
Deep Brain Stimulation has been proven to be the most effec-
tive surgical intervention for those suffering from Parkinson’s 
Disease. As with most medical issues, invasive surgery is not 
the first choice for treatment, but if necessary DBS is the gold 
standard in invasive treatments for PD. It provides relief to many 
of the motor symptoms associated with the disorder.  Although 
success varies, it has developed into the most viable surgical 
treatment for PD. 
List of Acronyms:
DBS Deep brain stimulation
PD Parkinson’s Disease
MAO-B Monoamine Oxidase B
DA Dopamine Agonists
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Introduction
Staphylococcus aureus is a gram positive pathogen and the most 
common cause of skin and soft-tissue infection (SSTI) in the 
world. A study done in 2008-2009, spanning more than nineteen 
European countries and more than 3000 cases of complicat-
ed skin and soft tissue infections (cSSTI), found that about one 
third of these cases were due to S. aureus (Russo, et al., 2016). 
S. aureus is responsible for common skin infections such as im-
petigo, cellulitis, folliculitis, carbuncles, abscess, pyomyositis, and 
necrotizing fasciitis, as well as more deep-rooted infections that 
lead to blood stream infections, nosocomial pneumonia, and 
infection of wounds and surgical sites (Popovich, et al., 2008). 
S. aureus is so prevalent that about 25% of humans are consis-
tent carriers of this microorganism, while 50% are observably 
intermittent carriers. Colonies of S. aureus can be found in the 
anterior nares and other areas of skin throughout the body.
Penicillin was the first antibiotic used to treat S. aureus infec-
tions; however, within a few years S. aureus developed resistance 
to this “miracle drug”. A specific strain of S. aureus started to 
produce an enzyme capable of destroying penicillin, called pen-
icillinase. The plasmid that produced the penicillinase quickly 
spread among the different strains of S. aureus. To combat this 
new development, methicillin, which is a semisynthetic β-lact-
amase-resistant penicillin, was created in 1959. After only two 
short years, the first case of methicillin-resistant staphylococcus 
aureus (MRSA) was reported. This case of bacterial resistance 
was the result of a more complex mechanism than found in 
the penicillin resistant strain of S. aureus. Methicillin works by 
blocking the protein penicillin binding protein (PBP), found in S. 
aureus that is associated with the construction and maintenance 
of the cell wall. Instead of using these PBP proteins, resistant 
strains of S. aureus acquired a new protein, PBP2a, which has the 
same function as PBP but is not susceptible to methicillin. PBP2a 
is encoded by the gene mecA, located on the chromosome, 
unlike the penicillinase gene which is found on the plasmid. This 
mecA gene is a distinguishing characteristic of MRSA and the 
presence of PBP2a means that S. aureus is resistant not only 
to methicillin, but to all β-lactam antibiotics, including synthetic 
penicillin, cephalosporin and carbapenem (Mastofsky, et al, 2011; 
Pantosti, Veniti, 2009; Popovich, Hota,2008).
HA-MRSA
MRSA has become a worldwide problem and is common 
throughout hospitals as well as smaller healthcare facilities. 
Since its origins in the 1960s, the spread of healthcare-associ-
ated MRSA has become a public health concern (Mastofsky et 
al, 2011; Pantosti, Veniti, 2009). The common strains of MRSA 
found today originated from a few clones that developed in-
dependently of each other (Gardam, 2000). MRSA is spread by 
direct contact and most often in a healthcare setting where 
contamination can spread through the hands of healthcare pro-
viders (Okado et al, 2016). This spread of infection has led to 
the definition of HA-MRSA which is an annotation for health-
care-associated MRSA or for hospital-acquired MRSA. Patients 
with compromised immune system or those that have had ex-
tended hospital stays are more susceptible to the contraction of 
MRSA. In addition, use of antibiotics and undergoing surgery are 
factors that can contribute to MRSA infection. Once a patient 
has acquired HA-MRSA it is extremely difficult to eradicate and 
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the person can be a carrier for an extended period of time 
(Gardam 2000). A patient can be a carrier for HA-MRSA for 
longer than six months, long after his discharge from the hospi-
tal (Pantosti, Veniti, 2009). 
In order to reduce the prevalence of HA-MRSA and to stop 
the spread of this nosocomial pathogen, hospitals take on two 
different approaches. The first recommendation is prevention 
based and includes barrier precautions, hand washing and en-
vironmental cleaning for MRSA patients. The second approach 
is an implementation of an antibiotic stewardship program. The 
purpose of the program is to control antibiotic prescribing in 
order to reduce the adverse effects of antibiotics, such as drug 
resistance and more specifically decreasing the spread of infec-
tion caused by multi-drug resistant bacteria. A 10-year program 
implemented in Saint-Joseph Hospital in Paris, France focused 
on applying a combination of these two aspects to decrease the 
prevalence of HA-MRSA found in their hospital. The program, 
implemented from 2000-2009, showed an 84% decrease in HA-
MRSA colonization throughout the hospital. Researchers found 
that there was an increase in the use of alcohol based hand rubs 
(ABHR) from 6.8 L to 27.5 L per 1000 patient-days. Additionally, 
antibiotic use, measured with the Defined Daily Dose (DDD) 
per 1000 patient-days decreased by 31%. The implementation 
of this program and its results were significant in that it was 
conducted in a region known to be endemic for MRSA. From 
2000-2009, France had MRSA rates greater than 25%, an alarm-
ingly high rate (Chalfine et al, 2012).
CA-MRSA
In the 1990s a new strain of MRSA emerged. Known as com-
munity-associated methicillin resistant staphylococcus aureus 
(CA-MRSA) This new epidemiology has the capability of causing 
infections in otherwise healthy individuals who have had no pre-
vious exposure to a healthcare setting. These reported cases of 
CA-MRSA have statistically worse clinical outcomes than those 
of HA-MRSA (Mostofsky et al, 2011; Pantosti,Veniti, 2009). CA-
MRSA is a more infectious form of S. aureus than HA-MRSA and 
can carry the genes that encode Panton-Valentine leucocidin 
(PVL) which is “associated with tissue necrosis and a greater 
severity of disease” (Russo et al, 2016). However, in most cases 
CA-MRSA causes skin and soft tissue infections (SSTI) such 
as furuncles, abscesses, impetigo, and cellulitis (Pantosi,Veniti, 
2009). CA-MRSA is the most common cause for patients pre-
senting with SSTI in emergency departments around the United 
States (Albrecht et al., 2015),
CA-MRSA has a number of distinguishing characteristics that 
differentiate it from HA-MRSA. Firstly, CA-MRSA, unlike HA-
MRSA, is vulnerable to most non-β-lactam antibiotics and con-
tains what is known as SCCmec element of type IV and type 
V. SCCmec stands for staphylococcal cassette chromosome 
mec and is the mobile genetic element for S. aureus that is 
responsible for its resistance to methicillin and other β-lact-
am antibiotics. This SCCmec element is encoded by the gene 
mecA and is divided into subtypes I-VIII (The Working Group 
etc., 2009). Conversely, HA-MRSA is multidrug-resistant to 
non-β-lactam antibiotics and contains SCCmec type I, II, III. A 
second difference, as mentioned above, is that CA-MRSA con-
tains PVL, which is a strong virulence factor (Mostofsky et al, 
2011; Pantosti,Veniti, 2009). 
With the growing number of MRSA cases reported each year, 
the clearly defined lines between HA-MRSA and CA-MRSA are 
being blurred. Asymptomatic colonization of MRSA can persist 
for years and a HA-MRSA can be easily misconstrued for CA-
MRSA. Cases have been reported of community-onset HA-
MRSA, as well as nosocomial CA-MRSA infections (Mostofsky 
et al, 2011). The definitions abound as to how to clearly classify 
and differentiate between HA-MRSA and CA-MRSA. There are 
many uncertainties as to how to define prior hospitalization and 
length of time since hospitalization. This question is crucial as it 
determines if one is still a carrier of MRSA or not. The common 
definition of prior hospitalization is “hospitalization within six 
months to one year of current admission”. Sometimes, MRSA 
acquired from long term care facilities and nursing homes is 
not considered healthcare associated, but rather CA-MRSA, 
skewing the statistics (Gardam,2009). One way to differentiate 
between the two strains it to test the isolate’s susceptibility to 
non-β-lactam antibiotics, as this is one key difference between 
HA-MRSA and CA-MRSA (Popovich et al, 2008).  
There are many different treatment options available to treat 
MRSA infections, including incision and drainage, oral antibiotics, 
parenteral antibiotics, and topical therapies. More than one mode 
of therapy can be used. Treatment options can be administered 
on both an inpatient and outpatient basis (Popovich et al, 2008).
The purpose of this paper is to review some of the current and 
leading parenteral and oral treatment options used to best treat 
SSTIs caused by both HA-MRSA and CA-MRSA. It will explore 
and compare different antibiotics, their uses, benefits and side 
effects in an effort to understand the most effective way to treat 
MRSA.
Methods
This study was performed through the analyzation of various 
original and peer reviewed articles which were accessed using 
databases such as the Touro Database, PubMed, and Google 
Scholar. The research collected in this study was used to under-
stand MRSA, its effects and the best way to treat it when found 
as the cause of SSTIs.
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Discussion
There are many different treatment options for MRSA that are 
currently in use or in development. Some are administered oral-
ly or parenterally, while others are administered topically. 
Incision and Drainage
The most important part in the treatment of complicated SSTI 
(cSSTI) is the incision and drainage of the infection site. This 
procedure is common in the case of furuncle, soft tissue ab-
scesses and other purulent SSTI. An estimated 80% of patients 
presenting in the emergency departments with acute, purulent 
SSTI require drainage. Most patients with infections caused by 
CA-MRSA are cured via incision and drainage alone and do not 
require any antibiotics. Thus, incision and drainage, where ap-
propriate, is the first step to treating cSSTI caused by MRSA 
(Ruhe et al., 2007; Stryjewski et al., 2008). 
However, there is still much to learn regarding the effective-
ness of incision and drainage of infection sites. A study done on 
children with SSTI, with an infected site of greater than 5 cm, 
showed that pediatric patients are more likely to experience 
failure of incision and drainage alone and antibiotic therapy is 
usually necessary. Additionally, patients with other risk factors 
such as systemic illness, comorbidities, as well as multiple areas 
of SSTI are more likely to need antibiotic therapy in addition to 
or in place of incision and drainage (Popovich et al., 2008). 
Vancomycin
Vancomycin is the standard drug used today to treat SSTI 
caused by MRSA (Stryjewski et al., 2008). Since its introduction 
in 1958, it has been used to combat gram positive bacteria with 
great success. Vancomycin is administered parenterally on an 
inpatient basis. Vancomycin, a glycopeptide, works against MRSA 
by inhibiting the bacteria’s cell wall synthesis. It interacts with a 
peptide precursor of the peptidoglycan at an important site of 
attachment and thereby inhibits peptidoglycan polymerase and 
transpeptidation mechanisms.  Penicillin is also bactericidal by 
hindering biosynthesis of cell wall; however, vancomycin inhibits 
an earlier stage of the peptidoglycan synthesis thereby eliminat-
ing cross-resistance (Wilhelm et al., 1999).
The clinical practice guidelines set by the Infectious Diseases 
Society of America states that the recommended dose for the 
average adult with normal renal function for intravenous van-
comycin is 15-20mg/kg/dose every 8-12 hours. Dosage amount 
should not exceed 2000 mg regardless of a patient’s weight. 
For more serious cases, in which a patient is systemically ill and 
has a suspected MRSA infection, the dosage level may be ele-
vated to 25-30 mg/kg/dose. However, in such a case, one must 
be cautious for red man syndrome, a reaction associated with 
a high dosage of vancomycin that can cause anaphylaxis. As a 
precaution, infusion time can be lengthened to two hours and 
an antihistamine can be administered prior to the loading dose. 
Antibiotics can be administered on an empirical basis until culture 
results are obtained (Liu et al., 2011). For patients who have prob-
lems with renal function, careful monitoring should be ensured 
while administering vancomycin, as vancomycin can sometimes 
be associated with nephrotoxicity (Wilhelm et al., 1999). 
As with the development of resistance to β-lactam antibiotics 
which led to the new subset of S. aureus, specifically MRSA, new 
reports have come out of vancomycin resistance. The levels of 
resistance range from intermediate susceptibility to full resis-
tance of vancomycin (Pantosti et al., 2009). These new strains of 
S. aureus resistant to vancomycin are known as vancomycin-in-
termediate S. aureus (VISA) and as vancomycin-resistant S. aureus 
(VRSA) (Popovich et al., 2008). There is even a third category of 
vancomycin resistant bacteria known as hetero-VISA, that seems 
to be vancomycin susceptible when routinely tested, but contain 
a minority of cells that have intermediate vancomycin suscepti-
bility. Upon exposure to vancomycin, these hetero-VISA bacteria 
can multiply in number and spread (Pantosti et al., 2009). 
VRSA developed from a prolonged use of vancomycin in re-
sponse to chronic MRSA infection. Over time, the bacteria 
changed from MRSA to VRSA by the plasmid exchange of vanA, 
the gene for vancomycin resistance, possibly from a co-infect-
ing vancomycin-resistant enterococcus (Pantosti et al., 2009). 
A minimum inhibitory concentration (MIC) to vancomycin has 
been observed nationwide in MRSA isolates. This phenomenon, 
known as the MIC creep, has led to the lowering of the MIC 
breakpoint for vancomycin in 2006 to ≤ 2 µg/ml for suscepti-
ble, 4-8 µg/ml for intermediate, and ≥16 µg/ml for resistant. As 
a result, higher dosage amounts are being recommended for 
therapy, yet there is no substantial data to prove its efficacy and 
a higher dosage may cause greater toxicity, especially nephro-
toxicity (Popovich et al., 2008). 
S. aureus that displays a decrease in vancomycin susceptibility 
generally has phenotypic features that are different than the 
strains of both original S. aureus and MRSA. The main phenotyp-
ic change of vancomycin-susceptible S. aureus (VSSA) to cause 
resistance is a general thickening of the cell wall. Involved in this 
alteration of cell wall structure is an overexpression of PBP2 
and PBP2a, increased level of abnormal muropeptide protein, 
increased amount of D-alanyl-D-alanine residue, and reduction 
of peptidoglycan cross-linkage (Sirichoat et al., 2016).
Linezolid
Many test results have shown Linezolid to be a comparable drug, 
in terms of results, to vancomycin. Linezolid is an oxazolidinone 
antibiotic that was first discovered in the 1990s and approved 
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for use in standard medicine in 2000 (Dumitrescu, Lina., 2014). 
Linezolid is the first antibiotic of this class to be brought to 
market. Oxazolidinone represents a new systemic antimicrobial 
class.  Linezolid works by blocking protein function in the cell. 
It binds to the 50s subunit of the pathogenic cell which pre-
vents it from complexing with the 30s subunit, mRNA, initiation 
factors, and formylmethionyl-tRNA. This inhibition prevents 
the formation of the protein initiation complex, preventing 
the translation step of protein synthesis. Other drugs that are 
classified as protein synthesis inhibitors, such as macrolides and 
tetracyclines, have different mechanisms, as each allows the 
process of mRNA translation to begin, while stopping peptide 
elongation. This mode of action of linezolid seems to work par-
ticularly well against staphylococcal infections. Additionally, its 
target site is unique and does not interfere with the mechanism 
for other protein synthesis inhibitors. Linezolid is bacteriostatic 
(Livermore, 2003). 
Reported cases of linezolid resistance have been rare and a 
number of reasons for the low level of resistance have been 
proposed. First, linezolid is an entirely synthetic compound, so 
it is unlikely that naturally occurring mechanisms of resistance, 
such as those found in antibiotic producing organisms will be 
employed. Second, oxazolidinones inhibit ribosomal protein 
synthesis while other antibiotics of similar ribosomal protein 
synthesis mechanisms do not propose cross-resistance to 
linezolid. Additionally, linezolid acts by binding to the 23s rRNA 
of the 50s ribosomal subunit. There are multiple copies of the 
gene that code for 23s rRNA in each cell. For resistance to 
occur, mutations would be necessary in each of the copies of 
the gene. Because of the fear of resistance, caution should be 
employed when there is a long and repeated use of antibiotics 
(Meka, Gold, 2004).  
Linezolid is administered either intravenously or orally. It has 
100% oral bioavailability and therefore allows for rapid transi-
tion from parenteral form to an oral one, possibly resulting in 
early discharge from the hospital. This can result in decreased 
length of stay and a decrease in overall cost of treatment. MRSA 
can be treated with oral linezolid exclusively. Outcomes were 
the same for patients treated only with oral linezolid compared 
to intravenous vancomycin despite the difference in routes of 
administration and antibiotic (Dumitresu, Lima, 2014; Weiglet 
et al., 2005). Standard dosage of linezolid is 600 mg every 12 
hours. For uncomplicated SSTI the recommended dose is 400 
mg every 12 hours. Because of its 100% bioavailability, dos-
age amount is not dependent on the route it is administered 
(Moellering 2003). 
Linezolid can cause some minor side effects, including gastro-
intestinal discomfort such as nausea, vomiting and diarrhea, 
and dermatological effects, like rash and itchiness. Most re-
ported adverse effects ceased with the cessation of therapy. 
When therapy exceeded 14 days, 12.6% of patients studied, 
experienced hematologic effects such as decreases in platelet 
count, hemoglobin level, hematocrit and white blood cell count 
(Birmingham et al., 2003). Linezolid can also cause reversible 
myelosuppression when administration of antibiotics exceeds 
14 days (Weigelt et al., 2005). 
In clinical studies linezolid has performed comparably to vanco-
mycin in treating cSSTI caused by MRSA, with possible advantage. 
A study showed that “linezolid [was] superior … to vancomycin 
in the MRSA subset. The difference between linezolid and vanco-
mycin results was most dramatic in patients with abscesses and 
surgical-site infections caused by MRSA”. Linezolid is more effec-
tive in treating SSTI caused by MRSA due to the enhanced pen-
etration of linezolid into the skin and tissue (Weigelt et al.2005). 
Linezolid has also shown to be less nephrotoxic than vancomycin 
(Dumitrescu et al., 2014). In a study comparing the treatment of 
cSSTI caused by MRSA with linezolid and vancomycin in diabetic 
and non-diabetic patients, similar results indicated no significant 
difference in therapy of diabetic patients. However, for non-dia-
betic patients, results showed a greater success rate for patients 
treated with linezolid (Lipsky et al., 2011). Other studies have 
shown no significant benefit of using linezolid over vancomycin. 
Szczypinska et al. claims that by examining length of stay (LOS) 
as the determining factor of efficacy of an antibiotic, no signifi-
cant difference was found between vancomycin and linezolid. As 
of now, linezolid is used as a secondary choice to vancomycin in 
cases of vancomycin resistance, despite the proven success and 
efficacy of linezolid in treating MRSA, in order to prevent the rise 
of linezolid resistance (2013).        
Daptomycin
Daptomycin is another viable antibiotic for the treatment of 
SSTI caused by MRSA that was brought to market in 2003 
(Popovich et al., 2008). Cell death is caused by rapidly depolar-
izing the bacterial membrane. The lipophilic tail of daptomycin, 
a cyclic lipopeptide compound, inserts itself into the bacterial 
cytoplasmic membrane, in this case MRSA, and causes a rapid 
depolarization of the membrane. This ultimately leads to a loss 
of DNA, RNA, and protein synthesis. Daptomycin is bactericidal 
at all of the bacterial growth stages, including the stationary 
phase (Aikawa et al., 2013; Gonzalez-Ruiz et al., 2016; Seaton, 
2008).
Daptomycin resistance is rare but is a growing concern in the 
healthcare field (Hayden et al., 2005). The mechanism of resis-
tance is unknown but it has been suggested that the mechanism 
of resistance may be due to irregular dltA transcription factor 
which “may result in a change of the bacterial cell membrane 
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fluidity and therefore lead to a reduced affinity of daptomycin to 
its target site” (Gonzalez-Ruiz et al., 2016). It has been hypoth-
esized that the mechanism for daptomycin resistance is similar 
to that of vancomycin by VISA. Daptomycin is similar in size and 
weight to vancomycin and may not be able to penetrate the cell 
wall to reach the cell membrane, which daptomycin interacts 
with, if the cell wall thickens as it does in VISA. Daptomycin 
would never have the opportunity to reach the bacterial cy-
toplasmic membrane in the face of such an obstacle, resulting 
in daptomycin resistance (Cui et. al. 2006). Resistance to dap-
tomycin without previous exposure has so far proved to be 
extremely rare, with an observation of only 0.04% of 10,000 
cultures tested shown to have an MIC of 2 µg (Gonzalez-Ruiz 
et al., 2016). 
The recommended dose of daptomycin to treat cSSTI is 4 mg/kg/
day to be administered parenterally with a 30-minute IV infusion. 
Course of treatment for daptomycin is 7-14 days. Daptomycin 
use has not been approved for pediatric patients (Gonzalez-Ruiz 
et al., 2016; Seaton, 2008). Daptomycin is administered only once 
daily to reduce the risk of elevated creatine phosphokinase (CPK) 
levels and skeletal muscle toxicity. Elevated CPK levels were re-
solved upon discontinuation of daptomycin treatment. The most 
common adverse effects reported are constipation, nausea, and 
headache (Gonzalez-Ruiz et al., 2016).    
In some cases, such as difficult-to-treat infections like recurrent 
MRSA due to vancomycin resistance, a higher dosage of dapto-
mycin (≥6 mg/kg/day) may be recommended. A higher dosage 
of daptomycin would allow for rapid clearing of bacteria and 
would lower the risk for emerging resistance. Daptomycin has 
also been used in combination with other antimicrobial thera-
pies to prevent the rise of resistance. Such combination ther-
apies should be considered for patients who are at high risk 
of developing resistance to daptomycin alone. Daptomycin and 
linezolid combination therapy was synergistic in its effect and 
was bactericidal for MRSA. Daptomycin has also been used with 
rifampin, trimethoprim-sulfamethoxide, fosfomycin, and tigecy-
cline (Gonzalez-Ruiz et al., 2016). 
Many studies have been performed measuring the efficacy of 
daptomycin compared with that of vancomycin. Most show 
daptomycin and vancomycin to be comparable and a selec-
tion should be made based upon physician and patient pref-
erence, resistance factors and economic cost/ benefit analysis 
(Gonzalez-Ruiz et al., 2016; Kauf et al. 2015). Patients treated 
with daptomycin showed a greater probability of clinical suc-
cess by day 2 than those receiving vancomycin therapy, however 
length of stay for patients from both antibiotic groups averaged 
to be the same- four days. Vancomycin is also significantly cheap-
er than daptomycin (Kauf et al. 2015).  
Clindamycin
Clindamycin is especially useful in treating MRSA in an outpatient 
setting (Frei et al., 2010). Clindamycin is a lincosamide drug and 
belongs to the class of antibiotics known as macrolides, lincos-
amides and streptogramin B (MLS). Although similar in function 
to macrolides, lincosamides and streptogramin B are structurally 
different. Clindamycin works by binding to the large ribosomal 
subunit, which is the center responsible for catalyzing the for-
mation of peptide bonds during protein elongation. Clindamycin 
blocks this ribosomal tunnel, allowing peptide elongation to con-
tinue until it reaches a point of steric hindrance caused by the 
clindamycin. This inhibition will lead to eventual dissociation of the 
peptidyl-tRNA from the ribosome. Once a peptide has reached 
a certain length on the ribosome, clindamycin loses its ability to 
inhibit protein synthesis (Tenson et al., 2003). 
Resistance to clindamycin therapy is a cause for concern. The 
resistance mechanism involves modification of the drug binding 
site on the ribosome. The mechanism is the same for all MSL 
antibiotics, and is known as MSLB resistance. MSL drugs bind 
to the 23s rRNA-binding site. The erm gene is responsible for 
the methylation of the 23s rRNA-binding site. In the presence 
of the erm gene, resistance can be expressed constitutively as 
well as when induced into production. Because of the presence 
of the erm gene, resistance can occur during the course of clin-
damycin therapy (Lewis II et al., 2005; Popovich et al., 2008). 
In testing for clindamycin resistance, MRSA strains may appear 
susceptible, but can later develop resistance. To test for induc-
ible resistance, a D-zone test is used. This a double-disk diffusion 
test in which two disks, a clindamycin disk and an erythromycin 
disk are placed on a plate growing S. aureus. The strain is induc-
ible resistant if the zone of inhibition around the clindamycin 
disk facing the erythromycin disk is blunted, forming a D shape. 
Rates of inducible clindamycin resistance varies by region in the 
United States. Use of clindamycin should be determined by local 
rates (Popovich et al., 2008). 
Clindamycin can be administered parenterally or orally for SSTI. 
When administered intravenously, the appropriate dosage is 600 
mg every 8 hours. For oral administration, patients should be 
given 300-450 mg four times daily. Courses of treatment range 
from 10-14 days (Popovich et al., 2008). Clindamycin has a 90% 
oral bioavailability and can penetrate well into skin and skin 
structure. It is also less costly than some newer drugs used to 
treat SSTI caused by MRSA (Lewis II et al., 2005). Clindamycin 
may also inhibit the PVL gene that is common in CA-MRSA 
(Forcade et al. 2011). 
Clindamycin is commonly associated with gastrointestinal side 
effects. Most common were reports of diarrhea and pseudo-
membranous colitis (PMC). In a study comparing gastrointestinal 
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effects caused by clindamycin and ampicillin, another medication 
known to have gastrointestinal side effects, it was found that 
29.8% of patients developed diarrhea following clindamycin ther-
apy. Patients were evaluated for side effects for six weeks follow-
ing discontinuance of clindamycin therapy (Lusk et al. 1977). 
The findings of a study involving a retrospective chart review 
to compare the efficacy of vancomycin to the efficacy of clin-
damycin indicated that vancomycin and clindamycin had similar 
treatment results (Frei et al. 2010). In some cases, clindamycin is 
used in conjunction with vancomycin as a combination antimi-
crobial therapy. However, it has been reported that clindamycin 
often “antagonizes the antistaphylococcol activity of vancomy-
cin” (Deresinski, 2009). 
Trimethoprim-Sulfamethoxazole
Trimethoprim-Sulfamethoxazole (TMP-SMX) is another anti-
biotic that is used for the treatment of MRSA. TMP-SMX is 
the most commonly prescribed oral antibiotic for outpatient 
treatment of CA-MRSA infections, in addition to clindamycin 
(Forcade et al., 2011; Johnson, Decker, 2008). TMP-SMX is a 
two part drug consisting of one part trimethoprim to five 
parts sulfamethoxazole. The interaction of these two drugs 
inhibits the bacterial synthesis of tetrahydrofolic acid, which 
is used in the production of bacterial nucleic acid.  TMP-SMX 
inhibits two consecutive steps in the formation of folic acid. 
Sulfonamides inhibit dihydropteroate synthetase (DHPS), 
which is responsible for para-aminobenzoic acid to be cata-
lyzed into dihydrofolate. TMP inhibits dihydrofolate reductase 
(DHFR) which causes dihydrofolate to be catalyzed into tet-
rahydrofolate (Huovinen, 2001; Michalek et al., 2015).   TMP-
SMX has also been shown to have anti-inflammatory and 
immunomodulatory effects, enhancing its antimicrobial capa-
bilities (Michalek et al., 2015).
Resistance to TMP-SMX can be found against both drugs, 
trimethoprim and sulfonamides, with different mechanisms 
against each. Resistance of S. aureus to TMP is suspected of 
being caused by a single amino acid change in the dhfr gene, al-
tering DHFR. A single amino acid mutation in the dhps gene is 
responsible for sulfonamide resistance of S. aureus (Huovinen, 
2001). However, a study performed in three cities in the 
United States in 2005, showed that 97% of CA-MRSA isolates 
were susceptible to TMP-SMX (Johnson et al., 2008; Popovich 
et al, 2008). 
TMP-SMX is most commonly administered orally with the 
standard dose of 160/800 mg twice daily for 7-15 days. TMP-
SMX can also be administered intravenously with a dosage of 
trimethoprim (80 mg)/sulfamethoxazole (400 mg) per 5 ml to 
be given as 5 mg/kg every 6-12 hours (Michalek et al., 2015; 
Popovich et al., 2008). TMP-SMX has a high bioavailability, at 
around 85% for both complexes (Stein et al., 2016). Some rec-
ommend a higher dosage, 320/1600 mg twice daily for 7-15 days, 
of oral TMP-SMX to treat SSTI caused by MRSA. Yet Cadena 
et al. found that patients treated with the two different doses 
had similar clinical results. For the treatment of SSTI caused by 
MRSA, a higher dose may not be necessary (2011). A lower dose 
may also minimize gastrointestinal adverse effects (Michalek et 
al., 2015). In studies testing TMP-SMX patients were found to 
have side effects of diarrhea, nausea, vomiting, pruritus, and rash 
(Miller et al., 2015). 
Studies comparing TMP-SMX to clindamycin, show TMP-SMX to 
be a comparable treatment option (Frei et al., 2010; Miller et al., 
2015). TMP-SMX can be used in combination with clindamycin 
to treat pediatric patients (Stein et al., 2016). TMP-SMX bacteri-
cidal activity against MRSA was greater than that of linezolid, ri-
fampicin, and clindamycin, other popular oral antibiotics used to 
treat MRSA. The use of TMP-SMX is economically beneficial as 
well. When compared to linezolid, at $1352 for a 10-day course 
of treatment, TMP-SMX is significantly cheaper, costing only 
$18 for a 10 day course. These numbers are average wholesale 
numbers in the United States (Kaka et al. 2006). According to 
Johnson et al. studies comparing the effectiveness of TMP-SMX 
to vancomycin, the leading drug, are lacking (2008). However, all 
VISA strains in the United States are susceptible to TMP-SMX, 
and TMP-SMX has been used, in combination with other drugs, 
in its treatment (Cosgrove et al., 2004).
Conclusion
Staphylococcus aureus is the leading cause for SSTI in the world. 
In an effort to combat this growing concern, many antimicrobial 
agents have been used. The method of defense was penicillin 
and then methicillin which lead to what is commonly known 
as MRSA. Initially found only in hospitals and other healthcare 
facilities, MRSA soon spread to the community at large. Patients 
with no previous healthcare exposure were now susceptible to 
MRSA. These infections are typically manifested as SSTI in the 
form of impetigo, cellulitis, folliculitis, and abscess. 
With the rise of methicillin resistance, and subsequently re-
sistance to all β-lactam antibiotics, new treatment options 
were needed. Vancomycin became the treatment option of 
choice. However, vancomycin resistance was soon reported as 
well, though not to the extent of methicillin resistance. Other 
antibiotics are also used to combat SSTI caused by MRSA. 
Daptomycin, a newer drug that is administered intravenous-
ly, shows great promise. Linezolid, can be administered both 
parenterally and orally, and therefore has potential to shorten 
hospital stay. Clindamycin and TMP-SMX are both popular oral 
drugs used in outpatient treatment of MRSA. 
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Regardless of the effectiveness and benefits of these non-β-lac-
tam antibiotics, vancomycin remains the “gold standard” of 
treatment therapy for MRSA. Fear of developing resistance 
to alternative drugs limits the extent of their use and keeps 
vancomycin as the leading choice. Healthcare professionals and 
researchers need to remain alert to any signs of resistance of 
antimicrobial agents to prevent its spread and to help stop the 
increased presence of MRSA in hospitals and the community.
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Introduction
One of the growing challenges in healthcare is the rising occur-
rence of antibiotic resistance. Many pathogens have developed 
resistance to an array of drugs; the discovery of new antibiotics 
has not been keeping up with the rate of the evolving antibiotic 
resistant bacteria. Many are concerned that the medical world 
may return to the times when small infections will be lethal.
For example, Methicillin Resistant Staphylococcus Aureus (MRSA) 
is an example of a bacterial strain that is resistant to every an-
tibiotic except for Vancomycin.  This bug is responsible for most 
hospital acquired infections., and these bacteria can colonize any-
where from surgical sites, lungs, blood, heart, skin and even brains. 
(Jensen et al., 2015). Unfortunately, there has been a recent dis-
covery of Vancomycin Resistant Staphylococcus Aureus (VRSA). 
The emergence of VRSA and its dangers have lead scientists and 
medical doctors to worry about the future of medicine. 
Felix d’Herelle co-discovered bacteriophages in the early 1920s. 
Bacteriophage therapy utilizes the killing powers of nature’s pred-
ators for bacteria; bacteriophages. Interest in phage therapy, and 
its associated research diminished once Flemings discovered the 
curative powers of penicillin. However, Russia and many Eastern 
European countries have continued studying this topic. The grow-
ing need for alternative treatments for bacterial infections gives rise 
to a resurgence of interest in this novel topic (Pincus et al., 2015). 
A bacteriophage is a virus that binds to receptors that are only 
found in bacterial cells.  Bacteriophages infect bacterial cells, 
reproduce and then lyse their host bacteria. Then the origi-
nal phage’s offspring then spreads and infects more bacterial 
cells. Bacteriophages have a specific receptor site and are thus 
antibacterial to a narrow range of bacterial cells. In addition, 
their specificity prevents them from infecting human cells. 
Bacteriophage therapy seeks to harness these powers and use 
them to treat human infections (Jensen et al., 2015).
Scientists are hopeful that bacteriophage therapy will success-
fully treat infections caused by many pathogens, specifically the 
hard to treat MRSA infections. Since research on this topic is 
fairly new, clinical trials need to be run prior to its institution in 
standard medicine. This paper will review some of the different 
experiments and their outcomes. The author wishes to determine 
how these experiments will impact the future of phage therapy.
Phage Infection Mechanism
Bacteriophages are viruses that infect bacterial cells. They are 
found all over the planet. The phages infect bacterial cells by bind-
ing the tips of their tails to receptor molecules on the bacterial 
cell. The viral DNA is then injected into the host cell. The virus 
now directs the creation of more phages, which can be created in 
less than thirty minutes. The phage bursts out of the bacterial cell, 
thereby killing the bacteria. The released phage’s offspring contin-
ue to infect more bacterial cells (Pastagia et al., 2013).
Bacteriophages produce two proteins in order to lyse the cell: Holin, 
creates a pore in the bacterial cytoplasmic membrane, and Lysin in-
teracts with the peptidoglycan in the cell wall. Lysin cleaves to the 
peptidoglycan bonds and ruptures the cell wall. Unable to withstand 
the osmotic pressure, the cell wall bursts (Wang et al., 2000). The re-
leased phages can then continue the cycle of infecting bacterial cells.
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Narrow Host Range
As a bacterial virus, bacteriophages can be extremely host spe-
cific. Consequentially, they exhibit some major advantages in 
comparison to broad spectrum antibiotics. For instance, using 
phages to rid the body of infections does not pose a problem to 
the normal flora, whereas antibiotic treatments impact normal 
flora. The downside to the phage specificity is the rapid ability of 
the bacterial viruses to develop resistance, thus increasing the 
risk that the therapeutic effect is merely transient. 
One way to circumvent this problem is to create a personalized 
phage cocktail specifically for each patient. This would entail 
culturing every infection, and then creating a specific mixture 
of bacteriophage from a phage library. This would ensure that 
the specific viruses could be combined in accordance with the 
different infectious pathogens present in the patient.  In order 
for this to be a viable treatment option, the hospital would need 
to have a broad range of bacteriophage present at all times. One 
group of researchers studied how probable it is to have a wide 
resource of phages to treat infections.
The researchers purchased many strains of antibiotic resistant 
bacteria from both a lab and a hospital. In order to isolate the 
bacteriophages, they filtered sewage waste and then centrifuged 
the supernatant. Finally, the bacterial viruses were purified three 
times by plating and re-plating the plaques.
After multiple attempts, the researchers discovered that only one 
out of 117 strains of bacteriophages were effective against MRSA. 
After obtaining more samples of the bacterial viruses from other 
sources, the researchers still had difficulty isolating effective phage. 
The study resulted in the realization that it is not feasible to treat 
MRSA infections on demand; isolating effective strains presents 
significant challenges. In order to treat these infections, pre-made 
wide range cocktails would have to be available. It is important 
to note that on demand discovery of phages does seem possible 
for other bacterial pathogens such as Pseudomonas aeruginosa, 
Salmonella, and E. coli. Treating these infections with personalized 
cocktails is a viable option (Mattila et al., 2015).
Combination of Phage and Antibiotic Therapy
One way to use bacteriophage to combat infections is to com-
bine phage therapy with antibiotic therapy. The combination of 
phages and antibiotics so far seems to be synergistic; the interac-
tions between the two antibacterial agents provide a combined 
effect that is greater than the sum of the individual effects. One 
phenomenon that has been noted is called phage-antibiotic syn-
ergy (PAS). Research shows that administering sub-lethal doses 
of antibiotics brings about this effect, regardless of whether the 
pathogen is a multi-resistant or naïve bacteria or whether an 
old or new antibiotic is used. 
Evidence suggests that a high dosage of antibiotics leads to a 
tremendous evolutionary advantage for antibiotic resistant 
pathogens. So, combining phage and antibiotics may be the solu-
tion to the medical dilemma. A lower dosage can be used to 
target naïve bacteria, and the bacteriophage can simultaneously 
inhibit the growth of the antibiotic resistant strains (Torres-
Barceló et al., 2016).
Concerns in PAS Treatment
There are some concerns about the negative effects that can 
occur as a result of this two-fold treatment. Although there is 
no research that provides a basis for these fears, in order to 
ensure the complete safety of all patients, it is imperative to 
keep these concerns in mind. One major concern is regarding 
the possibility of breeding double resistant strains of a pathogen. 
This fear is an outgrowth of a similar phenomenon that has 
been noted for some antibiotic combination therapy (Torres-
Barceló et al., 2016). 
Researchers must also be mindful of specific antibiotic-phage 
combinations that inhibit the effectiveness of each individual 
component. For example, phages can block the bacteria’s ability 
to absorb the antibiotic, or the antibiotic may affect the host 
in a way that limits the phage’s ability to infect the bacteria or 
to produce sufficient offspring. Thorough screening of all the 
various combination before treatment can easily eliminate this 
concern (Torres-Barceló et al., 2016). 
Finally, researchers caution that PAS may increase the virulence 
factors of certain infections. This phenomenon can be seen in 
the instance of quorum sensing, the communication between 
different bacteria cells, which can coordinate the production of 
some virulence factors. It has been observed that certain ex-
posure to either phages or antibiotics has produced increased 
virulence. However, the bacterial viruses that target quorum 
sensing receptors can inhibit this response. Although there is 
little or no research indicating that these concerns are obstacles 
to the use of bacteriophage therapy, proper research must be 
done before combining antibiotics and phage therapy in treat-
ment of infections (Torres-Barceló et al., 2016).
Isolation and Host-Range Determination of 
Bacteriophage
n order to harness the therapeutic powers of phages, the ther-
apeutic index must be carefully studied and documented. One 
group of researchers bought bacterial cells from labs and public 
facilities. They isolated the methicillin resistant strains on agar 
plates. The next step required that they isolate the virulent 
phages. Upon obtaining samples from the environment, the re-
searchers purified the samples by filtration and centrifugation 
three times (Jensen et al., 2015).
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In the study they discovered 12 bacteriophages that exhibit lytic 
activity against SA and MRSA. In order to determine the host 
range, they took spectrophotometric assays of the cultures of 
phage-treated bacteria and performed spot testing. After fur-
ther testing the cocktails on fabric and on glass, they found that 
the bacteriophage viruses were able to reduce the colony count 
on cultures of fabric and glass. Interestingly, the phage cocktails 
showed greater lytic activity against human MRSA then against 
non-human Staphylococcus Aureus (SA) and against methicil-
lin-susceptible SA.  In conclusion, they isolated 6 unique lytic 
phages that show strong lysis of MRSA (Jensen et al., 2015). The 
information gathered from this research now opens the door 
to further studying of these specific bacteriophages. In order to 
advance the applications of this study in medicine, the efficiency 
of these phages need to be clinically tested in humans.
Phage Treatment Viability
In order for the bacteriophage to be therapeutically useful, 
there must to be a way to store it in pharmacies. In order to 
examine phage viability, researchers stored phage in the freezer, 
refrigerator, and at room temperature. They concluded that the 
phage was most stable at room temperature, and was almost 
100% viable after 60 days (Pincus et al., 2015). This is a positive 
discovery for the future of phage therapy, as the shelf life seems 
to be suitable for pharmaceutical storage and sale.
Isolation of Phages and Host Range 
Determination
Another area of life in which MRSA affects humans is its ability 
to infect livestock. Generally, animals are not harmed by these 
infections. However, they can be responsible for the transfer of 
infectious bacteria to humans, and this transmission has been 
documented. In particular, farmers and vegetarians who experi-
ence greater exposure to livestock are at a higher risk for this 
kind of infection. One group of researchers isolated three bac-
teriophages that were found in pig farms and tested the effec-
tiveness of their antibacterial qualities (Kraushaar et al., 2013). 
The methods used in the experiment are as follows. Researchers 
purchased bacterial strains, specifically MRSA CC398 strain 10-
1355, from a laboratory. The phages were taken from a variety 
of sources including dust swabs, nasal swabs, and fecal swabs 
from four German pig farms. They then centrifuged, filtered, and 
tested the phages on MRSA lawn. The host range was tested on 
agar plates of 86 different MRSA strains CC398 strains and 34 
other MRSA strains. The researchers also analyzed the DNA of 
the phages. None of the analyzed phages contained known vir-
ulence or resistant genes. Hence, the study could be conducted 
without concern that the phages would eventually cause more 
harm than good to the human host.
The MRSA strains belonging to complex 398 are commonly 
found on pig farms. These researchers aimed to combat live-
stock-associated MRSA infections by discovering the phages 
that naturally inhibit this pathogen. They screened 91 samples. 
Twenty percent of the samples exhibited lytic activity. An inter-
esting phenomenon was noted in the course of this process. 
One of the farms was negative for both MRSA and anti-MRSA 
bacteriophages. This discovery is important, because it con-
notes that phages are found in proximity to the bacteria that 
they infect. Thus, researchers can assume that if they have a 
bacterial pathogen it is likely that phage can be isolated from 
that environment (Kraushaar et al., 2013). This can simplify the 
process for future research as the knowledge of where to find 
the right phages is now known.
Genetics’ Effect on Phage Efficiency
The researchers studied three phages that are genetically related. 
The three PSa phages interestingly infect the same wide range 
of bacteria. Twenty- four MRSA strains were infected by these 
phages. These phages all have a receptor that researchers believe 
may be lipoteichoic acid. Of the three PSa types, type two and 
type three reduced the numbers of a specific MRSA strain more 
efficiently than type one. This aspect was observed with wider 
clearings on agar plates, but the plaques produced by type two 
and type three were ten times more reductive that the plaques 
produced by type one.  The genotyping of the three phage’s genes 
indicates that this property is a result of the differences in the 
lysis genes (Kraushaar et al., 2013). Further examination of the 
genes that favor greater bacterial lysis would be the next step in 
producing antibacterial cocktails for human medicine.
Another interesting result of this experiment was the discovery 
of mutant bacteria that were resistant to the phages used in the 
study. Even when the three different phages were combined in 
one cocktail, they still did not harm the mutant cells. This discov-
ery is important as it highlights the necessity of combining more 
diverse phages in a cocktail to prevent resistance to similar phag-
es (Kraushaar et al., 2013). This is another area of research that 
can be expounded upon based on the findings of this experiment.
Phage Therapy and Host Immuntiy
An important aspect of phage therapy research is the determi-
nation of specific bacteriophage’s therapeutic index. Additionally, 
it is vital to explore if the bacterial virus is equally effective in all 
human hosts or if different factors contribute to the optimal pro-
ductivity of the bacteriophage. One study explored the efficiency 
of phage SATA-8505 and its ability to prevent and treat infections 
caused by the MRSA strain USA300. The therapeutic index was 
examined in vitro with human cells and in vivo in mice. This spe-
cific strain was selected due to earlier research that proved its 
efficiency in combating MRSA USA300 (Pincus et al., 20). 
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All materials for the experiment, MRSA strain USA300, bac-
teriophage SATA-8505, and the phages were obtained from 
laboratories.  Using agar plates, the researchers were able to 
confirm that phage SATA-8505 has the ability to kill MRSA 
USA300. This phenomenon was seen when they observed the 
colony morphology of culture plates two to four hours after 
phage inoculation. 
Once it was clear that the phages were effective killing agents of 
MRSA, the researchers inoculated the mice with MRSA patho-
gens immediately after they injected bacteriophages into the 
skin. They then measured the diameters of the skin lesions for 
six consecutive days. The mice that were treated with an equal 
concentration of phages and bacteria displayed smaller skin le-
sions than the control group. The researchers also used Chronic 
Granulomatous Disease (CDG) immuno-deficient mice. CDG 
patients are more susceptible to MRSA infections due to their 
problematic neutrophil response.  Interestingly, the CDG mice 
developed bigger skin lesions than the healthy mice; usually 
CDG patients develop MRSA infections on deep tissue, such 
as the liver. (Pincus et al, 2015). This could be a positive sign, for 
despite the fact that the skin lesions were big, the infections 
resembled those of healthy patients. One may think that due 
to the large lesion size, the CDG mice did not benefit from 
the phage therapy. Upon further examination, one may conclude 
that these mice improved relative to their own individual states 
of immunity and infection.
Unfortunately, the phage treatment does not seem to be a 
magical injection. Both groups of mice exhibited an increased 
lesional inflammatory cytokines.  The fact that the actual lesion 
size was reduced while the bacterial count and cytokine re-
sponse did not decrease led the researchers to hypothesize that 
although the administered dose of phage reduced the ability of 
the bacteria to inflict toxin-generated damage, it did not affect 
the viability of USA300 (Pincus et al., 2015).  These researchers 
did a complete project. In order to completely understand this 
phenomenon, they repeated the experiment while changing the 
phage dosage and the original bacterial count. They discovered 
that an increase in phage administration brought about an in-
crease in the inflammatory response in the CDG mice. This may 
indicate why bigger lesions that are produced when a higher 
dosage of phage is administered. 
This discovery highlights the importance of phage dosage, espe-
cially in immunocompromised patients. The scientists noted that 
although the phage worked at certain concentrations, when the 
dosage was increased, negative side effects, such as an inflamma-
tion of the infectious site, were observed.  Further research is 
required in order to configure the optimal dosage for treating 
patients while incurring minimal or no harm. The researchers 
make a point in warning clinicians that before phage therapy is 
used on any immuno-deficient individual, the dosage must be 
reconfigured. Extrapolating data from healthy individuals would 
not work for the CDG patients who were more affected by 
increases in dosage.
Once researchers noted that the phages induced an inflam-
matory response in mice, they investigated whether a similar 
response could be noted in human cells. When human blood 
cells were exposed to dosages of phage, the human cells did 
not produce inflammatory responses. The response of human 
keratinocytes was also investigated. When compared to the di-
luent treatment, phage induced a small, yet significant, cytokine 
response (Pincus et al 2015). This is a potential roadblock in the 
implementation of phage therapy. The only way this treatment 
could work is if the scientists find a way to inhibit the human 
body’s negative response to the phage itself.
The next step involved investigation of the impact of phage SATA-
8505 on human blood in both healthy and immuno-deficient indi-
viduals. Unfortunately, the phage did not seem to affect bacterial 
growth or colony morphology. The bacteria cells that were ex-
posed to phage in blood and were then re-cultured grew just as 
well as bacteria that were unexposed to bacteriophage. The re-
searches further investigated the phage and bacterium used and 
found that the bacterial cells were killed by the phage in a culture 
plate. This negates the possibility that a phage-resistant strain of 
MRSA was used to inoculate the blood sample.  In order to elu-
cidate why the bacteria is unaffected by phage in the presence of 
human blood, further research is necessary. 
The last part of this research included the study of the effi-
ciency of SATA 8505 on Vancomycin Resistant Staphhylococcus 
Aruerus (VRSA). The researchers determined that this phage 
is incapable of killing out the VRSA strains (Pincus et al., 2015). 
This observation highlights the strain-specificity aspect of phage 
therapy, since the phage worked fairly well on the MRSA but did 
not affect the VRSA growth.
Strain Specificity
The strain specificity of phage has both positive and negative 
aspects to it. While it is true that phage therapy successfully 
avoids destroying normal flora, one must first determine the 
exact strain of the infection prior to beginning the treatment. 
Unfortunately, this determination often takes time, and while 
treating MRSA infection, time is often of essence. Therefore, 
phage therapy may not yet serve as the first line treatment 
against infections (Pincus et al., 2015).
Thus, possibility of using phage cocktails holds much prom-
ise. Similar to multivalent vaccines, phage cocktails combine 
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a few different strains of bacteriophage. This would increase 
the chances that one of the strains would cover the unknown 
pathogen in the human host. Although this solution seems scien-
tifically sound, there is a financial drawback. Each phage used in 
the cocktail must be separately tested in isolated therapy. Then 
research must be conducted on the combination to ensure that 
the combined effects are positive or synergistic. The added cost 
of all this research may be an issue (Pincus et al., 2015).
Phage Lysins: Pathogen Directed Treatment
One major drawback to phage therapy is the bacteria’s ability to 
develop resistance to phage attachment.  Recently researchers 
have developed ways to purify the lysins from the bacteriophag-
es. The lysins can be used on their own as an antibacterial agent 
by causing bacterial lysis on contact. The use of lysins is gener-
ally limited to bacterial organisms with a cell wall, although re-
searchers are searching for lysins with Gram-negative bacterial 
activity (Pastagia et al., 2013).
Lysin Mechanism
The lysins have two main functions: substrate recognition and 
enzymatic hydrolysis. The N-terminal domain enzymatically 
severs specific peptidoglycan bonds. This can be accomplished 
in multiple ways. They can hydrolyze the glyosidic bonds in the 
glycan strand of the cell wall, or the enzymes can hydrolyze 
the cross-bridge. The enzymes may also cleave the amide bond 
which is located between the glycan moiety and the main pep-
tide. There is a level of specificity of lysin binding which is based 
on binding ligands and the specificity of cell wall binding domains. 
Additionally, the lysins bind to their substrates with an affinity 
constant similar to antibodies (Ka  = 6x108). This suggests that 
lysins do not disengage from the receptors after they bind and 
cleave, just like antibodies. This also explains the speed of lysin 
action. Their high affinity constant accounts for their speedy 
identification of their target bacterial cells (Pastagia et al., 2013).
Lysin Clinical Potential
The primary benefit of phage lysins is that, to date there has 
been no documentation of bacterial resistance to phage lysins. 
Additionally, bacteria with thick capsules and bacteria in biofilms 
do not inhibit lysin activity. These reasons are enough to aim 
research toward harnessing bacteriophage lysin antibacterial 
potential.  
Lysins generally exhibit bactericidal activity against the bacterial 
host of the phages they were harvested from. Like bacteriophag-
es, lysins are strain specific, and therefore do not affect normal 
flora. One specific lysin, chimeric lysin (ClyS) has been proven 
to kill MRSA strains along with other staphylococci. Some ly-
sins have been proven to affect a broader range of bacterium 
(Pastagia et al 2013). These kinds of lysins would be a great first 
defense method against infections in which the exact strain of 
pathogenic bacteria is unknown.
Phage Lysin and MRSA Biofilm Eradication
Phage lysins have potential to fight biofilms, a serious health 
problem. All biofilms are harder to treat than planktonic bac-
teria; specific biofilms of antibiotic resistant pathogens, such 
as MRSA are even more difficult.  Biofilms exhibit antibiotic 
resistance up to 1000 times more than planktonic bacterial 
cells (Chopra et al., 2015). These biofilm infections develop in 
patients that have prosthetic objects implanted in their bod-
ies. Phage lysins seem to be the optimal way to combat MRSA 
infections because of the speed of their bactericidal activity, the 
small chances of bacterial resistance, and the low probability 
of it affecting the normal flora. Additionally, the usage of lysins 
allows for all the positive aspects of phage therapy without the 
negative possibilities such as resistant mutations. 
Lysins generally exhibit bactericidal activity against the bacterial 
host of the phages they were harvested from. Like bacteriophag-
es, lysins are specific to bacterial strains and therefore do not 
affect normal flora. One specific lysin, chimeric lysin (ClyS), has 
been proven to kill MRSA strains along with other staphylococ-
ci. Some lysins have been proven to affect a broader range of 
bacterium (Pastagia et al 2013 and sources within). These kinds 
of lysins would be a great first defense method against bacteri-
al infections when exact strain of the pathogenic bacterium is 
unknown.
Research was conducted on the efficiency of phage lysins in 
eradicating MRSA biofilms. The object of this study was to eval-
uate the success of a phage lysin in eradicating old and new 
biofilms alone and in conjunction with antibiotics. The MRSA 
bacteria strain and the antibiotic, Minocycline, were obtained 
commercially. The phage lysin was extracted from phage MR-10 
that had been previously been characterized by the same re-
search group. In order to isolate and confirm their results, the 
team followed a published method for isolating phage enzymes 
(Chopra et al., 2015). This method of obtaining the phage lysin 
left some room for potential error. The research team may have 
made some errors in isolating the original phage, and the meth-
ods that they used originally are not documented in their paper. 
Thus, the whole project could have operated with impure or 
misnomered materials. Conversely, the method they utilized to 
isolate the enzyme leaves little room for error because they 
followed a proven method of isolating the endolysin. They did 
not rely solely on their observations and research.  Additionally, 
they confirmed their results with SDS-PAGE analysis after every 
purification step (Chopra et al., 2015).
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The biofilms were grown in the lab, and their morphological 
characteristics were identified by scanning with electron mi-
croscopy.  The biofilms were developed on coverslips. Two dif-
ferent types of biofilms were formed; ica-positive and ica-neg-
ative. For the first part of the research, both types of biofilms 
were treated with the endolysin. The ica-negative biofilms were 
initially treated with 9 µg/ml. After three hours no significant 
reduction was observed. Even once they increased the duration 
of the treatment, there was no significant reduction. However, 
when the ica- negative biofilms were treated with 18µg/ml of 
lysin a statistically significant reduction was observed after six 
hours. This seemed to be the highest effective dosage for any 
increase in phage lysin concentration did not create a significant 
decrease in bacterial count. Contrarily, the ica-positive MRSA 
biofilm showed a reduction in bacterial cell count with an appli-
cation of 36µg/mL of phage lysin after six hours. Increasing the 
duration to 24 hours did not make a difference in the bacterial 
reduction (Chopra et al., 2015).   Although the two biofilms 
were very similar, the difference in the intra-cellular adhesion 
clearly affected the optimum concentration of lysin needed to 
eradicate the biofilms.
Phage Lysin and Antibiotics
The next step in this research was to examine the combined 
effects of phage lysin with antibiotics in treatment of biofilms. 
They were subjected to both minocycline (a tetracycline antibi-
otic,) and MR-10 endolysin. A significant decrease was observed 
in the first three days of the treatment. After that there was no 
more significant reduction in both forms of the biofilms The 
researchers also conducted this experiment on old biofilm This 
strong unit did not exhibit significant reduction in the cell count. 
They researchers theorize that this observation is a result of 
the two antibiotic agents acting primarily on the top layer of the 
thick biofilm. Other literature clearly states that antibiotics can-
not penetrate deep into the biofilm because of the complicated 
nature of the biofilm matrix. Since the lysins are one time use 
enzymes, it is possible that they acted on the same cells as the 
antibiotic at different receptor sites. This could be the reason 
for the lack of reduction in the very thick biofilms (Chopin et al., 
2015). Based on this theory, one way to combat thick biofilms 
would be continuous application of lysins.  Once they kill out 
the upper layers, the new lysins can kill the cells in the deeper 
layers of the matrix. 
The next step of this research team was to study how sequen-
tial treatment of phage lysin in conjunction with minocycline 
would affect the biofilms. There were two different sequences 
studied with different results.  The first time the researchers ap-
plied endolysin for six hours and then added minocycline before 
incubating overnight. The next time they applied the minocy-
cline first and then the phage endolysin. In comparison to both 
the controls and each other, the second method of sequential 
treatment delivered the strongest significant decrease in bacte-
rial cell count. Figure 1 below compares the difference in total 
bacterial cell concentration from the control group and the two 
separate sequential treatments.  Using the Live/Dead backlight 
kit, the researcher’s stained the biofilms to see the total live and 
dead cells in the biofilm. After the second sequential treatment 
the staining confirmed that the majority of the live cells were 
killed (Chopin et al., 2015).
The positive results of biofilm treatment with three hours of 
minocycline followed by overnight incubation with endolysin 
MR-10 has a two-fold explanation. First, the antibiotic, mino-
cycline eradicated the metabolically active cells. According to 
literature, the active cells are in the upper layers in the biofilm. 
Since the antibiotics cannot penetrate the layers and it is only 
affective on active cells, using it first ensured that there were 
active cells in the biofilm that the antibiotics could access. Next, 
the endolysins were applied. These lysins are small, low molec-
ular weight proteins. Additionally, they act on both growing and 
stationary cells. Therefore, adding the lysins second enabled the 
smaller molecules to penetrate the biofilm and act on the met-
abolically inactive cells (Chopin et al., 2015). This reasoning also 
explains why the first sequential treatment was not nearly as 
successful. The endolysins probably killed the uppermost cells 
first, so subsequent treatment with antibiotics did not have a 
very strong additive benefit. By the time the antibiotic was ap-
plied there was not much more metabolically active cells pres-
ent in the uppermost layer where the antibiotics were able to 
access. Therefore, they did not do as much as they could when 
they were applied first.
MRSA biofilms are another manifestation of the dangers posed 
by this antibiotic resistant bacterium strain. Instead of using 
the whole bacteriophage, this study provided solid research 
that supports the idea that an isolated enzyme from the phage 
will work in eradicating these biofilms. Since the lysins attack 
the peptidoglycan of the bacterial cell, it is a great solution for 
the hard to treat metabolically inactive cells found in biofilms. 
With the foundation of this research, many more studies can be 
conducted in order to isolate other endolysins for all sorts of 
biofilm infections.
Conclusion
Although many are discouraged by the growth of MRSA in-
fections and the lack of treatment options, research suggests 
that bacteriophages may serve as the solution to this medical 
dilemma. Researchers have explored multiple aspects of bac-
teriophages and they have classified numerous strains of an-
ti-MRSA phages. In order for the medical world to harness the 
natural powers of these viruses, more clinical studies must be 
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performed. Scientists must first continue to experiment on an-
imals, in order to rule out all possibilities of the occurrence of 
negative side effects of phage inoculation. After the preliminary 
experimentation on animals has been completed, human trials 
can establish phages as tried and true medicinal option. If sci-
entists continue to diligently explore this topic, there may be 
reason to believe that the world will be rid of the inherent 
dangers of multi-resistant pathogens.
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Introduction
Two important characteristics distinguish stem cells from other 
cells. Firstly, they are unspecialized cells that have the ability to 
renew themselves through cell division, and secondly under 
certain conditions they can be induced to become tissue or 
organ-specific cells with special functions.
Until recently, scientists have mainly worked with embryonic 
stem cells and somatic stem cells. Embryonic stem cells are 
from the blastocyst of the embryo. The blastocyst is composed 
of an inner cell mass of stem cells that differentiate into differ-
ent types of cells, giving rise to the entire body of the organism. 
Embryonic stem cells are donated for research purposes by 
eggs that have been fertilized in vitro, and they are not derived 
from eggs fertilized in a women’s body. The donated stem cells 
are transferred to a culture dish that contains a nutrient broth 
called a culture medium where they divide and spread over the 
surface of the culture dish. When stem cells are grown under 
specific conditions, they can remain unspecialized. If the stem cells 
are allowed to clump together to form embryoid bodies, sponta-
neously they will begin to differentiate. Scientists can modify the 
stem cells by inserting specific genes or by changing the chemical 
make-up of the culture. Figure 1 illustrates the process of modify-
ing stem cells to become gene specific stem cells.
Adult stem cells are different from embryonic stem cells be-
cause they are found in mature tissues or organs. Adult stem 
cells are undifferentiated cells that can develop into specific 
cells of the tissue or organ where it is found. Adult stem cells 
are found in a specialized region called the stem cell niche. 
When needed the stem cells will divide and differentiate. This 
can occur when there is tissue damage or under normal wear 
and tear conditions – the stem cells will divide in order to re-
plenish the supply of cells. There are various types of adult stem 
cells that can differentiate into numerous types of cells hemato-
poietic stem cells (develop into blood cells), mesenchymal stem 
cells (develop into bone cells, cartilage cells and fat cells), and 
neural stem cells (develop into cells of the nervous system).
Human induced pluripotent stem cells are an additional type of 
stem cell. This stem cell is an adult cell that has been genetically 
reprogrammed to express the characteristics of an embryonic 
stem cell. The method used to reprogram these cells help re-
searchers learn more about the possibility of reprogramming 
damaged or diseased cells in the human body. 
Human stem cells have many uses in research and clinic. The 
most important use being cell-based therapy. Cell-based therapy 
is the potential to direct the differentiation of stem cells in order 
to transplant them as replacement cells or tissue. Today, tissue 
and organs are being donated, but the need for transplantable 
organs and tissue far outweighs the supply. Cell-based therapy 
can offer a renewable source of replacement cells which can be 
used to treat different diseases. (Bethesda, 2016).
There are several drawbacks of using transplanted stem cells to treat 
disease including rejection and long-term side effects are not known. 
Therefore, a lot of research is still being done before stem cell ther-
apy is used as an established treatment for disease.  (Ladock, 2016).
One disease scientists believe stem cell therapy can treat is mac-
ular degeneration. Macular degeneration is the most common 
cause of vision loss affecting more than 10 million Americans.
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Figure 1: Stem cells 
clump together to 
form embryoid bodies, 
and spontaneously 
they will begin to 
differentiate. The stem 
cells can be modified 
by inserting specific 
genes. (Bethesda, 
2016)
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The retina is the part of the eye that records the images we see 
and sends them via the optic nerve to the brain. The macula is 
located in the central area of the retina and is responsible for 
focusing central vision, seeing fine details, and recognizing faces 
and color. The anatomy of the human eye is illustrated in figure 
2 with the location of the macula shown. Macular degeneration 
is a disease which causes the deterioration of the cells of the 
macula. At the present time it is an incurable disease.
Age-related macular degeneration is the most common cause of 
blindness in people over the age of 60 years old. Age-related mac-
ular degeneration gets progressively worse as one ages. It starts 
with the dysfunction and death of retinal pigment epithelial (RPE) 
cells. It continues with photoreceptor loss, and insufficiencies 
in high acuity vision. There are 3 stages of age-related macular 
degeneration. Early age-related macular degeneration is the first 
stage where vision loss is not experienced. It can be diagnosed by 
the presence of small yellow droplets beneath the retina called 
drusen. The second stage is called intermediate age-related mac-
ular degeneration where some vision loss may be experienced. A 
comprehensive eye exam will look for drusen or pigment change 
in the retina. The last stage is called late age-related macular de-
generation. At this stage vision loss is noticeable. (Buchholz, 2009)
It is known that the causes of macular degeneration are both 
genetic and environmental, but the exact cause is not known. 
Age is the biggest risk; there is more of a chance one will devel-
op macular degeneration as one ages. (Akpek, 2013).
Methods
Literature for this article was obtained primarily using Touro 
College Online library. Other databases such as PubMed were 
used. Additionally, Google Scholar was valuable for finding nec-
essary and relevant articles.
Discussion
Only 5.5 millimeters in diameter, the macula is a part of the 
retina that is responsible for central vision. Researchers have 
been studying the possibility of using stem cells to treat mac-
ular degeneration. The macula is made up of photoreceptor 
cells called rods and cones. Rods and cones respond to light by 
sending electrical impulses to the brain through the optic nerve. 
The brain then interprets these impulses. Behind the rods and 
cones is a layer of cells called retinal pigmented epithelial cells. 
(ISSCR, 2015).
Functions of Retinal Pigmented Epithelium
Retinal pigmented epithelial cells have many functions in the 
eye. Firstly, these cells are responsible for transport in two 
directions. In one direction they transport glucose and other 
nutrients from the blood to the rods and cones. In the other 
direction the transport electrolytes and water from the subret-
inal area to the choroid. Another function of retinal pigmented 
epithelial cells is to absorb and filter entering light. The retina 
is made up of various pigments that are sensitive to different 
wavelengths of light. Additionally, retinal pigmented epithelial 
cells are responsible for phagocytosis.  (Simó Et. Al. 2010) 
The eye is an excellent part of the body for researchers to test 
stem cell therapy on because the eye is well contained by its 
many barriers. It is hard for the stem cells to move to other 
parts of the body. Additionally, researchers can assess the differ-
ences between a treated and untreated eye on the same patient. 
There is equipment available that allows one to see the interior 
and exterior of a person’s eye.   
The focus of scientists has been on using retinal pigmented 
epithelial cells for stem cell therapy. This is because it is a lot 
harder to ensure the proper placement of rods and cones in a 
patient’s eye. Rods and cones connect with nerve fibers, and it is 
extremely complex to correctly integrate these photoreceptor 
cells with the nerve fibers. Retinal pigmented epithelial cells do 
not connect to nerve fibers; therefore they are a better option 
for stem cell therapy. 
It is the goal of scientists to be able to transplant retinal pigment-
ed epithelial cells before the disease has progressed such that 
the photoreceptor cells have died. In this way, the transplanted 
retinal pigmented epithelial cells can take on some function of 
the damaged retinal pigmented epithelial cells and prevent the 
rod and cone cells from dying, thereby stopping the progression 
of the disease. (ISSCR, 2015).
Delivery of Stem Cells into the Eye
The following method was used to deliver retinal epithelial 
cells into rats. The rat was put under anesthesia. A sharp ster-
ilized needle was inserted to make a hole right beneath the 
limbus, which is the border between the cornea and the sclera 
Figure 2: Anatomy of the human eye showing the location 
of the macula. (ISSCR, 2015)
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of the eye. The tip of the syringe was inserted into the hole, 
injecting the retinal pigmented epithelial cells. The syringe was 
then taken out slowly, and eye moisturizing drops were given. 
(Westenskow Et. Al. 2015). 
A study of rats with macular degeneration, treated with human 
embryonic stem cells has shown evidence of rescued photo-
receptors and vision loss prevention. Three different levels of 
pigmented cells were used; light, medium and heavy. Different 
amount of cells were used in each group of rats. Visual acuity 
improved in the groups of rats treated with a dose of between 
5,000 – 100,000 retinal pigmented epithelial cells. The cells in-
jected into the rats sustained visual function for at least 60 days. 
The cells survived in the rats for at least 220 days. All the groups 
of rats showed deterioration of visual acuity over time. There 
is no evidence that showed any group having a slower deteri-
oration over time. The deterioration of the visual acuity of the 
rats in this study may be related to the inadequate use of im-
munosuppressive drugs to treat the rats. Another hypothesis of 
why the cells didn’t last is that cell transplantation may need to 
be repeated several times in order to sustain their therapeutic 
effect. The study confirmed the long-term safety of retinal pig-
mented epithelial cells for treatment of macular degeneration 
in rats. It is a promising step in the research of stem cell therapy 
to treat specific types of macular degeneration in humans. (Lu 
Et. Al. 2009).
In one study researchers tested whether human embryonic 
stem cells can safely be used to treat patients with macular 
degeneration. Although human embryonic stem cells were first 
discovered in 1998, this was the first study to report trans-
planting human embryonic stem cells into human patients. The 
study tested for signs of hyperproliferation, carcinogenicity, 
abnormal tissue formation, and rejection. Two patients were 
selected for the study. One patient had dry age-related macular 
degeneration and the other had Stargardt’s macular dystrophy 
(most common pediatric macular degeneration). (Schwartz Et. 
Al. 2012). 
In the experiment human embryonic stem cell culture MA09 
(classification of human embryonic stem cells) were used to 
generate a master cell bank. (Schwartz Et. Al. 2012) Cell line 
MA09 has contact with the environment before transplanted 
into the patient and therefore is classified as a xenotransplan-
tation. Xenotransplantation is any procedure that involves the 
transplantation, infusion, or implantation to humans of nonhu-
man live cells. (Samdani, 2014)  After embryoid bodies were 
formed and there was multiplication of the cells, retinal pigment 
epithelial patches were isolated. Embryoid bodies are the first 
phase of embryonic stem cell differentiation. There are various 
ways to form embryoid bodies, but it has been a challenge to 
form embryoid bodies uniform in size. (Xu Et. Al. 2011) The 
retinal pigmented epithelial cells were tested for pathogens and 
phagocytosis. They were also tested for RPE and hESC markers.
Human embryonic retinal pigment cells were successfully cul-
tured. The cells showed typical retinal pigmented epithelial cell 
behavior by losing their pigmented cobblestone morphology 
during proliferation and re-differentiating into a monolayer of 
polygonal cuboidal pigmented epithelium.
One hundred and fifty nanoliters of retinal pigmented epithelial 
cells were injected into the patients’ eyes through a cannula that 
delivered a dose of 500,000 viable retinal pigmented epithelial 
cells into the subretinal space. Immunosuppressive drugs; tacro-
limus and mycophenolate mofetil were given to each patient a 
week before the surgery and continued for six weeks after the 
surgery. Tacrolimus was not given after week six and the myco-
phenolate mofetil was continued for an additional six weeks. 
(Schwartz Et. Al. 2012).
There was no hyperproliferation or abnormal growth in either 
of the patients following surgery as determined by biomicro-
scopic and ophthalmoscopic clinical examinations. (Schwartz Et. 
Al. 2012).  
Anatomical evidence showed survival of human embryonic 
stem cells in the patient with Stargardt’s macular dystrophy. The 
transplanted cells were localized to exactly the correct ana-
tomical location. Increased pigmentation was seen in the retinal 
pigmented epithelial cells beginning from week one after the 
surgery up until month three after the surgery. 
The patient with age-related macular degeneration did not take 
the immunosuppressive drugs after the operation; therefore 
anatomical evidence was difficult to confirm. 
Both patients displayed functional visual improvement. The 
Figure 3: A 
series of images 
showing the 
macula before 
the operation 
until after the 
operation. 
Increased RPE 
are seen post 
operation. 
(Schwartz Et. 
Al. 2012)
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patient with Stargardt’s macular dystrophy was able to read study 
letters of 20/500 immediately following surgery. By week six, the 
patient was reading letters of 20/320 which remained stable 
through the postoperative period. The patient with age-related 
macular degeneration showed mild visual improvements. 
The series of images in figure 4 illustrate the area in the eye called 
the macula from before the operation until after the operation. 
Increased retinal pigmented epithelial cells are seen post operation. 
In this study human embryonic stem cells were safely trans-
planted into 2 patients. (Schwartz Et. Al. 2012). 
A second study compared the effectiveness of using human in-
duced pluripotent cells with using human embryonic stem cells. 
Both types of stem cells have the ability to differentiate, but it is 
unclear if they both have the same potential for use in stem cell 
therapy. The results were determined by finding differentiating 
ocular cells called retinal pigmented epithelium (RPE). 
Transcription factors, protein arrangement, and gene expression 
were looked at when comparing the two types of stem cells. 
The study concluded that human induced pluripotent stem 
cells are a feasible candidate for cellular therapy since they have 
similar cellular function and possess proper gene expression. 
(Buchholz Et. Al. 2009).
Where we are now
There are still several difficulties that must be overcome before 
stem cell therapy is used as a widespread treatment. Many con-
tinued years of research are needed. 
There are legal and ethical issues with using embryonic stem 
cells for stem cell therapy; therefore, a lot of effort is being put 
into generating induced pluripotent stem cells. There is a risk, 
however, that the induced pluripotent stem cells will turn into 
cancer cells, and that is a risk not worth taking. Therefore, it has 
been a challenge for researchers to obtain a readily available 
bank of stem cells to be used for stem cell therapy.
Can the stem cell therapy be effective if the condition that 
caused the cells to die in the first place is still present? Most 
likely, stem cell therapy will need to be combined with addition-
al treatments in order to limit further damage in macular de-
generation patients. These additional treatments are still being 
researched and developed.
An additional difficulty that must be overcome is to find out 
what exactly is the correct dosage of cells to transplant. There 
have only been a limited number of clinical procedures done. 
In order to figure out the correct dosage more clinical studies 
must be performed. 
Scar tissue is present in the damaged eyes of patients with mac-
ular degeneration. When new cells are transplanted there is a 
barrier between the host retina and the grafted cells. This can 
affect the way the light is transmitted, and the way the patients 
will see. Treating patients before scar tissue has formed, or dis-
covering ways to get rid of scar tissue is crucial before stem 
cells can be transplanted. (Barnstable). 
Conclusion
There is promising research for use of retinal pigmented epi-
thelial cells to treat macular degeneration. Continued research 
is needed before stem cell therapy can be used as a widespread 
treatment for macular degeneration. It is a goal of researchers 
to treat patients earlier on in the progression of the disease, 
before complete visual function has been lost. 
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Introduction
Zika virus (ZIKV) is an emerging disease that has gone from 
a mild endemic, circulating only locally in Africa and parts of 
Asia, to a worldwide pandemic, spreading rapidly throughout 
the Americas. (Lupton, 2016; Paixão, et. al. 2016).
ZIKV is an arbovirus which belongs to the genus Flavivirus, fam-
ily Flavivirdae. It is known to be transmitted by mosquitoes of 
the Aedes species – such as Ae. luteocephalus, Ae. aegypti, Ae. 
africanus, Ae. alboictus, and Ae. hensilli, which are usually found 
in areas with warm climate; however, Ae. albopictus inhabits as 
far north as the Great Lakes in the U.S. (Fellner, 2016) Ae. aegyp-
ti is considered to be the most efficient vector for ZIKV, which 
creates a bigger threat of spread of the virus, because this specie 
is characterized by an easy adaptation to human environments, 
indoor and daytime feeding, preference of feeding on humans, 
and an ability to breed in extremely small amounts of water. 
(Bell, et. al. 2016) As all other flaviviruses, including Dengue 
virus, Yellow fever virus, West Nile virus, Japanese encephalitis 
virus, Tick-Borne encephalitis virus, ZIKV carries a positive sin-
gle-stranded RNA, which encodes a polyprotein that is then 
processed into three structural proteins: the envelope, the 
capsid, and the precursor of membrane. It also encodes seven 
nonstructural proteins: NS1, NS2A, NS2B, NS3, NS4A, NS4B, 
and NS5. (Al-Quahtani, et. al. 2016).
ZIKV was discovered in 1947, in Uganda’s Zika forest, near 
Entebbe, during regular surveillance for sylvatic yellow fever 
in Macacamulatta rhesus monkeys. (Paixão, et. al. 2016) Shortly 
after, in 1952, the first case of ZIKV infection in humans was 
reported in Uganda and the United Republic of Tanzania. 
For the next 4 decades, ZIKV had spread to equatorial Asia 
(India, Pakistan, Malaysia, Indonesia, etc.), but infections were 
mild, sporadic, and without large epidemics. (Al-Quahtani, et. 
al. 2016) However, in 2007 the first major outbreak of ZIKV 
infection occurred on Yap Island in the Federated States of 
Micronesia, where well-nigh 75% of population was infected 
with the virus. (Fellner, 2016; Al-Quahtani, et. al. 2016) Next 
major epidemic of ZIKV was reported in 2013 in French 
Polynesia. The most recent outbreak of ZIKV happened in 
Brazil in 2015, with first confirmed case reported in May 2015. 
(Al-Quahtani, et. al. 2016).
Due to an increasing number of microcephaly cases being re-
ported in the ZIKV affected areas, WHO and Brazilian Ministry 
of Health have confirmed possibility of a link between ZIKV 
outbreaks and such severe fetal neurological defects as micro-
cephaly and recommended that all pregnant women residing 
in or traveling to the affected areas should take precautions to 
avoid contact with possible vectors. (Calvet, et. al. 2016) Having 
a virus as a cause of birth defects is not surprising (for exam-
ple, cytomegalovirus or rubella virus can be a source of micro-
cephaly and other anomalies), but there has never been a time 
when a virus caused an epidemic of congenital birth anomalies. 
(Rasmussen, et. al. 2016) The CDC has advised that all infants, 
whose mothers traveled or resided in areas affected by ZIKV 
during pregnancy, should be suspected for congenital ZIKV in-
fection if either intracranial calcifications or microcephaly were 
detected at birth or prenatally or if mother’s ZIKV testing re-
sults were positive. (Fleming-Dutra, et. al. 2016) Can there really 
be a connection between Zika virus and neonatal microcephaly?
Methods
This systematic review was composed after reviewing and 
evaluating clinical data reports of Zika virus outbreaks in Haiti, 
French Polynesia, Philippines, and Cambodia, case-studies of in-
fants and fetuses with presumed or confirmed ZIKV infection, 
and review articles; this data was obtained via searching engines 
as MEDLINE and ProQuest, or directly from published sources.
Discussion
Zika Virus: Diagnosis and Treatment
ZIKV infection starts in dendritic cells near the site of inocula-
tion (if mosquito-mediated), which is followed by spreading to 
lymph-nodes and the bloodstream. (Al-Quahtani, et. al. 2016) 
Replication of flavaviral RNA occurs in both cellular cytoplasm 
and nucleus. Infectious ZIKV appears in human blood as early as 
day 1 of illness onset, and can stay in blood as late as day 11 after 
onset. (Hayes, 2009) The incubation period for ZIKV has been 
determined to be 3-12 days. The outcome of infection depends 
Abstract
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on competition between viral replication and the host immune 
response. (Al-Quahtani, et. al. 2016) Usually, human infections 
with ZIKV are mild, and lethal outcomes are rare; common 
symptoms include fever, arthralgia and muscle pain, conjuncti-
vitis, rash, and headaches, lasting up to one week. (Pastula, et. al. 
2016) However, 80% of ZIKV are asymptomatic, which makes it 
extremely hard to diagnose and treat.
In addition to diagnosis based on epidemiological circumstanc-
es and clinical symptoms, there are not so many laboratory 
diagnostic tests available, because ZIKV as a pandemic is very 
recent. Existent assays for ZIKV diagnosis include use of reverse 
transcriptase-polymerase chain reaction (RT-PCR) to detect 
viral nucleic acid in the blood and other body fluids, such as 
saliva or urine. This test is useful only if performed on serum 
collected within day one to day three of symptom onset or 
on saliva or urine collected up to day five of symptom onset. 
Serological tests using enzyme-linked immunosorbent assays 
(ELISA) are able to detect the presence of anti-Zika virus im-
munoglobulin M (IgM) and immunoglobulin G (IgG) antibodies, 
which develop in human organism by the end of the first week 
of infection. (Al-Qahtani, et. al. 2016; Fellner, 2016) However, as 
specific as these two test are (compared to NAT or reduction 
neutralization assay, for example), cross-reaction with related 
flaviviruses, such as West Nile and yellow fever, and dengue, is 
very common; therefore, additional tests should be performed 
to exclude those options.
Microcephaly
Microcephaly (micro- small; cephal- head) is a congenital condi-
tion which is diagnosed when newborn children have a small-
er brain and skull compared to those of others of the same 
sex and age (See Fig. 1). (NINDS, 2016) Microcephaly can be a 
result of both environmental and genetic causes. Most common 
environmental factors that lead to microcephaly in infants are 
radiation, lead and mercury intoxication, in utero exposure to 
alcohol and drugs, and infections, such as TORCHES. (Calvet, 
et. al. 2016; Teixeira, et. al. 2016) Common genetic causes are 
autosomal recessive microcephaly, Aicardi-Goutières syndrome, 
Rett syndrome, and chromosomal trisomy. (Calvet, et. al. 2016) 
Frequently, microcephaly is associated with mental retardation, 
Down’s syndrome, and neurometabolic syndromes.
There is no treatment available in order to return a baby’s head 
to a normal size and shape; and all treatment techniques focus 
on decreasing the impact of accompanying disabilities. (NINDS, 
2016) Therefore, understanding whether there’s indeed a rela-
tionship between maternal infection with ZIKV and congenital 
microcephaly and the mechanism, in which the virus affects pre-
natal development, is extremely important for decreasing the 
number of microcephaly cases.
Evidence for a Link between ZIKV and Microcephaly
After the emergence of ZIKV in Brazil in 2015, a 20-fold average 
annual increase of microcephaly cases was reported. In 2015, 
there has been 1248 new suspected cases – prevalence of 99.7 
per 100 000 livebirths. (Ventura, et. al. 2016) On November 28, 
2015 Brazil declared congenital ZIKV to be responsible for the 
microcephaly epidemic. The very first alert was raised by the 
State Secretariat of Health of Pernambuco, Brazil in October 
2015 after analyzing the obvious spike in microcephaly cases: 
from January to July 2015 there had only been 6 cases reported, 
6 cases in August, 11 in September, and 39 in October. Mothers 
of 38 newborns were interviewed, 24 of whom reported having 
a rash during pregnancy. They also reported not to have had any 
common exposure to pesticides, drugs, alcohol abuse, radiation, 
or any other possible teratogenic factors. (Teixeira, et. al. 2016) 
As ZIKV has spread to other states in Brazil, 49th epidemiologic 
week had the highest rate of cases of microcephaly reported – 
900 cases in a week; women delivering then would have been in 
the first trimester of pregnancy during the peak of ZIKV out-
break. (Kleber de Olivera, et. al. 2015; Teixeira, et. al. 2016) This 
observation suggests a very strong association, both geographic 
and temporal, between ZIKV and microcephaly epidemics. 
In addition, a retrospective study, using serologic and statis-
tical data, of 2013-2014 outbreak of ZIKV disease in French 
Polynesia identified that 1% of mothers infected with ZIKV in 
the first trimester, had given birth to neonates with microceph-
aly, which suggests a prevalence to be 50 times as high as the 
estimated baseline. (Rasmussen, et. al. 2016) Yet, this study was 
based on small numbers of patients, fetuses were not tested for 
ZIKV, and other brain anomalies were not included in the study. 
Figure 1 
Microcephaly in 
an Infant (Bottom) 
Compared With an 
Infant With a Normal 
Head Size (Top)
Source: CDC
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Eight-eight pregnant women in Brazil, who reported having an 
onset rash for the previous 5 days, were tested and evaluated 
for ZIKV RNA. There were 72 with positive test results and 
16 negative.  Ultrasonography of 42 of those testing positively 
and the 16 negative ones revealed fetal brain anomalies were 
present in 29% of the former and 0% of the latter. (Rasmussen, 
et. al. 2016) Yet, this study is very limited by lack of tests for 
other viruses in mothers’ serum and amniotic fluid for ZIKV 
or other viruses. Also, there were no postnatal observations of 
the patients. 
Link between congenital ZIKV and microcephaly is strong-
ly supported by histopathologic evaluation of 4 formalin-fixed, 
paraffin-embedded tissue samples from two newborns, born 
at 36 and 38 weeks of gestation, who died shortly after birth 
and had microcephaly, parenchymal calcification, microglial nod-
ules, gliosis, brain cell necrosis, and two miscarriages (lost at 11 
and 13 weeks gestation) with chorionic villi with calcification, 
fibrosis, and focal villitis. All four mothers reported having clini-
cal signs of Zika during the first trimester of pregnancy – fever 
and rash. Laboratory testing was performed by the CDC; the 
samples included brain tissues from both newborns, placenta of 
one newborn, and products of conception from the two miscar-
riages. These samples were tested by ZIKV RT-PCR and all four 
cases turned out positive for NS5 and envelope genes. Further 
sequence analysis revealed the highest matches with ZIKV strains 
isolated from Brazil in 2015. The same samples were also tested 
for viral antigens by immunohistochemistry using a mouse poly-
clonal anti-Zika virus antibodies, and viral antigens were found 
in glial cells and neurons of one newborn and in chorionic villi 
of one of the miscarriages.  RT-PCR for dengue was performed 
and tests results were negative, which eliminates the possibility 
of cross-reaction of the virus. (Martines, et. al. 2016) Also, the 
mothers’ tests for rubella, herpes simplex, HIV, toxoplasmosis, 
and cytomegalovirus were negative, which points at ZIKV infec-
tion as the cause of microcephaly and fetal demise.
Another piece of evidence that supports the suggestion that 
ZIKV can negatively affect fetal CNS and cause microcephaly 
was obtained by a research team at Hospital Geral Roberto 
Santos in Salvador, Brazil. There, tissues and fragments of a fe-
male fetus, delivered after fetal demise in the 32nd week of 
gestation, were examined and tested for congenital ZIKV. Fetus 
had signs of microcephaly and arthrogryposis. Samples of ce-
rebral cortex, medulla oblongata, cerebrospinal and amniotic 
fluids tested positive by ZIKV-specific RT-PCR, which targets 
viral NS5. Samples from other organs, such as extracts from the 
heart, lungs, and liver, didn’t test positive and appeared to be 
undamaged. Also, the mother’s tests for HIV, HTLV, hepatitis C, 
toxoplasmosis, rubella virus, and cytomegalovirus during the 4th 
gestational week were negative, which leaves responsibility for 
fetal brain anomalies to the virus. (Sarno, et. al. 2016) However, 
this study is limited by not performing histopathological analysis 
of the sample tissues.
In addition, a different group of researchers tested the amniotic 
fluid of two pregnant women with microcephalic fetuses. Both 
women had normal fetal ultrasounds in the first trimester, but 
ultrasounds done later on in weeks 25 and 27 revealed severe 
microcephaly (head circumference below the third percen-
tile), hypoplasia of the cerebellar vermis, and posterior fossa 
enlargement in one fetus and asymmetry of hemispheres, and 
hypoplastic cerebellum with the cerebellar vermis completely 
missing. Both mothers did not report being on any medications 
during pregnancy, alcohol and drug use, or smoking. Tests for 
autoimmune and immunodeficiency diseases, and TORCHES 
were negative as well. However, they both reported having 
ZIKV infection symptoms at 10 and 18 weeks of gestation, re-
spectively; also, they haven’t reported travelling outside of Brazil 
during the previous years, or being in contact with any infected 
individuals. The amniotic fluid from each patient was then tested 
for any non-human genomic sequences, and ZIKV genome was 
identified in both samples. (Calvet, et. al 2016; Schuler-Faccini, 
et. al. 2016) The samples were also tested with RT-PCR for den-
gue and chikungunya, and the results were negative. ELISA test 
identified the presence of anti-ZIKV IgM in both samples as 
well. (Calvet, et. al. 2016) This study proves that ZIKV infection 
can cross the placental barrier. And since the ultrasounds at 
earlier gestation stages (during the first trimester) appeared to 
be normal but during the second trimester the fetuses started 
to develop signs of microcephaly and other brain anomalies 
(after the mothers being infected in the first trimester), the link 
between ZIKV and microcephaly is evident.
Also, according to Shepard, a pioneer in the field of teratology, 
in order to consider something a teratogen, there has to be an 
association of a rare environmental exposure with a rare defect. 
(Rasmussen, et. al. 2016) Considering the stats for microceph-
aly obtained in Brazil would not qualify because exposure to 
ZIKV wasn’t rare. Yet, ZIKV is a rare exposure for the people 
that spent only a short time in the ZIKV affected areas and 
gave birth to infants with such brain anomalies. Considering 
microcephaly statistics in the United States of America, it can 
be assumed to be a rare defect, with only 6 cases in 10000 
live-born infants. One of the recent reports in the U.S. illus-
trates this connection: a pregnant woman traveled to Mexico, 
Belize, and Guatemala during her 11th gestation week. She was 
tested positive for ZIKV IgM after her return. Ultrasonography 
and MRI of the fetus was performed during gestation weeks 19 
and 20 and severe brain anomalies were diagnosed; the head 
circumference had dropped from the 47th percentile during the 
16th week of gestation to the 24th percentile at gestation week 
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20. The pregnancy was terminated in the 21st gestation week, 
but considering the trend of the head circumference decrease, 
microcephaly would have developed if the pregnancy continued. 
(Rasmussen, et. al. 2016).
Mechanisms of infection of the fetal brain by Zika virus
The most recent research suggests that ZIKV is able to infect 
human neural progenitor cells, dysregulate transcription and 
stunt their growth. Human induced pluripotent stem cells (hiP-
SCs) were used as an in vitro model to investigate the mech-
anism of ZIKV infection and impact on neural cells. This study 
was able to determine that cells of different cell lines have vari-
ation in their susceptibility to the virus; hiPSCs showed one of 
the highest permissiveness levels. Further investigation of hiP-
SCs established that human neural progenitor cells (which can 
further be differentiated into cortical neurons, astrocytes, and 
oligodendrocytes) are a direct target of a ZIKV. Within 72 hours 
after being infected with ZIKV, total number of viable cells was 
observed to be reduce by 29.9 +/- 6.6%. Levels of caspase-3, in-
volved in apoptotic pathway regulation, in infected hNPCs were 
found to be significantly higher than those in control group. 
(Tang, et. al. 2016) However, it is hard to conclude if all strains 
of ZIKV affect human embryotic brain cells in the same manner, 
for only one strain of virus was used in this research. In addition, 
assessing the level of neurotropism expressed by ZIKV is intri-
cate because Zika infects other types of cells as well.
Conclusion
Evidence linking frequent occurrence of microcephaly in regions 
with ongoing ZIKV is deficient and scarce, for the pandemic is 
very recent and emerging. There are still many questions that 
remain unanswered, such as whether there’s a range of associat-
ed birth defects, how this range is affected by the timing of fetal 
exposure to the virus and severity of maternal infection, if such 
range exists, and whether severe anomalies are only limited to 
the CNS. 
However, based on the data available for analysis, it may be con-
cluded that ZIKV can cross the placental barrier and exhibit 
higher tropism to a specific range of tissues. The accumulation 
of geographical and temporal and rare exposure-rate defect as-
sociations between maternal ZIKV infection and microcephaly 
in fetuses and neonates, and multiple case-study findings sup-
port a causal relationship present between the two events. Yet, 
more research must be conducted to have a better understand-
ing of the effects and mechanisms of infection and to be able to 
propose possible treatment solutions.
List of Acronyms
Arbovirus Arthropod-borne virus
CDC Centers for Disease Control and Prevention
ELISA Enzyme-Linked Immunosorbent Assays
HIV Human Immunodeficiency Virus
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HTLV Human T-Cell Lymphotropic Virus
IgG Immunoglobulin G
IgM Immunoglobulin M
NAT Nucleic Acid Amplification Test
RT-PCR Reverse Transcriptase-Polymerase Chain   
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TORCHES Toxoplasmosis, rubella, cytomegalovirus,   
 herpesvirus, and syphilis
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Introduction
Fuel Source During Exercise
While the human body is at rest, skeletal muscle is responsible 
for 30% of oxygen consumed. During strenuous exercise, skeletal 
muscle can account for more than 90% of the total metabolism. 
ATP is required in order for skeletal muscles to contract and 
relax during exercise. As such, the purpose of muscle metabolism 
is to generate ATP via oxidative phosphorylation. Skeletal mus-
cle can use free fatty acids, glucose, or ketone bodies as fuel for 
ATP production (Garrett et al., 2012). Since cellular respiration 
involves several complex metabolic pathways, the relative utiliza-
tion of fat and carbohydrate during exercise can vary enormously 
and depends strongly on exercise intensity (Loon et al., 2001). 
Generally, as intensity of exercise is increased, the amount of ox-
ygen available decreases and the muscle carries out anaerobic 
respiration. This refers to glycolysis, a metabolic pathway that 
primarily uses carbohydrates as substrate. The increased carbo-
hydrate metabolism (glycolytic flux) limits the transport of long 
chain fatty acids into the mitochondria where fat oxidation gen-
erally occurs. Consequently, increased carbohydrate usage as fuel 
will inhibit the use of fat as fuel (Christmass et al., 2000). In high 
intensity intermittent exercise it’s often found that carbohydrate 
breakdown decreases, and fat oxidation increases as the exercise 
progresses (Talanian et al., 2006). This can be attributed to the 
interval nature of HIIE and is known as the “substrate-shuttle” 
effect. (EG Trapp et al., 2007).
The “Substrate-shuttle” Effect
Intramuscular triglycerides are an important supply of fuel for skel-
etal muscle. Each one is composed of three fatty acids esterified 
to a glycerol backbone. When glycerol levels are elevated, it’s in-
dicative of an increased reliance on fats for fuel. (Trapp et al., 2007).
Lactate is a waste product of glycolysis, generated from the an-
aerobic breakdown of glycogen. While exercising steadily, there 
is normally a balance between lactate production and lactate re-
moval. When the intensity of exercise reaches a point at which 
there is an abrupt increase in lactate levels, lactate threshold has 
been reached. If lactate levels are above threshold, the excess 
blood lactate will inhibit carnitine- acyl CoA transferase, an es-
sential enzyme which enables beta-oxidation to occur. (Trapp et 
al., 2007) (explain beta oxidation).
Lactate and glycerol levels were analyzed in one particular study 
of HIIE. 16 women, 8 trained and 8 untrained, participated in 
two 20 minute short sprint sessions (8 second sprint/12 second 
recovery) and two 20 minute long sprint sessions (24 second 
sprint/36 second recovery). After exercising, they found that 
plasma glycerol levels went up dramatically for both groups 
(P<.0001). Lactate levels rose as well; they were higher during 
long sprints for trained women than for short sprints (P<.01). 
(Trapp et al., 2007).
The elevated glycerol levels indicate that there was an increased 
fat oxidation for fuel. This enhanced fatty acid oxidation, seems 
contradictory to the fact that lactate levels were elevated above 
threshold (3.5mmol/L - 4.0mmol/L). The solution proposed 
for this contradiction is the intermittent nature of HIIE. The 
intervals in HIIE create a “substrate shuttle” with alternating 
anaerobic and aerobic energy sources. During the high inten-
sity periods, ATP and creatine phosphate are broken down to 
produce energy. During the rest periods, they are resynthesized 
aerobically. However, since the rest interval isn’t that long, it is 
likely that the resynthesis is incomplete and anaerobic glycol-
ysis provides the rest of the needed energy. This is verified by 
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Bangsbo et al. 1991, who found that glycogen, the substrate for 
anaerobic glycolysis, was shown to be progressively diminished 
over the course of HIIE. Eventually, repeated exercise results in 
an accumulation of cytosolic citrate which inhibits phosphofruc-
tokinase activity and impairs glycolysis. It is suggested that the 
progressive depletion of glycogen and phosphocreatine along 
with the increased levels of cytosolic citrate, act together to 
inhibit glycolysis, and allow for repeated bouts of high inten-
sity exercise, while reducing lactate accumulation. The aerobic 
metabolism that accompanies lower lactate levels may enhance 
fatty acid oxidation. (Trapp et al., 2007).
Methods
This comprehensive review is based on critical analysis of lit-
erature obtained using the Touro College Online library and 
Google Scholar. References in these articles were retrieved and 
served as additional points of reference for further research. 
Review articles were useful in helping provide additional refer-
ences to source material. 
Discussion
Many studies have been performed in an effort to establish the 
relationship of HIIE with increased fat loss. The studies examine 
whether HIIE causes enhanced fat loss, and via which mecha-
nisms this may occur. Since the mechanisms of carbohydrate 
metabolism, fat oxidation, and fat loss in general are complex 
and detailed, there are many different ways to determine if fat 
loss occurred as a result of exercise. The study of energy ex-
penditure, the analysis of skeletal muscle, the catecholamine re-
sponse, and the respiratory exchange ratio can all provide useful 
information regarding whether enhanced fat oxidation occurred 
as a result of HIIE.
Energy Expenditure and Fat Loss
The volume of physical work done is often the factor that plays 
the greatest role on energy expenditure (EE). This volume is 
based on the duration and intensity of the exercise done. For 
example, more energy is expended when walking 5 miles than 
when walking 3. Generally, as long as the activity is done at the 
same intensity, there is a linear relationship between EE and 
work carried out. However, when exercise intensity is changed, 
it affects how efficiently work can be performed. There is a 
negative relationship between exercise intensity and efficiency 
(Hunter et al., 1998). For example, for the same amount of cy-
cling, EE was 22% greater when it was carried out at a high 
intensity than at a low intensity (Treuth et al., 1996). The exact 
reasons behind this inverse relationship between efficiency and 
exercise intensity are unknown. In any case, it seems to be that 
the best way to increase EE is to carry out a high volume of 
work at high intensity. However, this kind of exercise can bring 
about fatigue very quickly. Therefore, high intensity exercise 
interspersed with rest intervals seems to be an ideal way to 
increase EE by combining high intensities with multiple rest in-
tervals (Hunter et al., 1998). 
The question that follows is if two exercises have equal EE, yet 
one was reached via HIIE and the other via low intensity contin-
uous exercise, will HIIE generate more fat loss?
One study that compared results of high and moderate intensi-
ty exercise programs with equivalent EE found that this was in-
deed the case. This 15 week intervention study was performed 
on 34 healthy women aged between 18 and 30 years old. They 
were divided into an HIIE group, a continuous exercise group, 
and a control group. The HIIE protocol consisted of 8 seconds 
sprinting on an ergometer(?), alternating with 12 seconds of 
turning the pedals slowly. As each subject was able to complete 
20 minutes of HIIE at a resistance of .5kg, the resistance for 
that subject was increased by increments of .5kg. The continu-
ous exercise protocol consisted of a five minute warmup and 
cooldown, and a 15-20 minute (later increasing to 40 minute) 
work session pedaling at a continuous intensity of 60% VO₂ 
peak. VO₂ peak is the point when a subject’s oxygen consump-
tion plateaus at ≤150 ml/min VO₂ as the test progressively gets 
more difficult. When this happens, it’s indicative of the fact that 
the subject is close to his actual VO₂max capacity, or maximal 
oxygen intake. In the continuous exercise group as well, the re-
sistance was raised by incremnets of .5kg as the fitness of each 
subject improved. The control group was instructed to maintain 
their usual diet and physical activty. Total EE for the continuous 
exercise group and HIIE group was 36.3 ± 3.4 MJ and 41.5 ± .81 
MJ, respectively. This is considered a non-significant difference. 
Nevertheless, there was a substantial decrease in total body 
mass for the HIIE group compared to the other groups. The 
HIIE group also displayed a significant decrease in fat mass while 
the other two groups had a fat mass gain. (Trapp et al., 2008). 
Not only did the HIIE group expend the same amount of energy 
in a shorter amount of time, that equivilent EE caused more fat 
loss when reached via higher intensity exercise. 
It should be noted that studies have indicated a direct correla-
tion between initial adiposity and amount of fat lost. Research 
has shown that subjects with higher fat levels to begin with, 
tend to lose more fat (Trapp et al., 2007), (Trapp et al., 2008). 
This would support the notion that HIIE would generate a more 
significant loss of fat in overweight individuals than in thinner 
subjects.That being said, there were four lean women in the 
HIIE group of the aforementioned study who possesed signifi-
cantly lower fat mass than the rest of the group. With these four 
women removed, the HIIE group displayed a 4.3% decrease in 
total body mass, a 14.7% decrease in total fat mass, and a 9.5% 
decrease in central abdominal fat. Conversely, the continuous 
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exercise group displayed a 10.5% increase in central abdominal 
fat. (Trapp et al., 2008). These results futher demonstrate that 
for a given expenditure of energy, fat loss is greater when in-
tensity is high.
Another study was performed on 21 middle aged obese women 
with the metabolic syndrome, displayed similar results. During 
this 16-week exercise intervention program, the women were 
divided into 3 groups – control, low intensity exercise train-
ing (LIET), and high intensity exercise training (HIET). The LIET 
group trained five days a week at an intensity at or below their 
lactate threshold. The duration of each session was adjusted so 
that the participants expended a specific amount of energy per 
week. The HIET group also exercised 5 days a week, with high 
intensity sessions for three of the days and moderate intensity 
exercise sessions for the remaining two. Participants exercised 
at an intensity between their lactate threshold and VO₂peak on 
the high intensity days and at an intensity at or below their lac-
tate threshold on the lower intensity days. Again, the duration of 
sessions was modified based on the progression of caloric ex-
penditure as the training intervention proceeded. The findings 
indicate that exercise of higher intensity generates greater fat 
loss compared to exercise of lower intensity under isocaloric 
training conditions. (Irving et al., 2008).
It should be noted that the HIET group in this study likely had 
a total EE that was slightly greater than that of the LIET group. 
This is because the total EE per session was a combination of 
the kcal expended during training as well as resting metabolism. 
Therefore, on HIET days when the duration of exercise was 
slightly shorter, the resting metabolism would contribute to a 
lower fraction of the total EE. This caused a 25 kcal difference 
between the HIET and LIET groups per week, totaling a differ-
ence of 400 kcal over the course of the training intervention. 
(Irving et al., 2008).
The previous studies examined the difference in fat loss when 
EE was equal between groups. Overall, greater fat loss was 
noted when exercise was done at higher intensites. Research 
has also been done to compare HIIE and continuous exercise 
when EE is not equivalent.
In one study, the mean estimated total energy cost was 120.4 MJ 
for the continuous/endurance training (ET) exercise program, 
and 57.9 MJ for the HIIE program. Nevertheless, the reduction 
in the sum of six skin folds was greater after HIIE. Since there 
is an association between exercise duration and fat loss, the 
changes in subcutaneous fat were corrected based on the total 
energy cost of training. As demonstrated when the decrease 
in the sum of the skinfolds was divided by energy expenditure 
and expressed as changes in subcutaneous skinfolds per MJ, the 
participants in the HIIE program lost nine times more subcuta-
neous fat than those in the ET program (Tremblay et al., 1994). 
However, not all studies show HIIE to be the superior to ET. 
Very often, when the EE is not equivalent, HIIE will not bring 
about more favorable results than ET. Nevertheless, if HIIE brings 
about the same results with a smaller time investment, it is still 
extremely worthwhile. In the present study is an example of 
HIIE that brought about results copmarable to ET. Sprint interval 
training is a form of HIIE where the high intensity intervals in-
volve 30 second “all-out” sprints on an ergometer. 16 active men 
were separated into a sprint interval training (SIT) group and a 
high volume endurance training (ET) group. In this study, the SIT 
protocol consisted of 6 sessions of 4-6 repeats of 30 seconds 
“all-out” cycling at about 250% VO₂peak with 4 minute recovery 
periods. The ET program consisted of 90-120 minutes of contin-
uous cycling at 65% of VO₂peak. Total EE was 630 KJ for the SIT 
group, and 6500 KJ for the ET group. Despite the fact that EE for 
the ET group was 10 times more than the EE for the SIT group, 
the results showed that SIT brought about similar improvements 
in muscle oxidative capacity. (Gibala et al., 2006). 
Another SIT study yielded similar results. 20 young men and 
women were separated into SIT and ET groups for 6 weeks of 
training.  The SIT consisted of 4-6 30 second “all-out” cycling 
tasks (at 500W) three times a week, and the ET group consist-
ed of 40-60 min of continuous cycling at about 65% VO₂peak 
five days a week. Total weekly exercise volume was 90% lower 
in the SIT group. Moreover, since most of SIT exercise time is 
actually spent in recovery from the 30 second bouts of cycling, 
actual weekly exercise time was only about ten minutes in SIT, 
compared to 4.5 hours in ET. Nevertheless, results between 
the two groups were very similar: whole body fat oxidation 
was increased and carbohydrate oxidation was decreased. 
(Burgomaster, 2008).
Skeletal Muscle Analysis
As mentioned earlier, the “substrate-shuttle” effect supports 
enhanced fat oxidation by activating aerobic metabolism and 
enabling the mitochondria to produce ATP. In line with this, it’s 
likely that HIIE will result in increased mitochondrial enzyme 
activity. Therefore, when studying the effects of HIIE on skeletal 
muscle, many researchers focus on changes in mitochondrial 
enzymes. Based on increased activity of mitochondrial enzymes 
and the fact that aerobic metabolism favors enhanced fatty acid 
oxidation, it’s possible to surmise that an increase in mitochon-
drial enzyme activity during HIIE will correlate with fat loss. 
Citrate synthase and β-HAD (Hydroxyacyl- Coenzyme A dehy-
drogenase) activity, are important indicators of enhanced fatty 
acid metabolism, that were significantly increased in an HIIE 
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intervention in just 2 weeks. In this study, skeletal muscle en-
zyme activity was measured to confirm an increase in the use of 
fats as fuel. 8 healthy recreationally active women participated 
in this study. Each of them performed a VO₂peak test before and 
after 2 weeks (7 sessions) of HIIE. The VO₂peak tests involved 
a 60 minute cycling trial at about 60%VO₂peak. The seven HIIE 
sessions consisted of 10 cycles of 4 minutes of high intensity 
cycling at 90%VO₂peak alternating with 2 minute resting pe-
riods. Whole body fat oxidation and total fat oxidation were 
both significantly increased during the 60 minute cycling session 
after HIIE. Accordingly, there was a significant decrease in whole 
body carbohydrate oxidation and a 23% decrease in total car-
bohydrate oxidation. These results were then supported with a 
skeletal muscle analysis. (See Table 2)
ANALYZED IN 60 MINUTE SESSION 
AFTER HIIE
β-HAD activity increased by 32%
citrate synthase activity Increased by 20%.
HSL protein content Increased by 13% 
FABPpm increased 25%
FAT/CD36 remained unchanged
Resting muscle glycogen 
content
Unchanged
Net muscle glycogen utilization Decreased by 12%
Intramuscular triglycerides Decreased by 17% 
(before HIIE, by 12%)
Table 2 Summary of skeletal muscle analysis conducted 
after a 2 week HIIE intervention study (Talanian et al., 
2006).
Usually, exercise training results in increased fat oxidation from 
fatty acids stored in adipose tissue and intramuscular triglycer-
ide (IMTG) stores. In this study, however, HIIE did not cause a 
significant increase in IMTG utilization. HSL (hormone sensitive 
lipase) protein content was also not seen to be significantly in-
creased. HSL is a key regulatory enzyme in lipolysis of IMTG 
stores. It’s possible that the HIIE protocol in this study was too 
short to bring about significant adaptations in skeletal muscle 
(Talanian et al., 2006). 
FABPpm (plasma membrane fatty acid-binding protein) and FAT/
CD36 (fatty acid translocase) are two proteins that transport 
long chain fatty acids  (LCFA) across the plasma and mitochon-
drial membranes. They are useful in determining if skeletal fat 
oxidation was enhanced or limited during exercise. In this study, 
FABPpm concentration was increased by 25% after HIIE,, and 
FAT/CD36 concentration remained unchanged. It is true that an 
inhibition of FABPpm will reduce the uptake of LCFA, but an un-
changed FAT/CD36 doesn’t necessarily mean the same thing. It’s 
possible that there was a shift in the fractional concentrations 
of FAT/CD36 on the mitochondrial and plasma membranes that 
could have increased LCFA uptake without a notable increase in 
FAT/CD36 concentration. (Talanian et al., 2006).
The elevated citrate synthase and β-HAD levels indicate in-
creased use of fats for ATP. Citrate synthase is a critical enzyme 
in the citric acid cycle, a cycle which favors aerobic metabolism, 
and likely the use of free fatty acids as fuel. β-HAD, or 3-hy-
droxyacyl-CoA dehydrogenase, is an enzyme that catalyzes an 
important step in fatty acid metabolism. (Talanian et al., 2006) 
In another SIT program, citrate synthase and β-HAD were 
analyzed as well. The results after 6 weeks of training showed 
that both citrate synthase and β-HAD increased after SIT in a 
similar manner to that of ET (See Figure 1), suggesting that fatty 
acid oxidation was occurring. This was further proven by the 
tremendous increase in whole body fat oxidation noted after 
training (Burgomaster, 2008).
Malate dehydrogenase (MDH) is another enzyme that is needed 
in the citric acid cycle. Increased MDH is indicative of aerobic 
conditions, and likely increased fat oxidation. In one particular 
study that compared HIIE to ET, increased MDH was found in 
both groups. 27 men and women partook in this study. 8 men 
and 9 women participated in a 20 week ET intervention, and 5 
men and 5 women participated in the 15 week HIIE intervention. 
The ET program included a 30 minute (increasing to 45 minutes) 
cycling session, 4 times (increasing to 5) times) a week. Intensity 
corresponded to 60% (and increasing to 85%) of the maximal 
heart rate reserve. The HIIE intervention consisted of 25 sessions 
with 30 minutes of continuous exercise at an intensity similar to 
the endurance training program. Half of these were completed by 
the fifth week of the program. It also included 16 short interval 
sessions (10-15 bouts of 15-30 seconds of high intensity intervals, 
alternating with recovery periods to allow heart rate to return 
to 120-130 beats per minute), and 19 long interval sessions (4-5 
bouts of 60-90 seconds of high intensity intervals alternating with 
recovery periods to allow heart rate to return to 120-130 beats 
per minute). The results showed that participants in the HIIE pro-
gram lost nine times more subcutaneous fat than those in the ET 
program. These results were supported by the increased MDH 
activity. Furthermore, there was a substantial increase in β-HAD 
in the HIIE group alone, another indication of the fact that HIIE 
leads to better lipid utilization (Tremblay et al., 1994).
Catecholamine Response
Epinephrine is a catecholamine known for stimulating lipolysis. 
As such, elevated epinephrine concentrations after exercise 
would indicate an increased use of fat as fuel. Trapp et al., 2007 
demonstrated this in their study when examining the differ-
ent responses of trained and untrained women during HIIE. 
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It was found that epinephrine and norepinephrine levels both 
increased after short sprint and long sprint exercise (see Figure 
8). The elevated catecholamine levels serve as another expla-
nation of why the glycerol levels in that previously mentioned 
study were increased despite lactate levels above threshold.
Respiratory Exchange Ratio (RER)
RER is the ratio of carbon dioxide produced to oxygen con-
sumed. Based on the RER, it is possible to estimate which partic-
ular fuel is being oxidized to produce energy. An RER close to .7 
is indicative of fat as the energy source, and an RER close to 1.0 
is indicative of carbohydrate as the energy source. An RER value 
between the two indicates a mixture of fat and carbohydrate. 
Therefore, by measuring RER after an exercise intervention, one 
can deduce what fuel was oxidized in order to produce ATP. 
In one study, 10 obese males participated in 6 sessions of sprint 
interval training over a 2 week period. After the 2 week inter-
vention, it was noted that the RER decreased from .78 +/- .01 
to .73 +/- .01, suggesting that fat was the primary substrate used 
for oxidation. This was further confirmed by the fact that resting 
carbohydrate oxidation was significantly lower after training and 
that resting fat oxidation was increased by 18.2%. Even though 
significant weight loss wasn’t noted in this study, (body mass was 
somewhat lower (P=.055), and waist and hip circumference were 
reduced by ≈1 %,) the magnitude of increase in resting fat oxida-
tion is used in order to predict the extent of exercise-induced 
fat loss. This estimate is based on resting fat oxidation alone and 
is independent of exercise energy expenditure and change in 
resting metabolic rate. The fact that no noteworthy weight loss 
was noted in this study is explained by the fact that the inter-
vention was short-term. Based on the increased fat oxidation, it 
can be inferred that a longer-term intervention would likely yield 
more substantial weight loss results (Whyte et al., 2010).
Can HIIE really help the overweight population?
The actual benefits of interval training can be seen when com-
paring it to another weight loss method. 62 overweight adoles-
cents were divided into two groups- aerobic interval training 
group (AIT) and multidisciplinary approach group (MTG). The 
AIT group did HIIE on a treadmill twice a week for 3 months, 
and were then encouraged to perform at least 2 interval ses-
sions for the next 9 months. The HIIE sessions included 4, 4 
minute bouts at 90% of maximal heart rate, alternating with 3 
minute lower intensity sessions at 70% maximal heart rate. The 
MTG were subjected to a 12 month regimen which included 
meeting every 2 weeks with a doctor, a clinical nutritional phys-
iologist, and a nutritional psychologist. After 3 and 12 months, 
only the subjects in the AIT group had a decreased percentage 
of body fat. It’s interesting to note that the subjects in the AIT 
group followed a better diet than those in the MIT group even 
though they were not given clear guidelines regarding caloric 
intake. This is possibly because AIT brought about a motivation-
al side effect of improving their aerobic capacity. Indeed, some 
members commented that they became more conscious of 
their eating habits after 3 months of the AIT program. (Tjonna 
et al., 2009).
Limitations
When analyzing fat loss over an extended period of time, it is 
difficult to isolate the cause of it. Even though subjects in the 
HIIE studies were instructed to maintain their regular diets, it’s 
not guaranteed that they did. As a result, it’s possible that some 
of the fat loss displayed after an exercise intervention was partly 
due to dietary modifications.
Another limitation the study of HIIE poses, is the varying inten-
sities and duration of intervals. Most studies mentioned in this 
paper prescribed a different HIIE “formula.” Since there hasn’t 
yet been a study that tests every combination of intensity and 
duration of exercise, it is difficult to determine the minimum 
length and intensity needed in order to bring about the benefits 
of HIIE. It’s possible that the results discussed in this review 
would not be successfully replicated if done at a slightly lower 
intensity, or for a shorter amount of time. 
Conclusion
HIIE is an arduous method of exercising which requires subjects 
to push themselves to their maximum capacity for short inter-
vals of time. Most studies conducted regarding HIIE involve high 
Figure 1 Activity 
of citrate synthase 
and β-HAD before 
and after 6 weeks 
of SIT training 
(Burgomaster, 2008).
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intensity intervals that are extremely difficult and demanding. 
Although HIIE has been shown to enhance fatty acid oxida-
tion and increase fat loss, it may be dangerous for an obese, 
non-physically active person to attempt.
That being said, for individuals who could handle the workload 
of HIIE, the short duration of intense intervals might encourage 
exercise because there’s only a small span of time where they 
are required to push themselves. Moreover, more people might 
be motivated to exercise daily since only a few short sessions of 
HIIE are needed to improve whole body fat oxidation. As men-
tioned earlier, it took only 7 sessions of HIIE to increase total fat 
oxidation by 36% in previously untrained women (Talanian et al., 
2006), and only 6 sessions of sprint training for overweight men 
to increase resting fat oxidation by 18.5% (Whyte et al., 2010).
Further research is needed in order to determine the minimum 
intensity and duration required for HIIE-induced fat loss. Because 
there are a large number of potential variables regarding the kind 
of exercise, the intensity and duration of the exercise, and the 
population exercising, it is difficult to create an exact guideline 
for HIIE. Consequently, more research is needed before HIIE is 
prescribed, to help decrease fat in overweight individuals.
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Introduction
Transplanting new organs is a way of trying to deal with life 
threatening diseases. Instead of the chronic maintenance of dis-
eased organs medical professionals would be able to replace 
them, thus curing the condition. One leading major health cri-
sis is the shortage of organs available for transplants. Although 
medicine’s advancements help people live longer, organs tend 
to fail more often as a result of longer lifespans. For instance, 
in the United States, a name is added to the Transplant List 
on an average of every ten minutes. Additionally, the number 
of patients needing organs have doubled while the amount of 
transplant procedures has barely increased (OPTN, 2016). 3D 
organ printing technology is a promising step to help solve the 
organ transplantation crisis. 
The field of regenerative medicine deals with replacing, engi-
neering, or regenerating human cells, tissues, or organs in order 
to help achieve normal function. Regenerative medicine is not 
a new field; Alexis Carrel, a Nobel Prize winner, writes in his 
book, “The Culture of Organs” (Carrel, Lindbergh, 1938) about 
technologies that are still used today for blood vessel grafting.
Thomas Boland, self-described as the “grandfather of bioprint-
ing,” took an old Lexmark computer, emptied the ink cartridge 
and filled it with collagen instead. He then glued a thin, black 
silicon sheet onto blank paper and inserted it into the printer. 
He opened a Word document on his PC, typed his initials, and 
hit print. The paper came out with “TB” clearly presented in off-
white proteins. By 2000, Boland and his team had reconfigured 
a Hewlett-Packard DeskJet 550C to print with E. coli bacteria. 
Then they expanded to larger mammalian cells obtained from 
Chinese hamsters and lab rats. Once printed, 90 percent of the 
cells remained viable, which meant the product was useful , not 
only art. Boland introduced 3D printing for cellular construct 
when he patented the process for using the ink-jet printer for 
printing cells.  Boland’s process used a system where cells were 
deposited into 3D matrices placed on a substrate. Instead of 
using ink, 3D printers use cells in a cartridge where the cells are 
being layered in order to create a three-dimensional structure 
that can lead to functional organs and tissues (Wilson, Boland, 
2003). This paper will review the current progress in organ 
printing technology with its promises and challenges and evalu-
ate whether functional organs can be produced. 
Methods
The information in this paper was obtained by the analysis of 
scientific articles and research papers obtained from the Touro 
College Online Library, specifically, the Health Science relat-
ed databases such as Pubmed, Proquest Medical Library, and 
EBSCO multisearch. Additionally, websites like NIH.gov, Webmd.
com, Mayoclinic.com and OPTN.com were used to gain general 
knowledge and information about the subject. Keywords such 
as “3D organ printing” and “regenerative medicine” were used 
to search for scientific articles.
Discussion: The Bladder
At first, researchers were pipetting cells into petri dishes by 
hand without the use of 3D printers. To do so, researchers 
would seed the cells from the petri dishes onto artificial scaf-
folds; a suitable base for the organs. The scaffolds were made 
from biodegradable polymers or collagen which provided a 
temporary matrix for the cells to cling to until they were able 
to stand on their own. Dr. Anthony Atala, the lead researcher 
at Wake Forest Institute for Regenerative Medicine, implanted 
the first lab grown bladder organs into seven patients at Boston 
Children’s Hospital between 1999 and 2001 (Atala et. al., 2006). 
There are a variety of injuries that can lead to damage or loss 
of the bladder, requiring eventual replacement or repair of the 
organ. Children with congenital anomalies such as: bladder ex-
strophy, myelomeningocele, or posterior urethral valves, can 
develop high-pressure and hypertonic low compliant bladders. 
Often times, these patients require cystoplasty when drug 
treatment fails. Gastrointestinal segments are frequently used 
as donor tissues for cystoplasty. However, when such tissues 
are incorporated into the urinary tract, several complications 
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can ensue; such as metabolic disturbances, urolithiasis, increased 
mucous production, and malignant disease (Emedicine, 2016).
Atala, along with his research team, explored an alternative ap-
proach using autologous engineered bladder tissue for recon-
struction. Seven patients with myelomeningocele, aged 4-19 years 
old, with poorly compliant bladders were identified as candidates 
for cystoplasty.  Urethral and muscle cells from the patients 
were grown in a culture, and seeded on a biodegradable bladder 
shaped scaffold made of collagen, or a composite of collagen and 
polyglycolic acid. About seven weeks after biopsy, the autologous 
engineered bladder constructs were used for reconstruction and 
implanted into patients. Tests such as serial urodynamics, cyto-
grams, ultrasounds, bladder biopsies and serum analyses were 
performed. The bowel function of the patients returned to nor-
mal promptly after surgery with no metabolic consequences and 
renal function was preserved (Atala et. al., 2006). 
Researchers soon adopted 3-D printers to make scaffolds 
more precisely because manually placing the cells onto scaffold 
remained a time-consuming and arduous process. Engineered 
bladders were made possible because they can be made with 
just two cell types however, an organ such as a kidney consists 
of thirty cell types. When attempting to engineer more complex 
tissues, there is no way to manually place different cell types into 
different locations that can replicate the native tissue structures. 
Manual placement is not the optimal method for delivering cells 
(Murphy, Atala, 2014).
The Heart
The human heart is a complex biological machine. It pumps 
blood to all parts of the body, begins to beat three weeks after 
conception and does not stop until the day of death. It is re-
markable how the heart can last that long and function with the 
same redundancy and efficacy. The heart operates for billions of 
cycles, it is chemically powered and electrically synchronized. 
The heart is composed of over a hundred billion cells including 
cardiomyocytes, conduction system, fibroblasts, endothelial cells, 
smooth muscle cells and neurons. The main reason researchers 
are trying to 3D print the heart is because the heart is unable to 
regenerate itself and for this reason heart disease is the leading 
cause of death in first world countries (Mayo Clinic, 2016).
A heart transplant is a lifesaving procedure which removes a 
damaged or diseased heart and replaces it with a new one. 
Heart failures come as a result of different conditions such as 
coronary heart disease, damaged heart muscle or valves, con-
genital heart defects, or viral infections of the heart. Once the 
human heart is damaged, there is only a limited amount of re-
generation that can occur and may require a heart transplant. 
A heart transplant comes with many risks and complications 
such as infection or the recipient’s body attempting to reject 
the newly placed heart. To prevent rejection, the patients must 
immediately be given immunosuppressants as a lifelong treat-
ment (Mayo clinic, 2016). There are currently 4,138 candidates 
who are on the UNOS list for a heart transplant (OPTN, 2016). 
The high number of candidates results in an agonizing wait for 
a new heart which usually does not have a positive ending. This 
long waiting list can be reduced through the possibility of 3D 
printing of the human heart.
The hierarchical structure and function in the heart has levels 
that scales from the nanometer level up to the macroscopic 
level. Every heart beat is powered by molecular motors, the 
actin and myosin, which are only a few nanometers in size and 
generate pico newtons amount of force. The actin and myosin 
are built into larger structures called the sarcomeres, the con-
tractile unit of a muscle cell. Then, these are built into myofibrils 
which form tissue and surrounds the ventricles of the heart. At 
this present day, technology is unable to engineer something 
this complex starting from the nanometer scale and up. Yet, sci-
entists are able to figure out where they are able to interface 
with the system, by providing information into the biology that 
can guide the living system to do the work of producing the 
components of the microstructures. Once the cells are formed, 
they themselves manufacture the microstructures necessary 
and the 3D bioprinting scaffolds, the suitable base, are used to 
build larger structures up to the size of a whole organ. 
The embryo is a perfect example of biological manufacturing, it 
starts off with one cell and those cells divide and build an extra-
cellular matrix around themselves until there is a full function-
ing organism. The extracellular matrix is a nanofiber network of 
protein and other molecules. It mechanically integrates cells into 
tissues, acts as an insoluble signaling network and functions as a 
scaffold that fills the space between the cells and tissues. This ma-
trix acts as information because it provides cells with instructive 
cues on how to organize and form tissue. It signals between the 
cells using physics, chemistry and mechanics and is integral to 
tissue formation and function (Rozario, Desimone, 2010). A tech-
nique called Bottom Up Engineering of the Extracellular Matrix 
(ECM) was an attempt to build the ECM in the same way cells do; 
from single molecules into a complex 3D fiber with tissue specific 
structure and function according to the organ that is being engi-
neered. This technique thereby accelerates the system of tissue 
formation (Szymanski et. al., 2014).
The idea of using the extracellular matrix is utilized in the fol-
lowing technique for 3D bioprinting organs and other struc-
tures. Soft materials such as collagen and fibrin are difficult for 
scientists to work with because they collapse under their own 
weight and do not have the mechanical strength to be printed 
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in air. To overcome this problem, a gel in gel technique dubbed 
Freeform reversible embedding of suspended hydrogels is used. 
This approach involves soft materials such as fibrin, collagen 
and the polysaccharide alginate. The materials are inside a thick 
slurry of gelatin microparticles and water in a petri dish. The 
semiliquid mixture of gelatin microparticles is able to flow 
around the printing needle as it operates. At the same time, the 
soft biomaterials being released are firmly implanted during the 
layer by layer printing technique. Once the printing of the scaf-
folds is completed, the dish is warmed up to 37 degrees Celsius 
thereby removing the gelatin and revealing the scaffold replica 
of an organ or tissue (Hinton et. al., 2015, Figure 1).
One application of this technique is using magnetic resonance im-
aging (MRI) to print patient specific scaffolds to engineer tissues. 
Through magnetic imaging the right coronary arterial tree is 3D 
printed. The right coronary artery along with the left coronary 
artery supplies blood to the heart. The right coronary artery is 
specifically responsible to supply blood to the right atrium, right 
ventricle, bottom portion of the left ventricle and the back of 
the septum. Additionally, the coronary arteries become blocked 
during a heart attack. The 3D printed artery was made of ECM 
materials such as fibrin, hyaluronic acid and alginate with solid 
walls and an open lumen. On a makerbot 3D printer the artery 
took about one hour to print which is the timeframe within the 
viability of cells. The wall thickness, lumen diameter and density 
can be tailored based on patient anatomy. To evaluate whether 
the 3D printed arterial tree was manifold it was set up in a cus-
tom made 3D printed perfusion fixture. A solution of CaCl₂ and 
0.1% black food coloring was injected into the root of the tree. 
Perfusion was successful and captured on camera. The printed 
coronary artery has not been used for transplants such as a cor-
onary artery bypass, yet this technique is a step up from the cur-
rent printing of just straight tubes. This technique creates more 
complex architecture like the real coronary artery tree that can 
hold a better potential graft (Hinton et. al., 2015, Figure 2).
(D) A model of a section of a human right coronary arterial tree 
from 3D MRI is processed at full scale into machine code for FRESH 
printing  (E) An example of the arterial tree printed in alginate (black) 
and embedded in the gelatin slurry support bath  (F) A section of 
the arterial trees printed in fluorescent alginate (green) and imaged 
in 3D to show the hollow lumen and multiple bifurcations  (G) A 
zoomed-in view of the arterial tree shows the defined vessel wall that 
is <1 mm thick and the well-formed lumen. (H) A dark-field image of 
the arterial tree mounted in a perfusion fixture to position a syringe 
in the root of the tree  (I) A time-lapse image of black dye perfused 
through the arterial tree false-colored at time points of 0 to 6 s to 
show flow through the lumen and not through the vessel wall. Scale 
bars, 4 mm (B), 10 mm (E), 2 5 mm (F), 1 mm (G), and 2 5 mm (H 
and I)  (Hinton et  al , 2015) 
Another application of the Freeform reversible embedding of 
suspended hydrogels technique is used to build the embryonic 
heart. The 3D model of the embryonic chick heart was gen-
erated from 3D optical imaging data of a fluorescently labeled 
5-day-old heart. The embryonic stage is the time when the heart 
muscle forms. It is the only time where the human body has the 
potential to form new heart muscle. In order to accurately 3D 
print an organ, there needs to be accurate data input to the 
system. The first step is the 3D imaging of the embryonic heart 
to identify the ECM macrostructure and microstructure asso-
ciated with myogenesis and vascularization. 3D imaging goes 
through the embryonic heart and images the entire heart, ven-
tricles, and trabeculated tissue together with all the exquisite 
details. A 3D computer model of the trabeculated embryonic 
heart is generated based on confocal imaging of cells and the 
extracellular matrix. Then, based on the computer model the 
3D heart is printed and compared with the computer generat-
ed image (Hinton et. al., 2015, Figure 3). 
Figure 1 (Hinton et. al., 2015)
Freeform reversible embedding of suspended hydrogels 
technique
Figure 2 (Hinton et. al., 2015)
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One step further in 3D cardiac printing is the ability to print 
cardiac cells called organoids. This research called “Body on 
a Chip” is currently ongoing at Wake Forest Baptist Medical 
Center. The research converted human skin cells into a net-
work of functioning heart cells, and also fused them with lab 
grown liver cells using a 3D printer. The heart organoid is able 
to beat because it contains specialized cardiac cells and the cells 
receive correct environmental cues such as keeping them at 
the same temperature as the human body. The organoid heart 
cells are made by genetically modifying adult human skin cells 
into induced pluripotent stem cells. Then, these cells are repro-
grammed to produce the organoids which have a diameter of 
0.25 millimeters. The organoids grow and form balls which then 
are 3D printed into different forms and sizes. These cells will 
create tiny organ-like structures that mimic the function of the 
real organ. The organ structures are then placed on a chip to 
provide for an online monitoring. The ultimate goal is to create 
mini organs to test them with different biological and chemical 
agents and the effectiveness of various treatments against dis-
eases (Wakehealth.edu 2016, Figure 4).
The Kidney
In addition to the great need of heart transplants there is even 
a greater number of patients waiting for a kidney transplant. 
Currently, there are over a hundred thousand people anxiously 
waiting for a lifesaving kidney (OPTN, 2016). The kidneys are 
responsible for removing excess fluid and waste from the blood. 
When the kidneys lose their filtering ability, there is a danger-
ously high level of fluid and waste accumulating in the body. This 
condition is known as kidney failure or end stage kidney disease. 
A kidney transplant procedure is often the best way to treat 
a kidney failure. Only one kidney is necessary to replace two 
failed kidneys, thus making a living donor kidney transplantation 
possible (Kidney.org, 2014). 
A kidney transplant can pose risks to both the donor and the 
recipient. There can be possible surgical complications such as 
pain, infection, blood loss, blood clots, allergic reactions to an-
esthesia, pneumonia, injury to surrounding tissue and organs, or 
even death. There are also long term risks for donating a kidney 
such as hypertension, large amounts of protein in the urine, her-
nia, organ impairment or failure that can lead to the need for di-
alysis or transplantation and can even cause death. Additionally, 
there is the problem of the recipient’s body rejecting the kidney 
as a foreign invader. Just as in a heart transplant, the patient will 
need to remain on immunosuppressants every day to prevent 
rejection of the new kidney. These anti-rejection medications 
have a large number of possible side effects because the body’s 
immune system is suppressed (kidney.org, 2014). 
Dr. Anthony Atala demonstrated an early stage experiment that 
could solve the kidney organ donor problem. The experiment 
uses a 3D printer that contains live cells and kidney shaped struc-
ture of collagen to output a transplantable kidney. A blueprint is 
created through a CT scan that goes layer by layer using com-
puterized morphometric imaging analysis and 3D reconstruction 
which leads to actually imaging the kidneys. The image can even 
do a full 360-degree rotation to analyze the kidney in its full volu-
metric characteristics. This information is then taken and scanned 
into a printing computerized form. The printer is then guided by 
the computer imaging and drips the cells layer by layer over the 
scaffold causing the inert mold to come to life. Overtime, the 
millions of cells begin to communicate and function as one organ. 
It took the research team about seven hours to print the 3D 
kidney structure (Murphy, Atala, 2014, Figure 5, Xu et al., 2013).
Vascularization
The kidney represents a challenge more than other organs due 
to the kidney’s detailed, tiny structures that allow the organ 
Figure 3
Printed embryonic heart scaffolds with complex internal 
and external architectures based on 3D imaging data from 
whole organs
Figure 4 (Wakehealth.edu
3D printed beating, cardiac cells called “organoids)
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to perform its sophisticated filtration job by removing waste 
chemicals from blood and turning the waste into urine. The 
function of removing waste is processed by roughly one million 
nephrons which are tiny vessels made up of even smaller urine 
collecting structures called tubules. The kidneys are also respon-
sible to measure chemicals such as sodium and potassium that 
are then released back into the bloodstream in healthy dosag-
es. The kidney’s complex vascular structure especially poses a 
challenge. The vascular tree of the kidney can come down to 
the size of a capillary about eight microns in diameter. Due to 
the kidney’s complexity, it has not been printed for transplant 
in humans at this present time, however researchers are avidly 
looking for ways to make it a reality and help people suffering 
from dialysis treatments while being on a multiple year waiting 
list for a kidney (Murphy, Atala, 2014). 
For a transplant tissue to thrive, a complex level of vasculariza-
tion must be achieved. To some extent, capillaries can branch 
out from already existing blood vessels and into transplanted 
tissue on their own. Researchers have seen signs of sponta-
neous vascularization in small areas of engineered tissue such as 
in healed rat bone defects around three millimeters in diameter 
(Fielding, Bose, 2013). Rather than letting blood vessels sponta-
neously branch off and expand to engineered tissue, researchers 
are crafting templates for more orderly vascular growth. The 
idea is to create hierarchical microvascular networks that will 
guide the endothelial cells that line blood vessels to form tubes 
along predetermined courses. However, capillaries are small, 
measuring just a few microns in diameter. Therefore, even with 
high resolution printers, such small vascular structures would 
most likely collapse especially when printed into soft, biocom-
patible gel. 
Jennifer Lewis researched the vascularization problem using 
a customized, high resolution 3D printer that can form mi-
crochannels in biocompatible gels. Lewis’s research group is 
able to print hydrogel materials down at the micron length 
scale. The smallest microvascular channel the group was able 
to print was about ten microns in diameter. To solve the prob-
lem of collapsing channels, she prints them in fugitive ink which 
is a substance designed to melt away forming the channels 
pattern. The fugitive ink used is called Pluronic 4127, a gel that 
is often used in eyeglass lense cleanser and cosmetics. Pluronic 
4127 is made up of three parts, the two poles of the molecule 
are hydrophilic while the middle segment is hydrophobic. The 
ink also liquefies when it is cooled down as opposed to most 
materials that solidify when they are cooled down (Wu et. 
al.,2011). 
Lewis also used Pluronic F127 as the matrix for the printed 
channels, but the matrix molecules were modified so that they 
polymerize, and thus solidify, in the presence of UV light. This 
allows the matrix to become firm before cooling the gel so that 
the fugitive ink melts away. Taking advantage of the printer’s fine-
tipped nozzle, the research team printed a capillary network 
of fluorescently labeled fugitive ink into the Jello-like matrix. 
Through this technique, a way to pattern hydrogels with vascu-
lar channels was accomplished (Wu et. al., 2011). The next step 
is to take advantage of the self-organizing quality of endothelial 
cells in the 3-D–printed constructs, seeding the printed vascular 
structures with these blood vessel–lining cells. The self orga-
nizing quality is the tendency of the finest capillaries to grow 
spontaneously out of larger microvascular structures which is 
the work of biology when the cells are given a reasonable envi-
ronment (Perryn et. al., 2008). 
Inspired by some of Lewis’s lab work with “fugitive inks,” Jordan 
Miller, at Rice University, created a technique for 3D printing of 
vasculature-mimicking channels. Using a simple open-source 3D 
printer, Miller and his team constructed a carbohydrate lattice 
made from a combination of simple and complex sugars. There is 
a major difference between Miller’s experiments and those done 
by Jennifer Lewis. Lewis uses machines that are very high-end 
and have incredible precision, but they are not easily duplicated 
by others. Miller saw potential in a cheaper printer called the 
Frostruder, a printer originally used to extrude sugar frosting for 
printing fancy designs onto edible treats. Miller adapted a printer 
to incorporate elements of the Frostruder printer’s design and 
was soon able to print dissolvable lattices of carbohydrate fila-
ments (Miller et. al., 2012). The experiment used a process called 
“3-D sacrificial molding” that is similar to the lost-wax method 
used by sculptors. His printer deposits filaments of carbohydrate 
on top of each other in sequence so they are self-supporting. 
Then the entire lattice structure is covered in a protective layer 
of a biodegradable polymer. After pouring and cross linking a cell-
filled gel over the carbohydrate lattice, the lattice is dissolved with 
an aqueous solution (Miller et. al., 2012).
Figure 5 (Murphy, Atala, 2014) (TED.com 2011)
Dr. Atala holding his printed kidney during a TED talk 
called “On Printing a Human Kidney,” in March 2011.
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Miller’s channels are not as small as Lewis’ channels. His chan-
nels range from 150 microns to around a millimeter in diameter. 
However, when he and colleagues seeded the channels with 
endothelial cells, they lined the interiors of the channels and 
even began to penetrate the surrounding cell-gel mixture. By 
guiding blood cells into the larger channels, he can set the stage 
for endothelial cells to spontaneously form their own capillary 
networks. Miller has successfully pumped human blood through 
his constructs in vitro, and the research team plans to cooper-
ate with a surgeon to connect one of his printed tissues to the 
vascular system of a rat to see how long he can get blood to 
flow through his channels (Miller et. al., 2012).
Vascularization procedures done by Miller and team take a 
short amount of time to complete which benefits the large 
scale tissues, like liver cells. Large scale tissue cannot survive 
the several hours it takes in the extruder nozzle long enough to 
build something the size of the human liver. Additionally, quickly 
pouring the cells and gels over the 3-D–printed lattice is easier 
on fragile cells than the arduous process of printing. The one 
disadvantage is that the researchers cannot control the exact 
placement of the cells. Therefore, this may not be the optimal 
method for experiments involving multiple cell types. In the 
versions of the constructs printed with rat liver cells or with 
human embryonic kidney cells, the cells near the channels sur-
vive longer than the cells deeper in the gel, suggesting that the 
experiment is leading in the right direction (Miller et. al., 2012).
Conclusion
At this present time, a 3D printed organ is unable to be inserted 
into a patient with the same efficacy as a normal organ. Many more 
years of research need to be conducted. There are constantly 
many advances being made by countless numbers of research 
teams who are devoted to help suffering patients and increase 
the availability of organs for transplant. However, even though 3D 
printed organs cannot be inserted into patients, they can be used 
to assist doctors and surgeons in surgery. Advanced models of 
organs that are 3D printed are able to prepare surgeons on what 
they might encounter in the operating room. Simply by looking 
at models, doctors are able to avoid potential complications that 
could have been unforeseeable without the physical model. 3D 
printed organs can also help train medical students and profes-
sionals. Researchers and Doctors are able to replicate the part of 
the patient with the complicated problem so students can learn 
how to go about saving lives. It also allows healthcare profes-
sionals to better explain situations to the patient. The healthcare 
provider can physically hold the model and explain what is wrong 
and the different procedures available for the patient. Currently, 
the main use of the 3D printed organs has been for screening 
new medications and modeling various diseases. 
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Introduction
DNA sequencing assays are highly efficient and economical and 
dramatically increase our understanding of genetic diseases. 
Once we identify and comprehend the cause of the disease, the 
quandary is to figure how to reverse the mutation and cure it. 
The ability to modify genes in mice serves as a crucial function 
to model human diseases (Yang et al., 2014).  Conventional ap-
proaches to study and develop disease models utilize homolo-
gous recombination, such as retroviral insertion (Kuehn et al., 
1987), in embryonic stem cells, to knockout the gene of interest 
(Thomas and Capecchi, 1987). Genetic variations among embry-
onic stem cells (Ledermann, 2000) coupled with relatively long 
time requirements (Markel et al., 1997) cause significant limita-
tions to this approach (Carbery et al, 2010).  Other methods 
used in gene editing include zinc-finger nucleases (ZFNs) (Kim 
et al., 1996; Geurts et al., 2009) and transcription activator–like 
effector nucleases (TALENs) (Nanjidsuren et al., 2016; Tesson 
et al., 2011).
Plasmids, bacteriophages, and transposons promote adaptation 
and survival by inducing the development of toxic compound 
degradation, antibiotic resistance, and other evolutionary ad-
vantages (Frost el at., 2005). Among mechanisms used to resist 
harmful infections and monitor the entry of genetic material, 
bacterial species utilize clustered regularly interspersed short 
palindromic repeats (CRISPR) (Labrie et al., 2010).  CRISPR, a 
defense mechanism ensuring resistance against viral invasion, 
is exhibited by an estimated 40 percent of eubacterial and 90 
percent archaeal species (Hatoum-Aslan et al., 2011). Kunin et 
al. (2007) used PILAR-CR, an algorithm that identifies CRISPR 
repeats, and found 561 arrays in 44 percent of the genomes 
tested. A population of ~1031 viruses coupled with ~1025/s 
rates of infection promoted the evolution of defense pathways 
that effectively identify foreign genetic elements and mount a 
response to degrade harmful foreign nucleic acids (Hendrix, 
2003; Richter et al., 2012).  These repeats are ubiquitous in ar-
chea and evident in some bacteria (Lillestøl et al., 2006).
While sequencing the Escherichia Coli iap gene in 1987, a re-
searcher identified an “unusual structure” at the 3’ end flanking 
the gene, noting five repetitive sequences of 29 nucleotides each 
having unique 32 bp spacer segments (Ishino et al., 1987).  In 
2005, Francisco Mojica was first to suggest a relationship be-
tween the CRISPR-Cas system and bacterial immunity.  This ob-
servation later turned out to be extremely significant, yielding 
a dramatic benefit to genetic research.  CRISPR, an adaptive 
bacterial immunological response mechanism, consists of alter-
nating sequences, one repetitive and the other a segment of a 
viral genome or a plasmid sequence.  CRISPR utilizes CRISPR 
associated (Cas) proteins and small non-coding RNAs for its 
function.  Abutting each CRISPR loci, CRISPR-associated (CAS) 
genes encoding for various enzymatic proteins couple with 
CRISPR to form a multitude of different CRISPR/CAS pathways 
(Horvath and Barrangou, 2010).   Incorporation of phage DNA 
into the spacer portion of a CRISPR array in Streptococcus 
thermophilus yielded resistance towards viral infection of the 
corresponding phage (Barrangou et al., 2007).  CRISPR can be 
involved in several processes such as; replicon partitioning in 
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halo bacteria (Mojica et al., 1995), DNA rearrangements within 
a replichore (Deboy et al., 2006), and thermal adaptation in E. 
Coli (Riehle et al., 2001).  There is a direct correlation between 
an increased sensitivity to viral infection and a mutation to the 
Cas genes or the spacer sequences of the corresponding virus 
(Barrangou et al., 2007; Brouns et al., 2008; Oost et al., 2014). 
CRISPR/Cas systems can be used to manipulate genes with sub-
stantial precision and accuracy, effectively giving researchers the 
ability to develop causal linkages between known mutations and 
observed phenotypes (Hsu et al., 2014).  This review article will 
assess the application of the CRISPR/Cas system as a therapeu-
tic approach to Duchenne muscular dystrophy.
Methods
An analysis of scholarly articles with a focus on papers pub-
lished in peer-reviewed journals with high impact factors were 
performed through access to databases of the Touro College 
Online Library, Medline, Proquest, NCBI Pubmed, and Google 
Scholar.  In-print articles were obtained from the Touro College 
library in the Avenue J campus.  An analysis of both review and 
experimental research articles were conducted to delineate 
the mechanism and outline recent applications of CRISPR in 
a clinical setting.  In each database, the search word “CRISPR” 
prompted recent publications on that topic.  Articles that were 
labeled as “similar” to papers published recently were also used. 
Proteins associated with CRISPR discussed in this paper were 
analyzed using the uniprot database.  Original research papers 
describing aspects pertaining to the discovery, mechanism, and 
applications of CRISPR were found on the webpage of Dr. Lluís 
Montoliu’s Lab at Centro Nacional de Biotecnología.
Results
Spacer Acquisition
The genetic interference pathway of the CRISPR/Cas system 
is initiated with spacer acquisition upon entry of foreign ge-
netic material (Swarts, 2012; Richter et al., 2012; Marraffini, 
2010a).  This step is highly dynamic and involves the recogni-
tion of foreign DNA by the host as well as its first integration 
into the spacer portion of a CRISPR array.  Identification of the 
foreign genetic element is essential to the CRISPR mechanism. 
Proto-spacer adjacent motifs (PAMs) or spacer precursors are 
important components of the CRISPR systems.  Each CRISPR-
CAS variant can correspond to a specific spacer precursor or 
proto-spacer that will be evident on the foreign DNA particle. 
The interference target is determined by a specific short motif 
sequence that corresponds to each CRISPR variant. Using the 
classification of CRISPR variants determined by Kunin et al. 
(2007), a sequence of either two or three nucleotides abut-
ting each proto-spacer was found to be conserved in six main 
groups (Mojica et al., 2009). This finding suggests a correlation 
between PAMs and each CRISPR-CAS system.
Various Cas genes are found adjacent to all CRISPR arrays with 
the exception of Thermoplasma acidophilum (Marraffini and 
Sontheimer, 2010a). More than 45 distinct CRISPR associated 
protein families have been identified using Hidden Markov mod-
els (Haft, 2005).  Each subtype of CRISPR is classified based on 
associated Cas genes as well as its distinct repeat characteristics 
(Gesner, 2011).  Three main subtypes are classified based on the 
presence of a unique Cas protein: type 1 has Cas3, type 2 has 
Cas9, and type 3 has Cas10 (Gleditzsch et al.; 2016, Makarova 
et al., 2011a; Richter et al., 2012).  A fourth subtype, with its 
mechanism and function still uncharacterized, is called CRISPR 
type U (Koonin and Makarova, 2013).
Cas1 and Cas2, a metal-dependent nuclease (Wiedenheft et al., 
2012) and a pH-dependent nuclease (Ka et al., 2014), respec-
tively, are necessary in initiating spacer acquisition by incorpo-
rating non-self DNA into the leading end of the CRISPR array 
(Mojica et al., 2009).  Strains of E. Coli lacking the endogenous 
cas genes prevented spacer acquisition from occurring without 
affecting further steps in the pathway, outlining their importance 
in the first step.  Both Cas1 and Cas2 are evident among almost 
all CRISPR systems (Makarova et al., 2011b), possess a crucial 
role in spacer acquisition (Yosef et al., 2012), and contain highly 
conserved motifs.  CRISPR type U is the only known form of 
CRISPR that does not possess a CRISPR array or Cas1 (Koonin 
and Makarova, 2013).  These findings outline the importance of 
Cas1 and Cas2 in spacer acquisition (Oost et al., 2014).  Cas1 
and Cas2 form a complex determined by a 2.3Å resolution 
crystal structure (Nuñez et al., 2014).
Both DNA recognition and spacer acquisition will be prevented 
if the Cas1-Cas2 complex formation is disrupted by a mutation 
(Nuñez et al., 2014).  In addition to its role in the CRISPR/Cas 
system, Cas1 is believed to be involved DNA repair (Babu et 
al., 2010).  The recognition of a variant-specific adjacent short 
sequence on the foreign DNA particle prompts the incorpora-
tion of a spacer precursor.  This completes the first step in the 
CRISPR defense mechanism (Mojica et al., 2009).  Replication 
of the inserted repeat begins with the repeat most proximal to 
the leader portion of the array (Yosef et al., 2012).  The CRISPR 
response is amplified through the increase in spacer sequences 
corresponding to a specific foreign DNA element (Swarts et 
al., 2012).
crRNA Expression
The successful incorporation of a foreign DNA segment into 
the spacer region of the CRISPR array and the production of 
a multiunit precursor (Koonin, 2006) permits the subsequent 
processing of the precursor CRISPR RNA (pre-crRNA) (Oost 
et al., 2009; Wiedenheft et al., 2012).  The crRNAs specific to 
each CRISPR array are integral to the CRISPR pathway.  Analysis 
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of the CRISPR/Cas system in Escherichia Coli K12 determined 
that both the repeats and the spacers within the CRISPR 
are transcribed into a long precursor RNA (Marraffini and 
Sontheimer, 2010a).  The crRNA transcript transcribed from 
the CRISPR array requires cleavage prior to activation.
Cas proteins catalyze the conversion of precursor RNAs 
(pre-crRNA) into small crRNAs (Gleditzsch et al., 2016; 
Marraffini and Sontheimer, 2010b).  Eight Cas genes were 
identified in this strain: cas123 and casABCDE (Brouns et al., 
2008).  After knocking out each individual Cas gene using in-
frame single-gene deletions (Baba and Mori, 2008), the resulting 
transcript determined the position of each gene on the CRISPR 
array. Further, the RNA cleavage assays did not require ATP 
or divalent metal ions to progress.  CasE, an endoribonucle-
ase resembling an RNA-binding protein, fused together with 
the maltose binding protein (MalE) in Escherichia coli K12, did 
not require any other Cas proteins to cleave the pre-crRNA. 
Northern blot analysis determined His20 residue to be essen-
tial for catalysis of the pre-crRNA.  A casE knockout  prevents 
the processing of pre-crRNA in Escherichia coli K12 outlining 
its importance in the pathway (Brouns et al., 2008).  Cascade 
(CRISPR-associated complex for antiviral defense), a ribonu-
cleoprotein, is a 405 kDa undecamer made of five different 
Cas proteins. Cascade is coupled with a 61 nucleotide crRNA 
structure spanning the length of the protein complex that 
has a 5’-hydroxyl and 2’,3’-cyclic phosphate termini forming a 
seahorse configuration prior to target DNA binding (Jackson et 
al., 2014, Jore et al., 2011).
Cas3, essential to all type I CRISPR systems, functions both 
as an ATP-dependent type A superfamily 2 helicase and a ss-
DNA nuclease (Brouns et al., 2008; Gesner, 2011; Huo et al., 
2014; Sinkunas et al., 2011).  Cas3, together with the mature 
crRNA as a guide and Cascade as a targeting complex, catalyze 
the degradation of double stranded DNA elements (Huo et 
al., 2014).  Brouns et al. exposed Escherichia coli to virulent 
Lambda phage in various scenarios to determine the role of 
Cascade and Cas3 in resisting phage infection.  Two Escherichia 
coli strains each contain a CRISPR variant that targets four 
important lambda genes: the coding strain produced crRNAs 
complimentary to both the coding and non-coding strand of 
the four genes, while the template strain produced crRNAs 
complementary to the proto-spacer regions.  With both 
Cascade and Cas3 present, results showed a hundred-fold 
and ten million-fold decrease in sensitivity to phage infection 
with the coding strain and template strain, respectively.  Based 
on the aforementioned experiment, the presence of Cascade 
and Cas3 is crucial to phage resistance in the CRISPR defense 
mechanism (Brouns et al., 2008). 
High resolution X-ray structure analyses of Cse3, a component 
of Cascade, both before and after cleavage of pre-crRNA, sug-
gests a molecular basis for the mechanism of crRNA recognition 
by the Cascade.  Three structures of Cse3 bound to different 
RNA products all displayed a stem loop complex, suggesting the 
involvement of Cse3 in RNA recognition (Gesner et al., 2011). 
Processing of pre-crRNA into mature crRNA allows effective 
interference by the CRISPR-Cas system.
Interference
The interference stage differs mechanistically among the three 
main subdivisions of CRISPR: type I, II, and III. Each subtype ac-
complishes the same goal of foreign DNA degradation, differing 
only in the route of interference. The goal of CRISPR interfer-
ence is to degrade the foreign genetic elements that correspond 
to the acquired spacer sequences in the CRISPR array.
CRISPR type I, evident in both bacteria and archaea, exploits 
Cas3 for target degradation. Cascade is the multi-subunit crRNP 
(CRISPR ribonucleoprotein) complex that is unique to CRISPR 
type I.  Different routes, depending on the subtype of CRISPR 
type I, can induce a conformational change in the crRNP com-
plex which may cause the recruitment of Cas3 for degradation 
(Oost et al., 2014).  The interference in CRISPR type I is initi-
ated when the mature crRNA binds to a variant of Cas6, an 
endoribonuclease.  The variant will depend on the subtype of 
CRISPR type 1 (Richter et al., 2012).  The crRNA forms a stem 
loop within each repeat and bind to the corresponding Cas6 
protein. Cas5d, the Cas6 variant of type I-C/Dvulg, processes 
the pre-crRNA. Further, Cas5d binds to the mature crRNA 
(Nam et al., 2012) and recruits the Cascade which induces a 
conformational change in the complex (Oost et al., 2014).  In 
type I-E, CasA or Cse1, functions to discriminate between self 
and foreign DNA through the recognition of a proto-spacer 
adjacent motif (PAMs) (Sashital et al., 2012; Westra et al., 2013) 
as well as induce interactions between DNA and Cascade (Jore 
et al., 2011).  The initial interaction with the foreign DNA em-
ployed by a short loop on Cse1 recognizes a sequence of seven 
nucleotides near the 5’ end in addition to the PAM (Richter et 
al., 2012).
The CRISPR Type II system uses trans-activating crRNAs (tra-
crRNA) in crRNA processing. Strains lacking tracrRNA did not 
yield mature crRNA, demonstrating the importance of tracrR-
NA in crRNA processing.  The tracrRNA base pairs with 24 
nucleotides (Deltcheva et al., 2011) of the crRNA and recruits 
RNase III for cleavage.  The fusion of tracrRNA and crRNA to 
become a single-guide RNA (sgRNA) can be easily programmed 
and is used in the modification of multiple DNA sequences si-
multaneously (Bolukbasi et al., 2016; Cho et al., 2013; Mali et 
al., 2013).  The process of cleaving tracrRNA and crRNA also 
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requires a Cas protein called Csn1 determined by in-vivo in-
frame deletions of the gene.  The subsequent appearance of 
mature crRNA and cleaved tracrRNA after the induced ex-
pression of Csn1 further supports the hypothesis that Csn1 
is vital to the processing of crRNA and tracrRNA (Deltcheva 
et al., 2011).   However, Csn1 only serves to stabilize the in-
teraction between pre-crRNA and tracrRNA without a direct 
contribution to the catalysis, further emphasizing catalytic role 
of RNase III (Fonfara et al., 2013).  CRISPR-associated endo-
nuclease Cas9 or Csn1 is Mg2+-dependent and contains two 
endonuclease domains.  One is a RuvC-like nuclease domain 
and the other is a HNH nuclease domain cleaving the target 
DNA non-complimentary and complimentary to the crRNA, 
respectively (Jinek et al., 2012; Anders et al., 2014; Nishimasu 
et al., 2014).  Csn1 undergoes a conformational change upon 
binding to the tracrRNA and mature crRNA, effectively activat-
ing its nuclease activity (Jinek et al., 2014).  Although both type I 
and type II use PAM recognition to bind to DNA, there are two 
technical differences.  Firstly, the PAM motif is adjacent to the 5’ 
end of the crRNA in type I and the 3’ end in type II. Secondly, 
the PAM motif of the target DNA in type I is the strand that 
directly interacts with the crRNA whereas it is on the displaced 
strand in the mechanism of type II.  After the ribonucleoprotein 
complex is in its active form, the subsequent activation of the 
nuclease domains mediates site-specific double stranded breaks 
of the foreign DNA via Cas9 (Oost et al., 2014).  Sternberg et al. 
classified the interaction between the RNA-Cas9 and the target 
DNA to be through a three-dimensional collision outlining the 
specificity of the CRISPR mechanism (2014).
The crRNP complexes in CRISPR type III are structurally alike 
and have similar roles to type I. Type III-A and type III-B are 
associated with csm and cmr complexes, respectively. The type 
III-A system displays the ability to degrade double-stranded 
DNA and single-stranded RNA (Niewoehner and Jinek, 2016), 
whereas the type III-B system targets RNA (Hale et al., 2009). 
Type III-A, present in staphylococcus epidermidis RP62a, con-
tains nine csm genes (Hatoum-Aslan et al., 2014) and does 
not rely on PAM recognition for target degradation (Marraffini 
and Sontheimer, 2010b).  Instead, the csm complex uses the 
csm3 and cas10 subunits to target and degrade single-strand-
ed RNA and double-stranded DNA, respectively.  Csm6, a 
single-stranded RNA-specific endoribonuclease noted for 
its higher eukaryotes and prokaryotes nucleotide-binding 
(HEPN) domain, is integral to the function of the csm complex. 
Ribonuclease activity was determined to be a common feature 
among orthologs of csm6, outlining its importance in the type 
III pathway.  Although the mechanism of csm6 interference is 
currently inconclusive, a notable theory posits that when the 
csm complex is unsuccessful in resisting foreign invasion, csm6 
somehow activates and targets its own nucleic acids inducing 
apoptosis.  Such regulatory methods serve as an important 
defense in preventing further infection.  Structural analysis of 
csm6 in Thermus thermophilus describes multiple binding do-
mains which could indicate that there are ligand-dependent 
levels of catalytic activity (Niewoehner and Jinek, 2016).  Type 
III-B in Thermus thermophilus uses the cmr complex, an 11 
subunit protein complex comprised of six distinct proteins 
aptly labeled cmr1-6, for RNA degradation.  The cmr com-
plex is a Mg2+-dependent endoribonuclease that targets the 
RNA strand at multiple sites complementary to the crRNA. 
Degradation begins at the 3’ end of the target RNA strand 
and cleaves toward the 5’ end with each cleavage separated 
by six nucleotides.  The distance between two cmr4 subunits 
is consistent with the six nucleotide intervals present in the 
cleavage mechanism which suggests characterizing cmr4 as a 
ribonuclease within the cmr complex (Staals et al., 2013).  A 
significant distinction in the molecular mechanism of CRISPR 
type III is that it relies on Cas10/Csm or Cas10/Cmr complex 
for target interference whereas type I and type II require a 
recognition sequence (Samai et al., 2015).  
It is important to note the ability of the CRISPR/Cas system 
to differentiate its own genetic material from foreign nucleic 
acids. Without the basic capacity to distinguish self versus non-
self, all CRISPR mechanisms would act on their own DNA and 
subsequently induce autoimmunity and cell death.  The basic 
mechanism behind preventing self-degradation relies on a ge-
netic distinction between target and self.  Since the sequences 
incorporated in the spacers are meant to assist in the recogni-
tion of foreign genetic elements, they are the same and should 
cause self-interference.  However, analysis of the CRISPR array 
in Staphylococcus epidermidis yielded dissimilarities between 
sequences of target DNA and the CRISPR DNA that are not 
in the spacer region.  The higher degree of base complemen-
tarity between CRISPR DNA and crRNA in regions flanking 
the spacer sequences prompts evasion of interference.  Adding 
fifteen base pairs matching both sides of the spacer’s flanking 
sequences onto a target strand showed that interference was 
unsuccessful in the plasmid that had the 5’ flanking sequence. 
The exact “protective region” was determined to be eight base 
pairs flanking the spacer sequence.  It is the variable comple-
mentarity within sequences abutting the spacer region that 
prevents autoimmunity in all CRISPR systems (Marraffini and 
Sontheimer, 2010b).
CRISPR/Cas9 Genome Engineering
Jinek et al. (2012) was the first to propose the application of 
CRISPR/Cas9 for genomic manipulation.  CRISPR/Cas9 is a 
form a CRISPR type II and is well understood (Ran et al., 2013). 
The purpose of CRISPR/Cas9 is to induce double-stranded 
breaks at specific locations within a chromosome.  Cong et al. 
77
CRISPR/Cas9 as a therapeutic approach to Duchenne Muscular Dystrophy
(2013) investigated the application of CRISPR/Cas9 in genom-
ic engineering by reconstructing the CRISPR type II locus of 
Streptococcus pyogenes SF370 in mammalian cells.  A spacer 
sequence that resembles a specific portion of the EMX1 gene 
adjacent to the proper PAM sequence was designed and then 
transfected into 293FT cells along with RNase III, Cas9, tracrR-
NA, and pre-crRNA.  Notably, cleavage activity was prevented 
when a base mismatch between the protospacer and the guide 
RNA sequence was within eleven nucleotides of the PAM se-
quence, demonstrating the specificity and accuracy of CRISPR/
Cas9.  Results yielded effective cleavage even without the ad-
dition of RNase III.  This finding outlines three essential com-
ponents required for this method of genetic engineering; Cas9, 
mature crRNA, and trans-activating crRNA.
Cas9 is an endonuclease that requires a Mg cofactor in order to 
bind to target DNA (Jinek et al., 2012) and is inhibited by EDTA 
(Jiang et al., 2016).  The target sequence needs to abut the 5’ end 
of a protospacer adjacent motif.  Each ortholog of Cas9 requires 
a specific PAM sequence.  The crRNA contains the twenty nu-
cleotide sequence used to target the gene of interest that leads 
to the PAM. Furthermore, the crRNA requires tracrRNA for its 
activation into discrete units. When used in genome editing, the 
crRNA and tracrRNA are fused together to become a com-
plex commonly called single-guide RNA (sgRNA) or guide RNA 
(gRNA) (Ran et al., 2013).  
Mali et al. (2013) described how the CRISPR/Cas9 system can 
be used to both stimulate homologous recombination and mod-
ify a locus. They developed human embryonic kidney HEK 293T 
cells that contain a green fluorescent protein (GFP) sequence 
with an interruption that prevented functionally fluorescing 
GFPs.  Two gRNAs were designed to target the region that dis-
rupted florescence.  After transfection of a donor to repair the 
sequence, Cas9, and a gRNA, flow-activated cell sorting (FACS) 
began detecting fluorescing cells at ~20 hours, elucidating the 
efficiency of CRISPR/Cas9 in inducing homologous recombina-
tion with a repair donor.  To demonstrate how CRISPR/Cas9 can 
modify genomic loci, Mali et al. (2013) introduced two gRNAs 
that would each target nineteen base pairs with one base pair 
in-between them and then a double stranded donor sequence 
to take its place at the AAVS1 locus. PCR and Sanger sequenc-
ing assays confirmed the integration of a foreign sequence in a 
genome.  These findings demonstrate important applications of 
CRISPR in genomic engineering.
Another important application of CRISPR/Cas9 is the sin-
gle-step induction of mutations in multiple genes.  Developing 
disease models through targeted deletions and engineering 
in multiple chromosomes gives extensive insight into the 
formation of various illnesses.  Maresch et al. (2016) exploited 
electroporation to introduce CRISPR/Cas9 vectors in pancreat-
ic cells and demonstrated optimal results when targeting a “few 
hundred cells” in each organ.  To investigate pancreatic tumori-
genesis, sgRNAs for thirteen tumor-suppressor genes and two 
neutral genes were transfected into a mixture of C57BL/6J and 
129S mice strains.  Magnetic resonance imaging determined the 
average time for tumor development to be 10.7 weeks and a 
54% tumor incidence at 24 weeks.  Next generation sequencing 
analysis confirmed a significant number of mutations in the tar-
get sites of tumor tissue samples. Furthermore, it did not find 
any significant mutation rates in the target sites of the tissue 
surrounding the tumors which is explained by the electropora-
tion protocols that target only a few hundred cells in relatively 
small area (Maresch et al., 2016).  All the aforementioned capa-
bilities of CRISPR/Cas9 amalgamate to produce a highly efficient 
and effective method of genomic engineering with a short time 
period required to develop disease models.  Prospective appli-
cations of CRISPR/Cas9 can involve the introduction of targeted 
mutations that can prevent the acquisition of diseases such as 
Human Immunodeficiency Virus (Lombardo et al, 2007).  The fu-
ture applications of CRISPR engineering are limitless and serve 
as an extremely viable option for use as a therapy for Duchenne 
Muscular Dystrophy.
Duchenne Muscular Dystrophy
In 1836, Gaetano Conte was the first to describe a case of 
Duchenne muscular dystrophy (DMD) (Nigro, 2010), an X 
chromosome linked recessive disorder that is classified as 
a severe progressive muscle wasting disorder.  This neuro-
muscular disease is caused by a mutation in the DMD gene 
that codes for dystrophin (Hoffman et al., 1987), a 427 kDa 
rod-shaped cytoskeletal multi-domain protein made of 3,685 
amino acids (Koenig et al., 1988) that is expressed in all human 
muscle cell types.  Dystrophin interacts with dystrobrevin 
alpha (Sadoulet-Puccio et al., 1997), alpha-1-syntrophin (Ahn 
et al., 1996), and beta-1-syntrophin (Ahn and Kunzel, 1995). 
The primary function of dystrophin is to connect a cytoskele-
ton component, actin, with the extracellular matrix (Norwood 
et al., 2000).  DMD occurs when mutations affecting the open 
reading frame cause premature termination of dystrophin 
during translation, resulting in a protein with complete loss of 
function (Yiu, 2015).  The end result of a deficiency in dystro-
phin is muscle fiber degeneration and is believed to be second-
ary to factors such as sarcolemma impairment, structural dam-
age to the cytoskeleton, and an aberrant calcium homeostasis. 
Patients with DMD require respiratory, cardiac, orthopaedic, 
and nutritional management throughout their lives (Yiu, 2015). 
Life expectancy for DMD patients is usually 25 years with the 
cause of death commonly being cardiomyopathy or lung issues 
(Long et al., 2014).
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Pathophysiology
DMD, being a neuromuscular disorder, detrimentally affects 
the body’s mechanical abilities, calcium homeostasis, vascula-
ture, genetic regulation, glycosylation, tissue remodeling, and 
inflammatory response mechanisms.  The absence of dys-
trophin or other proteins within the dystrophin associated 
complex could significantly decrease normal contractions that 
increase tension as the muscle lengthens, or eccentric con-
tractions, thereby damaging the membrane of the muscle fi-
bers.  A muscle biopsy will show muscle fiber degeneration or 
necrosis.  Eventually, the continual attempts to regenerate the 
muscle fibers leads to a burnout and begin substituting muscle 
for connective and adipose tissues (Deconinck and Dan, 2007). 
DMD induces a leak within the calcium channels of the cell. 
The lack of dystrophin affects the structure of the membrane 
causing compensatory mechanisms that maintain calcium 
levels to eventually become ineffective. When there is a pro-
longed influx of extracellular calcium, proteases are activated, 
causing further degradation of the membrane, which leads to 
a further increase in intracellular calcium.  This glut of calcium 
can presumably lead to cellular death.  
Neuronal-type NO synthase (nNOS) is normally localized 
to the membrane of white muscle fibers and produces nitric 
oxide, which is a short-lived highly reactive signaling mole-
cule with important biological functions (Nelson and Cox, 
2013).  The absence or deficiency of dystrophin causes a 
reduction in nNOS activity as well as its delocalization from 
the sarcolemma (Brenman et al, 1995; Crosbie et al., 2002). 
Dabiré et al. (2012) demonstrated a link between vascular 
endothelial dysfunction and the expression of endothelial 
and neuronal nitric oxide synthases in DMD patients.
The conversion of mechanical stimuli into electrical or chemi-
cal signals is known as mechanotransduction and is involved in 
genetic expression and other important physiological process-
es (Katsumi et al., 2004). Goldspink (1998) demonstrates the 
effects of muscle activity on mechanotransduction.  The pro-
gressive loss of muscle tissue occurs secondary to the lack of 
autocrine insulin-like growth factor-1 production, which is used 
to repair muscle tissue. 
CRISPR/Cas9 Therapy
The human dystrophin gene contains seventy-nine exons and 
seventy-eight introns (Kole and Krieg, 2015) with at least seven 
promoters.  Alternative splicing yields different variants of dys-
trophin depending on the stage of development and type of 
tissue (Im et al., 1996).  A spontaneous mdx gene mutation in 
a colony of C57BL/10ScSnJ mice resulted in increased serum 
levels of specific proteins as well as histological similarities 
compared to that of human muscular dystrophy (Bulfield et al., 
1984).  This spontaneous point mutation yielded a stop codon 
affecting exon 23 in the dystrophin gene (Sicinski et al., 1989). 
Biochemical similarities coupled with cross-breeding analysis 
of mutant and normal mice set the precedent to use the mdx 
mouse as a model for muscular dystrophy (Bulfield et al., 1984). 
Although not entirely equivalent to the human disease, re-
searchers utilize the mdx mouse as the predominant model to 
investigate pathogenic mechanisms of DMD (Partridge, 2013).
The primary goal is to cure DMD by correcting any harmful 
mutations. Treatments either alleviate the symptoms or aim to 
cure the disease itself. Pharmacological approaches improve 
muscle function with corticosteroids (Mendell et al., 1989), 
maintain calcium homeostasis (Zhao et al., 2012), inhibit the 
IKK/NF-κB signaling pathway (Acharyya et al., 2007), reduce in-
flammation and induce the upregulation of uthrophin as a sur-
rogate to dystrophin (Gordon et al., 2013).  Glucocorticoids, 
such as prednisone or deflazacort, are beneficial to muscle 
function and are the only accepted drug therapy of DMD 
(Matthews et al., 2016).  Van Deutekom et al. (2001) describes 
a form of gene therapy that attempts to correct the reading 
frame through the induction of skipping an additional exon. 
An exon 45 deletion exhibited in DMD patients causes a stop 
codon in exon 46. The open reading frame is restored when 
exon 46 is deleted. The resulting protein is still dysfunctional 
yet displays a milder form DMD, outlining a method of treating 
the disease. Other attempted strategies of treatment include 
antifibrotic pharmaceuticals, myostatin inhibitors, nonsense 
suppression drugs, vector-mediated gene therapy, and cell 
transplantation (Shimizu-Motohashi, 2016).
The aforementioned therapeutic approaches to treat DMD 
focus on either reestablishing the expression of or compensat-
ing for a deficiency in dystrophin.  The efforts to treat DMD are, 
in many instances, relatively transient and compensatory with-
out any curative effects.  CRISPR/Cas9 is revolutionary for its 
attempt to treat the underlying cause of the disease— mutation 
or mutations in the dystrophin gene.  Long et al. (2014) demon-
strated the application of CRISPR/Cas9 to repair the genetic de-
fect in an animal model of DMD.  The zygotes of the mdx mouse, 
containing a nonsense mutation in exon 23 of the dystrophin 
gene (Sicinski et al., 1989), were injected with a 20 nucleotide 
single-guide RNA containing a PAM sequence, Cas9, and 90 base 
pair single stranded template.  This template strand incorporates 
four silent mutations as well as a TseI restriction site for data 
analysis.  After a double-stranded break was induced by Cas9, 
the strands were repaired by either homology directed repair 
(HDR) or nonhomologous end-joining (NHEJ).  The optimized 
condition involved injecting the Cas9, sgRNA, and template into 
the zygote and then performing re-implantation into a female 
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mouse.  The offspring of that mouse determined the results of 
the experiment. Analysis of eleven repaired mdx progeny re-
vealed adult development of all mice without signs of abnormal 
phenotypes.  Control groups were used to test for off-target 
effects and yielded data consistent with previous genome-wide 
studies outlining the specificity of Cas9. Using histological anal-
ysis of different muscles, the results of this experiment demon-
strated the capability of CRISPR/Cas9 to repair the primary 
mutation that causes DMD, thereby preventing the symptoms 
associated with the disease.  The determined threshold for suf-
ficient repair was 17% which effectively displayed a dystrophin 
level comparable to the wild-type mouse. This finding suggests a 
mechanism of selective advantage for the repaired skeletal my-
ocytes.  Soles and heart tissue immunostaining of a three-week 
old mdx repaired mouse of 40% displayed myofibers without 
dystrophin while the nine-week old mdx repaired mouse of 41% 
did not reveal any myofibers without dystrophin. The dystro-
phin expression levels between the three and nine week old 
mice were insignificant, suggesting a compensatory mechanism 
of rescue by the repaired nuclei in a myofiber.  Immunostaining 
revealed myofibers containing dystrophin secondary to a fusion 
between a repaired cell and dystrophic muscle, providing fur-
ther evidence of a rescue mechanism.  Additionally, the serum 
creatine kinase levels were inversely related to the percentage 
of genomic repair, which is consistent with previous data in this 
paper. A higher level of serum creatine kinase signifies muscle 
breakdown. The repair of only a percentage of cells can induce 
a total rescue, suggesting an unknown mechanism that induces 
muscle regeneration in mice treated with CRISPR/Cas9.  The 
results of this experiment yield a breakthrough in our approach 
to cure previously incurable diseases by effectively correcting 
the underlying cause of the disease.
Discussion & Conclusion
Analysis of the CRISPR/Cas system, both in terms of its mech-
anism and bioengineering applications, yields a plethora of data 
on various diseases. The short time requirements (Markel et 
al., 1997) coupled with the simultaneous manipulation of mul-
tiple genes (Bolukbasi et al., 2016) characterizes CRISPR as an 
advanced and highly efficient approach to modeling and thus 
understanding maladies. Applying a form of CRISPR type II to 
induce double stranded breaks provides researchers the ability 
to target a portion of DNA with high specificity and then stimu-
late homologous recombination to modify a specific locus (Mali 
et al., 2013).  Duchenne muscular dystrophy is a debilitating 
neuromuscular disease commonly affecting males and generally 
leads to death before the age of 25 (Long et al., 2014).  DMD is 
a prime example to be used in the application of CRISPR/Cas9 
for its well defined mutations that cause the disease.  The data 
presented in experiments using CRISPR/Cas9 to modify a gene 
seem to be consistent and display accuracy and efficiency (Cong 
et al., 2013; Mali et al., 2013; Maresch et al., 2016).  Based on 
current data, CRISPR/Cas9 genomic engineering is a promising 
and hopeful route to effectively reverse disease-causing genetic 
mutations such as Duchenne muscular dystrophy.
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